Bridged artificial nucleic acid ALNA

Abstract

The invention relates to a bridging type artificial nucleic acid ALNA. The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. More specifically, the present invention provides: a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or a salt thereof; oligonucleotide compound represented by general formula (I ') (wherein each symbol is the same as defined in the description) or salt thereof.

Description

[0001] This application is a divisional application of the Chinese invention patent application with the application date of November 11, 2019, application number No. 201980074116.0 (international application number PCT / JP2019 / 044182), and invention name “Bridged Artificial Nucleic Acid ALNA”. Technical Field

[0002] The present invention relates to monomers of amino LNA and oligomers containing the same. Background Art

[0003] Methods of treating diseases based on nucleic acid drugs include antisense method, antigene method, method using aptamer, method using siRNA, etc. Among them, antisense method is a method in which oligonucleotides (antisense strands) complementary to mRNA and non-translated RNA related to the disease are introduced from the outside to form double strands, thereby regulating the function of RNA related to the disease and treating or preventing the disease.

[0004] As raw materials for such nucleic acid drugs, various artificial nucleic acids have been developed, but there are still problems such as avoiding toxicity to organs such as liver and kidney where nucleic acid drugs are easily accumulated after systemic administration and showing sufficient drug efficacy, and there is no molecule that should be a trump card. 2'-amino LNA (Locked nucleic acid) (hereinafter referred to as "ALNA") developed by Wengel et al. in 1998 (Patent Document 1 and Non-Patent Document 1) can synthesize a variety of artificial nucleic acids by modifying substituents from the 2' position. Many ALNA derivatives have been synthesized so far, with alkyl and acyl groups as the center (Patent Documents 2 to 4 and Non-Patent Documents 2 to 11). Although characteristic tissue distribution after systemic administration has been reported (Non-Patent Document 12), it is insufficient in terms of pharmacological activity and has not been used in pharmaceuticals so far.

[0005] We applied the previously discovered efficient synthesis method of GuNA (Patent Document 5 and Non-Patent Document 13) to further synthesize a variety of novel ALNA derivatives and extensively carried out screening specifically for pharmacological activity evaluation. As a result, we discovered novel artificial nucleic acids with superior in vitro and in vivo pharmacological activities than existing ALNAs, thus completing the present invention.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: International Publication No. 99 / 014226

[0009] Patent Document 2: International Publication No. 2013 / 013068

[0010] Patent Document 3: International Publication No. 2014 / 124952

[0011] Patent Document 4: International Publication No. 2016 / 128583

[0012] Patent Document 5: International Publication No. 2017 / 047816

[0013] Non-patent literature

[0014] Non-patent document 1: SK Singh et al., J. Org. Chem. 1998, Vol. 63, pp. 6078-6079

[0015] Non-patent document 2: MD Sorensen et al., Chem. Commun. 2003, p. 2130

[0016] Non-patent document 3: BR Babu et al., Chem. Commun. 2005, Vol. 13, pp. 1705-1707

[0017] Non-patent document 4: T. Bryld et al., Nucleosides, Nucleotides & Nucleic Acids 2007, Vol. 26, pp. 1645-1647

[0018] Non-patent literature 5: M. Kalek et al., J. Am. Chem. Soc. 2007, Vol. 129, pp. 9392-9400.

[0019] Non-patent document 6: T. Umemoto et al., Org. Biomol. Chem. 2009, Vol. 7, pp. 1793-1797

[0020] Non-patent document 7: MW Johannsen et al., Org. Biomol. Chem. 2011, Vol. 9, pp. 243-252

[0021] Non-patent document 8: ASJ φrgensen et al., Chem. Commun. 2013, Vol. 49, pp. 10751-10753

[0022] Non-patent document 9: IKAstakhova et al., Acc. Chem. Res. 2014, Vol. 47, pp. 1768-1777

[0023] Non-patent document 10: C. Lou et al., Chem. Commun. 2015, Vol. 51, pp. 4024-4027

[0024] Non-patent document 11: A. Ries et al., J. Org. Chem. 2016, Vol. 81, pp. 10845-10856

[0025] Non-patent document 12: K. Fluiter et al., Chem. Bio. Chem. 2005, Vol. 6, pp. 1104-1109

[0026] Non-patent document 13: H. Sawamoto et al., Org. Lett. 2018, Vol. 20, pp. 1928-1931 Summary of the invention

[0027] Problems to be solved by the invention

[0028] The present invention relates to a novel bridged artificial nucleic acid and an oligomer comprising the same as a monomer.

[0029] Means for solving problems

[0030] The inventors of the present application have conducted intensive studies to solve the above problems, and as a result, have found novel 2′-aminoLNA and its salt, and oligomers containing the same as monomers, as shown below, thereby completing the present invention.

[0031] That is, the present invention relates to the following items [1] to

[33] , but is not limited thereto.

[0032] Item [1] A compound represented by the general formula (I) or a salt thereof.

[0033] [Chemical formula 1]

[0034]

[0035] [Wherein,

[0036] B is a base portion of a nucleic acid that may be substituted with one or more substituents;

[0037] R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl;

[0038] R5 and R6 are each independently a hydrogen atom, a protective group for a hydroxyl group, or a phosphate group which may be substituted;

[0039] m is 1 or 2;

[0040] X is a group represented by the following formula (II-1), (II-2), or (II-3);

[0041] [Chemical formula 2]

[0042]

[0043] Symbols described in formula (II-1), (II-2), or (II-3):

[0044] [Chemical formula 3]

[0045]

[0046] indicates the bonding site to the 2'-amino group;

[0047] R7 and R8 are each independently a hydrogen atom, a C 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, or an aromatic group which may be substituted with one or more substituents;

[0048] A is an aromatic group;

[0049] M is selected from C which may be substituted by one or more substituents 1-6 Sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.]

[0050] (Hereinafter, the compound represented by formula (I) or a salt thereof is referred to as "the compound of the present invention").

[0051] [2] The compound or salt thereof according to [1], wherein B is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

[0052] [3] The compound or salt thereof according to [1] or [2], wherein R1, R2, R3 and R4 are each independently a hydrogen atom;

[0053] m is 1.

[0054] [4] The compound or salt thereof according to any one of [1] to [3], wherein X is a group represented by formula (II-1); and

[0055] R7 and R8 are each independently a hydrogen atom, a C 1-6 An alkyl group or an aromatic group which may be substituted with one or more substituents.

[0056] [5] The compound or salt thereof according to [4], wherein R7 and R8 are each independently a hydrogen atom, a C 1-3 alkyl.

[0057] [6] The compound or salt thereof according to [5], wherein one of R7 and R8 is a hydrogen atom and the other is a methyl group.

[0058] [7] The compound or salt thereof according to [5], wherein one of R7 and R8 is a hydrogen atom and the other is an isopropyl group.

[0059] [8] The compound or salt thereof according to any one of [1] to [3], wherein X is a group represented by formula (II-2); and

[0060] A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, and the heteroaryl group contains one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

[0061] [9] The compound or salt thereof according to [8], wherein A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, the heteroaryl group contains two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, the two or three heteroatoms include at least two nitrogen atoms, and the substituents are each independently selected from a C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A group consisting of an amino group substituted by an alkyl group.

[0062]

[10] The compound or salt thereof according to [9], wherein the five-membered or six-membered heteroaryl group is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, and pyrazinyl groups which may be substituted with one or more substituents.

[0063]

[11] The compound or salt thereof according to

[10] , wherein the triazolyl group which may be substituted with one or more substituents is 1,5-dimethyl-1,2,4-triazol-3-yl.

[0064]

[12] The compound or salt thereof according to

[10] , wherein the oxadiazolyl group which may be substituted with one or more substituents is 5-methyl-1,2,4-oxadiazol-3-yl group.

[0065]

[13] The compound or salt thereof according to

[10] , wherein the thiadiazolyl group which may be substituted with one or more substituents is 3-methyl-1,2,4-thiadiazol-5-yl.

[0066]

[14] The compound or salt thereof according to any one of [1] to [3], wherein X is a group represented by formula (II-3); and

[0067] M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

[0068]

[15] The compound or a salt thereof according to

[14] , wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

[0069]

[16] A compound or a salt thereof as described in any one of [1] to

[15] , wherein R6 is a hydrogen atom or a DMTr group, and R5 is a hydrogen atom or -P(O(CH2)2CN)(N(iPr)2).

[0070]

[17] A compound selected from the group consisting of:

[0071] 3-[[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-6-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-methylsulfonyl-5-oxa-2-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 1 of the present invention);

[0072] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 2 of the present invention);

[0073] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 3 of the present invention);

[0074] N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-purin-6-yl]benzamide (Compound 4 of the present invention);

[0075] 3-[[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (compound 5 of the present invention);

[0076] N-[1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino)oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 6 of the present invention);

[0077] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 7 of the present invention);

[0078] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 8 of the present invention);

[0079] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(methylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 9 of the present invention);

[0080] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 10 of the present invention);

[0081] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 11 of the present invention);

[0082] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxopyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 12 of the present invention);

[0083] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(isopropylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 13 of the present invention);

[0084] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 14 of the present invention);

[0085] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 15 of the present invention);

[0086] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 16 of the present invention);

[0087] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 17 of the present invention);

[0088] 1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 18 of the present invention);

[0089] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-6-carboxamidine (Compound 19 of the present invention);

[0090] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 20 of the present invention);

[0091] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 21 of the present invention);

[0092] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 22 of the present invention);

[0093] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 23 of the present invention);

[0094] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 24 of the present invention);

[0095] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 25 of the present invention);

[0096] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-4-yl]benzamide (Compound 26 of the present invention);

[0097] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamine)phosphino]oxypropionitrile (Compound 27 of the present invention);

[0098] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[(6-dimethylamino)pyrimidin-4-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 28 of the present invention);

[0099] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)oxypropionitrile (Compound 29 of the present invention);

[0100] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 30 of the present invention);

[0101] 3-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 31 of the present invention);

[0102] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 32 of the present invention);

[0103] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 33 of the present invention);

[0104] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 34 of the present invention);

[0105] N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine (Compound 35 of the present invention);

[0106] N-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 36 of the present invention);

[0107] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 37 of the present invention);

[0108] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 38 of the present invention);

[0109] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 39 of the present invention);

[0110] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 40 of the present invention);

[0111] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]dihydropyrimidin-2-one (Compound 41 of the present invention)

[0112] N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethylformamidine (compound 42 of the present invention);

[0113] N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide (compound 43 of the present invention); and

[0114] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide (compound 44 of the present invention).

[0115] (Oligonucleotide)

[0116]

[18] An oligonucleotide compound or a salt thereof, which has one or more nucleosides represented by the general formula (I'),

[0117] [Chemical formula 4]

[0118]

[0119] [Wherein,

[0120] B is a base portion of a nucleic acid that may be substituted with one or more substituents;

[0121] R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl;

[0122] m is 1 or 2;

[0123] X is a group represented by the following formula (II'-1), (II'-2), or (II'-3);

[0124] [Chemical formula 5]

[0125]

[0126] Symbols described in formula (II'-1), (II'-2), or (II'-3):

[0127] [Chemical formula 6]

[0128]

[0129] indicates the bonding site to the 2'-amino group;

[0130] A is an aromatic group which may be substituted with one or more substituents, wherein the aromatic group contains one or more heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom;

[0131] M is selected from C which may be substituted by one or more substituents 1-6 Sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.]

[0132] (Hereinafter, the compound represented by formula (I') or a salt thereof is referred to as "the oligonucleotide compound of the present invention").

[0133]

[19] The oligonucleotide compound or a salt thereof as described in

[18] , wherein B is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

[0134]

[20] The oligonucleotide compound or salt thereof according to

[18] or

[19] , wherein R1, R2, R3 and R4 are each independently a hydrogen atom;

[0135] m is 1.

[0136]

[21] (Urea type compounds)

[0137] The oligonucleotide compound or salt thereof according to any one of

[18] to

[20] , wherein X is a group represented by formula (II'-1); and

[0138] R7 and R8 are each independently a hydrogen atom, a C 1-6 An alkyl group or an aromatic group which may be substituted with one or more substituents.

[0139]

[22] The oligonucleotide compound or a salt thereof according to

[21] , wherein R7 and R8 are each independently a hydrogen atom, a C atom which may be substituted with one or more substituents, 1-3 alkyl.

[0140]

[23] The oligonucleotide compound or a salt thereof according to

[22] , wherein one of R7 and R8 is a hydrogen atom and the other is a methyl group.

[0141]

[24] The oligonucleotide compound or a salt thereof according to

[23] , wherein one of R7 and R8 is a hydrogen atom and the other is an isopropyl group.

[0142]

[25] (Aryl compounds)

[0143] The oligonucleotide compound or salt thereof according to any one of

[18] to

[20] , wherein X is a group represented by formula (II'-2); and

[0144] A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, and the heteroaryl group contains one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

[0145]

[26] The oligonucleotide compound or salt thereof according to

[25] , wherein A is a five-membered or six-membered heteroaryl group which may be substituted by one or more substituents, the heteroaryl group comprises two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, the two or three heteroatoms include at least two nitrogen atoms, and the substituents are each independently selected from a C group which may be substituted by one or more halogen atoms. 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A group consisting of an amino group substituted by an alkyl group.

[0146]

[27] The oligonucleotide compound or a salt thereof according to

[26] , wherein the five-membered or six-membered heteroaryl group is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, and pyrazinyl groups which may be substituted with one or more substituents.

[0147]

[28] The oligonucleotide compound or a salt thereof according to

[27] , wherein the triazole group which may be substituted with one or more substituents is 1,5-dimethyl-1,2,4-triazol-3-yl.

[0148]

[29] The oligonucleotide compound or a salt thereof according to

[27] , wherein the oxadiazolyl group which may be substituted with one or more substituents is 5-methyl-1,2,4-oxadiazol-3-yl.

[0149]

[30] The oligonucleotide compound or a salt thereof according to

[27] , wherein the thiadiazolyl group which may be substituted with one or more substituents is 3-methyl-1,2,4-thiadiazol-5-yl.

[0150]

[31] (Sulfonamide type compounds)

[0151] The oligonucleotide compound or salt thereof according to any one of

[18] to

[20] , wherein X is a group represented by formula (II'-3); and

[0152] M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

[0153]

[32] The compound or salt thereof according to any one of

[18] to

[31] , wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

[0154]

[33] The sulfurized oligonucleotide or a salt thereof according to any one of

[18] to

[32] , wherein at least one of the phosphate bonds between nucleotides is a phosphorothioate bond.

[0155] Effects of the Invention

[0156] The present invention can produce novel 2'-amino LNA (hereinafter referred to as ALNA) and oligomers containing these ALNA as monomers (hereinafter referred to as ALNA oligomers). The ALNA oligomers of the present invention have functional inhibitory activity of target microRNA and strong target gene knockdown activity in vitro. In addition, when administered to a living body, they have strong target gene knockdown activity in various organs (e.g., muscle, etc.), and therefore, can be expected to be used as novel nucleic acid drugs. DETAILED DESCRIPTION

[0157] The present invention will be described in further detail below. It should be noted that all publications cited in this specification are incorporated herein by reference.

[0158] (definition)

[0159] First, the terms used in this specification are defined.

[0160] In this specification, the term "C 1-6 Alkyl", including carbon atoms of 1 to 6 (C 1-6 ), preferably has 1 to 4 carbon atoms (C 1-4 ), more preferably 1 to 3 carbon atoms (C 1-3 ), any branched alkyl group having 3 to 6 carbon atoms and having the same or different branches, any cyclic alkyl group having 3 to 6 carbon atoms, and a combination thereof having 4 to 6 carbon atoms. For example, specific examples of any linear alkyl group having 1 to 6 carbon atoms include methyl, ethyl, n-(abbreviated as "n") propyl, iso-(abbreviated as "i") propyl, n-butyl, n-pentyl, and n-hexyl. Specific examples of any branched alkyl group having 3 to 6 carbon atoms and having the same or different branches include isopropyl, isobutyl, tert-(abbreviated as "t")-butyl, secondary (abbreviated as "s")-butyl, neopentyl, and isopentyl. Furthermore, as any cyclic alkyl group having 3 to 6 carbon atoms, a three- to six-membered monocyclic cycloalkyl group is preferred, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, but are not limited thereto. Examples of the substituent include a hydroxyl group, a halogen atom, a nitro group, a cyano group, a C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, aryl, aryloxy, may be substituted with one or more C 1-3 Alkyl-substituted amino, oxo, thio, and C 1-6 The same or different one or more (or preferably 1 to 3) groups in the group consisting of the alkyl group are preferably groups that are not affected by the reaction conditions of oligomerization.

[0161] In this specification, the term "C 1-3 "Alkyl" refers to the aforementioned term "C 1-6 The term "alkyl" refers to a methyl group, an ethyl group, a n-propyl group, or an isopropyl group which may be substituted with one or more halogen atoms. Specific examples thereof include perfluoroalkyl groups (e.g., trifluoromethyl, pentafluoroethyl, heptafluoropropyl) and the like.

[0162] In this specification, the term "C 2-6 Alkenyl", including carbon atoms of 2 to 6 (C 2-6 ), preferably has 2 to 4 carbon atoms (C 2-4 ), more preferably 2 to 3 carbon atoms (C 2-3 ), any straight-chain alkenyl group having 3 to 6 carbon atoms and having the same or different branches, any cyclic alkenyl group having 3 to 6 carbon atoms, and a combination thereof having 4 to 6 carbon atoms. For example, specific examples of any straight-chain alkenyl group having 2 to 6 carbon atoms include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, etc., and specific examples of any branched alkenyl group having 3 to 6 carbon atoms with the same or different branches include isopropenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 1-methyl-2-butenyl, etc., and any cyclic alkenyl group having 3 to 6 carbon atoms is preferably a three- to six-membered monocyclic cycloalkenyl group, and specific examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, etc., but are not limited thereto. Examples of substituents include a group selected from hydroxyl, a halogen atom, a nitro group, a cyano group, a C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, aryl, aryloxy, may be substituted with one or more C 1-3 Alkyl-substituted amino, oxo, thio, and C 1-6 The same or different one or more (or preferably 1 to 3) groups in the group consisting of the alkyl group are preferably groups that are not affected by the reaction conditions of oligomerization.

[0163] In this specification, the term "C 2-6 Alkynyl", including carbon atoms of 2 to 6 (C 2-6 ), preferably has 2 to 4 carbon atoms (C 2-4 ), more preferably 2 to 3 carbon atoms (C 2-3), any straight-chain alkynyl group having 3 to 6 carbon atoms and having the same or different branches, any cyclic alkynyl group having 3 to 6 carbon atoms, and a combination thereof having 4 to 6 carbon atoms. For example, specific examples of any straight-chain alkynyl group having 2 to 6 carbon atoms include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl and the like. Specific examples of any branched-chain alkynyl group having 3 to 6 carbon atoms and having the same or different branches include isopropynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl, 2-methyl-1-propynyl, 2-methyl-2-propynyl, 1-methyl-2-butynyl and the like. Furthermore, any cyclic alkynyl group having 3 to 6 carbon atoms is preferably a three- to six-membered monocyclic cycloalkynyl group, and specific examples thereof include cyclobutynyl, cyclopentynyl, cyclohexynyl and the like, but are not limited thereto. Examples of the substituent include a hydroxyl group, a halogen atom, a nitro group, a cyano group, a C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, aryl, aryloxy, may be substituted with one or more C 1-3 Alkyl-substituted amino, oxo, thio, and C 1-6 The same or different one or more (or preferably 1 to 3) groups in the group consisting of the alkyl group are preferably groups that are not affected by the reaction conditions of oligomerization.

[0164] In this specification, the term "aromatic group which may be substituted with one or more substituents" means both aryl and heteroaryl. The aryl and heteroaryl groups may be substituted with one or more substituents. Examples of substituents include hydroxyl, halogen, nitro, cyano, C 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, hydroxyl, C 1-6 Alkoxy, aryloxy, may be substituted with one or more C 1-3 Alkyl-substituted amino, C 1-6 The same or different one or more (or preferably 1 to 3) groups in the group consisting of an alkyl group and an aryl group, preferably C 1-6 Alkyl, may be replaced by one or more C 1-3 More preferably, the alkyl-substituted amino group and the halogen atom include a trifluoromethyl group, a dimethylamino group, and a chlorine atom, etc. The group is preferably a group that is not affected by the reaction conditions of oligomerization.

[0165] In this specification, the term "aryl" refers to a functional group or substituent derived from an aromatic hydrocarbon, and also includes an aryl group formed by multiple rings. Specifically, it refers to a monovalent group having 6 to 14 carbon atoms formed by one or more five-membered rings and / or six-membered rings obtained by removing one hydrogen atom from an aromatic hydrocarbon group. Preferably, a five-membered ring or six-membered ring aryl group can be cited. Specific examples of aryl groups include phenyl, indenyl, naphthyl, phenanthrenyl, anthracenyl, etc. In addition, examples of substituents of aryl groups include a hydroxyl group, a halogen atom, a nitro group, a cyano group, a C 2-hydroxyl group which may be substituted by one or more substituents, and a cyclopentyl group. 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, C 1-6 Alkoxy, aryloxy, amino, may be substituted with one or more C 1-3 The same or different one or more (or preferably 1 to 3) groups in the group consisting of an alkyl-substituted amino group and an aryl group, preferably C 1-6 Alkyl, may be replaced by one or more C 1-3 More preferably, the alkyl-substituted amino group and the halogen atom include a trifluoromethyl group, a dimethylamino group, and a chlorine atom, and a group which is not affected by the reaction conditions of oligomerization is preferred.

[0166] Specific examples of the aryl group which may be substituted with one or more substituents include 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 2,4-dimethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 4-methoxyphenyl, 4-chloro-2-nitrophenyl, 4-nitrophenyl, 2-nitrophenyl, 2,4-dinitrophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-dimethylaminophenyl, 3-dimethylaminophenyl, 4-dimethylaminophenyl, and biphenyl.

[0167] In the present specification, the term "heteroaryl" refers to a monovalent group obtained by removing one hydrogen atom from any heteroaromatic compound having 5 to 12 carbon atoms and formed by one or more five-membered rings and / or six-membered rings, which contains one or more heteroatoms (e.g., nitrogen atoms, oxygen atoms, and / or sulfur atoms) in the ring structure, and preferably a five-membered or six-membered heteroaryl. Specific examples of heteroaryl include a five-membered heteroaryl selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, or thiadiazolyl; and a six-membered heteroaryl selected from pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl, preferably a triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, or pyrazinyl. Examples of the substituent of the heteroaryl group include a hydroxyl group, a halogen atom, a nitro group, a cyano group, a C 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, C 1-6 Alkoxy, aryloxy, amino, may be substituted with one or more C 1-3 The same or different one or more (or preferably 1 to 3) groups in the group consisting of an alkyl-substituted amino group and an aryl group, preferably C 1-6 Alkyl, may be replaced by one or more C 1-3 More preferably, the alkyl-substituted amino group and the halogen atom include a trifluoromethyl group, a dimethylamino group, and a chlorine atom, and a group that is not affected by the reaction conditions of oligomerization is preferred.

[0168] Specific examples of the heteroaryl group which may be substituted with one or more substituents include 1,2,4-triazolyl, 1,5-dimethyl-1,2,4-triazolyl, 1,2,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazol-3-yl, 1,2,4-thiadiazolyl, 3-methyl-1,2,4-thiadiazol-5-yl, 1,3-pyrimidinyl, 1,5-pyrimidinyl, 4-trifluoromethyl-1,5-pyrimidinyl, 4-dimethylamino-2,4-pyrimidinyl, 3-dimethylamino-2,4-pyrimidinyl, 3-chloro-1,5-pyrimidinyl, and 1,4-pyridazine. The group preferably includes 1,5-dimethyl-1,2,4-triazol-3-yl, 1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-thiadiazol-5-yl, 1,5-pyrimidinyl, 4-trifluoromethyl-1,5-pyrimidinyl, 4-dimethylamino-2,4-pyrimidinyl, 3-dimethylamino-2,4-pyrimidinyl, 3-chloro-1,5-pyrimidinyl and 1,4-pyridazinyl, and more preferably includes 1,5-dimethyl-1,2,4-triazol-3-yl, 1,2,4-oxadiazol-3-yl and 3-methyl-1,2,4-thiadiazol-5-yl.

[0169] In the present specification, the term "a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents and contains one or more hetero atoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms" includes a five-membered or six-membered heteroaryl group defined as the above term "heteroaryl group" which may be substituted with one or more substituents.

[0170] In the present specification, the term "a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents and comprises two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, including at least two nitrogen atoms" refers to a triazolyl group, an oxadiazolyl group, a thiadiazolyl group, a pyrimidinyl group, a pyridazinyl group and the like which are defined as the aforementioned term "heteroaryl group" and may be substituted with one or more substituents.

[0171] In this specification, the term "a C 1-6 The term "sulfonyl group substituted with one substituent in the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents" refers to a sulfonyl (S(O)2) group substituted with the one substituent. 1-6 The alkyl group or the aromatic group which may be substituted with one or more substituents is the same as defined above. Specific examples of the substituent include methyl, trifluoromethyl, phenyl, and 4-methylphenyl, and preferably methyl and phenyl.

[0172] In this specification, the term "C 1-6 "Alkoxy" refers to C 1-6A monovalent group formed by bonding an alkyl group to an oxygen atom is a C 1-6 Alkyl-O group: Specific examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, and 3-methylbutoxy, but are not limited thereto.

[0173] In the present specification, the term "aryloxy group" refers to a monovalent group in which an aryl group is bonded to an oxygen atom. Specific examples thereof include a phenoxy group and a p-tolyloxy group, but the group is not limited thereto.

[0174] In this specification, the term "can be used by one or more C 1-3 The term "alkyl-substituted amino group" refers to an amino group in which one or more hydrogen atoms on the amino group may be substituted by a C1-3 alkyl group. Specific examples include, but are not limited to, methylamino, ethylamino, isopropylamino, dimethylamino, diethylamino, and methylethylamino.

[0175] In the present specification, the term "halogen (atom)" includes, for example, a fluorine atom (F), a chlorine atom (Cl), a bromine atom (Br), or an iodine atom (I), and a fluorine atom or a chlorine atom is preferred.

[0176] In this specification, when there is a functional group (e.g., hydroxyl, amino, carboxyl, etc.) in the compound of the present invention, intermediate compound, raw material compound, etc., it can be protected with a protecting group commonly used in organic synthetic chemistry according to the method described in Theodora W. Greene, Peter GM Wuts, "Protective Groups in Organic Synthesis" 4th. ed., John Wiley & Sons, Inc., 1999, and after the reaction, the protecting group is removed to obtain the target compound. As the protecting group, the protecting group commonly used in organic synthetic chemistry described in the book can be cited, and the protecting group of each functional group is described below.

[0177] In this specification, the term "protecting group" as used herein in "protecting group for hydroxyl group", "protecting group for amino group", "protecting group for phosphate group" and "protecting group for thiol group" is not particularly limited, as long as it is a protecting group that can stably protect the amino group, hydroxyl group, phosphate group or thiol group during nucleic acid synthesis. Specifically, it refers to a protecting group that is stable under acidic or neutral conditions and can be cleaved by chemical methods such as hydrogenolysis, hydrolysis, electrolysis and photolysis. Examples of such protecting groups include alkyl groups having 1 to 6 carbon atoms; alkenyl groups having 2 to 6 carbon atoms; alkynyl groups having 2 to 6 carbon atoms; acyl groups; tetrahydropyranyl groups or tetrahydrothiopyranyl groups; tetrahydrofuranyl groups or tetrahydrothiofuranyl groups; silyl groups; methyl groups substituted by alkoxy groups having 1 to 6 carbon atoms; methyl groups substituted by alkoxy groups having 1 to 6 carbon atoms substituted by alkoxy groups having 1 to 6 carbon atoms; methyl groups substituted by alkoxy groups having 1 to 6 carbon atoms substituted by halogen atoms; ethyl groups substituted by alkoxy groups having 1 to 6 carbon atoms; ethyl groups substituted by halogen atoms; methyl groups substituted by 1 to 3 aryl groups; alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, methyl substituted by 1 to 3 aryl groups substituted by halogen atoms and / or cyano groups; carbonyl substituted by alkoxy having 1 to 6 carbon atoms; aryl substituted by halogen atoms, alkoxy having 1 to 6 carbon atoms and / or nitro groups; carbonyl substituted by alkoxy having 1 to 6 carbon atoms and silyl substituted by halogen atoms and / or 3 alkyl having 1 to 6 carbon atoms; alkenyloxycarbonyl; aralkyloxycarbonyl substituted by aryl which may be substituted by alkoxy having 1 to 6 carbon atoms and / or nitro groups; and the like.

[0178] The "protecting group for a hydroxy group" refers to a protecting group commonly used in organic synthetic chemistry (especially nucleic acid synthesis), and examples thereof include an aliphatic acyl group; an aromatic acyl group; an aminocarbonyl group which may be substituted; an alkoxycarbonyl group which may be substituted; an aliphatic sulfonyl group; an aromatic sulfonyl group; a methyl group substituted by 1 to 3 aromatic groups; a methyl group substituted by an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogen atom and / or a cyano group; or a silyl group. Specific examples include benzyl (Bn), 4,4'-dimethoxytrityl (DMTr), 4-methoxytrityl, triphenylmethyl, 2-naphthylmethyl, diphenylaminocarbonyl (DPC), cyanoethoxycarbonyl, tetrahydropyranyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triphenylsilyl, 4-methoxybenzyl (p-methoxybenzyl), 3,4-dimethoxybenzyl, 2,6-dimethoxybenzyl, p-phenylbenzyl, methanesulfonyl, trifluoromethanesulfonyl, methoxymethyl, benzoyl (Bz), phenoxyacetyl, or acetyl, but are not limited to these. For example, benzyl (Bn), 4,4'-dimethoxytrityl (DMTr), tert-butyldimethylsilyl, tert-butyldiphenylsilyl, trimethylsilyl (TMS), diphenylaminocarbonyl (DPC), methanesulfonyl, and trifluoromethanesulfonyl are preferred, and 4,4'-dimethoxytrityl (DMTr) is more preferred.

[0179] In this specification, the term "a phosphate group which may be substituted" includes phosphoric acid, phosphorous acid, or hypophosphorous acid which may have a substituent (including a protecting group). For example, a phosphoric acid group having the formula -P(R P1 )R P2 Represents a phosphate group, where R P1 and R P2 Each independently represents a hydroxyl group, a hydroxyl group protected by a protecting group for nucleic acid synthesis, a thiol group, a thiol group protected by a protecting group for nucleic acid synthesis, an amino group, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a cyanoalkoxy group having 1 to 6 carbon atoms, or an amino group substituted by an alkyl group having 1 to 6 carbon atoms. Here, in the above formula, R P1 OR P1a , and R P2 NR P2a The group that can be represented by is called a "phosphoramidite group" and is a preferred example. P1a , refers to an alkyl group having 1 to 5 carbon atoms or a cyanoalkyl group having 1 to 6 carbon atoms. P2a, represents an alkyl group having 1 to 6 carbon atoms. Specific examples of "phosphoramidite" include, but are not limited to, a group represented by the formula -P(O(CH2)2CN)(N(iPr)2) or a group represented by the formula -P(OCH3)(N(iPr)2). Preferably, the group represented by the formula -P(O(CH2)2CN)(N(iPr)2) is used. Here, iPr represents an isopropyl group.

[0180] In this specification, the term "phosphoric acid group which may be substituted" may form a chiral auxiliary containing phosphorus. Specific examples of chiral auxiliary containing phosphorus include optically active bicyclic oxazaphospholysine described in non-patent document N. Oka et al., J. AM. CHEM. SOC. 2008, 130, 16031, optically active 2-sulfenyl-1,3,2-oxathiaphosphorane containing a pentavalent phosphorus atom described in non-patent document KW Knouse et al., Science 10.1126 / science.aau3369 (2018), but are not limited thereto.

[0181] The term "amino protecting group" refers to a protecting group commonly used in organic synthetic chemistry (especially nucleic acid synthesis), and includes, for example, an aliphatic acyl group; an aromatic acyl group; an alkoxycarbonyl group which may be substituted; a methyl group substituted by 1 to 3 aromatic groups; and a methyl group substituted by 1 to 3 aromatic groups which are substituted by a halogen atom and / or a cyano group. Specific examples include acetyl (Ac), phenoxyacetyl (Pac), tert-butylphenoxyacetyl (Tac), p-isopropylphenoxyacetyl (iPr-Pac), trifluoroacetyl, propionyl, isobutyryl, benzoyl (Bz), methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl (Boc), trimethylsilylethoxycarbonyl (Teoc), cyanoethoxycarbonyl (Ceoc), benzyloxycarbonyl (Cbz), allyloxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc), dimethylaminomethylene, 2,2,2-trichloroethoxycarbonyl, tert-amyloxycarbonyl, 4-methoxybenzyl, triphenylmethyl, 2-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl, and 2-(trimethylsilyl)ethoxymethyl. For example, isobutyryl, benzoyl (Bz), tert-butoxycarbonyl (Boc), and trimethylsilylethoxycarbonyl (Teoc) are preferred.

[0182] The "protecting group for a phosphate group" refers to a protecting group commonly used in organic synthetic chemistry (especially nucleic acid synthesis), and examples thereof include, but are not limited to, an alkyl group having 1 to 6 carbon atoms and / or an alkyl group having 1 to 6 carbon atoms substituted with a cyano group; an aralkyl group; an aralkyl group substituted with a nitro group and / or an aryl group substituted with a halogen atom; an aryl group substituted with an alkyl group having 1 to 6 carbon atoms, a halogen atom, or a nitro group; a 2-cyanoethyl group; a 2,2,2-trichloroethyl group; a benzyl group; a 2-chlorophenyl group; or a 4-chlorophenyl group.

[0183] The "protecting group for mercapto group" refers to a protecting group commonly used in organic synthetic chemistry (especially nucleic acid synthesis), and examples thereof include, but are not limited to, aliphatic acyl groups, aromatic acyl groups, and benzoyl (Bz).

[0184] In the present specification, the term "leaving group" refers to a part of the substrate molecule having an electron pair when it is cut off by cleavage based on heterolysis during the reaction, for example, a halogen atom (for example, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom), a "leaving group of a hydroxyl group". Examples of the leaving group of a hydroxyl group include a sulfonyloxy group (for example, a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, etc.), an acyloxy group (preferably a saturated or unsaturated acyloxy group having 1 to 8 carbon atoms, for example, a hydroxyl group having 1 to 8 carbon atoms, such as a hydroxyl group having 1 to 8 carbon atoms, ... L -C(=O)-O- means that R LThe group represented by an aryl group which may be substituted by an alkyl group (preferably having a total carbon number of 6 to 8, such as phenyl, p-tolyl, etc.), an aryloxy group which may be substituted by an alkyl group (preferably having a total carbon number of 6 to 8, such as phenoxy, p-tolyloxy, etc.), an aralkyl group (preferably having a total carbon number of 7 to 9, such as benzyl, etc.), an arylalkenyl group (preferably having a total carbon number of 8 or 9, such as cinnamyl, etc.), an aralkyloxy group (having a total carbon number of 7 to 15, such as benzyloxy, 9-fluorenylmethyloxy, etc.), an alkoxy group (a linear or branched alkoxy group having a carbon number of 1 to 8, such as methoxy, ethoxy, tert-butoxy, etc.), as a group having Examples of the leaving group include, but are not limited to, iodine, bromine, chlorine, fluorine, methanesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, ethanesulfonyloxy, 2,2,2-trifluoro-ethanesulfonyloxy, propanesulfonyloxy, isopropylsulfonyloxy, butanesulfonyloxy, nonafluorobutanesulfonyloxy, heptafluoropropane-1-sulfonyloxy, pentanesulfonyloxy, pentafluoroethanesulfonyloxy, pentanesulfonyloxy, cyclopentanesulfonyloxy, hexanesulfonyloxy, cyclohexanesulfonyloxy, o-toluenesulfonyloxy, m-toluenesulfonyloxy, p-toluenesulfonyloxy, benzenesulfonyloxy, o-bromobenzenesulfonyloxy, m-bromobenzenesulfonyloxy, p-bromobenzenesulfonyloxy, o-nitrobenzenesulfonyloxy, m-nitrobenzenesulfonyloxy, and p-nitrobenzenesulfonyloxy. Examples of preferred leaving groups include, but are not limited to, methanesulfonyloxy (methylsulfonyloxy; Ms-O-), trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy.

[0185] In the present specification, examples of the term "acyl group" include aliphatic acyl groups and aromatic acyl groups. Specifically, examples of aliphatic acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, valeryl, isovaleryl, octanoyl, nonanoyl, decanoyl, 3-methylnonanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, 1-methylpentadecanoyl, 14-methylpentadecanoyl, 13,13-dimethyltetradecanoyl, heptadecanoyl, 15-methylhexadecanoyl, decanoyl, 1-methylhexadecano ... Alkylcarbonyl groups such as octadecanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl and heneicosanoyl; aryloxyalkylcarbonyl groups such as phenoxyacetyl (Pac); carboxylated alkylcarbonyl groups such as succinyl, glutaryl and adipoyl; carbonyl groups substituted with an alkyl group having 1 to 6 carbon atoms substituted with a halogen atom such as chloroacetyl, dichloroacetyl, trichloroacetyl and trifluoroacetyl; alkoxyalkylcarbonyl groups having 1 to 6 carbon atoms such as methoxyacetyl; and unsaturated alkylcarbonyl groups such as (E)-2-methyl-2-butenoyl. In addition, examples of aromatic acyl groups include arylcarbonyl groups such as benzoyl, α-naphthoyl, and β-naphthoyl; halogenated arylcarbonyl groups such as 2-bromobenzoyl and 4-chlorobenzoyl; arylcarbonyl groups substituted with an alkyl group having 1 to 6 carbon atoms such as 2,4,6-trimethylbenzoyl and 4-toluoyl; arylcarbonyl groups substituted with an alkoxy group having 1 to 6 carbon atoms such as 4-anisyl; carboxylated arylcarbonyl groups such as 2-carboxybenzoyl, 3-carboxybenzoyl, and 4-carboxybenzoyl; nitrated arylcarbonyl groups such as 4-nitrobenzoyl and 2-nitrobenzoyl; carbonylated arylcarbonyl groups substituted with an alkoxy group having 1 to 6 carbon atoms such as 2-(methoxycarbonyl)benzoyl; and arylated arylcarbonyl groups such as 4-phenylbenzoyl.

[0186] In the present specification, the term "aralkyl" refers to an alkyl group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, and more preferably 1 to 3 carbon atoms, which is substituted with an aromatic hydrocarbon group (for example, a 6- to 14-membered monocyclic, bicyclic or tricyclic aromatic hydrocarbon group). Specific examples include, but are not limited to, benzyl, phenethyl, 1-naphthylmethyl, and 2-naphthylmethyl.

[0187] In the present specification, examples of the term "silyl group" include, but are not limited to, silyl groups substituted with an alkyl group having 1 to 6 carbon atoms, such as trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-tert-butylsilyl, and triisopropylsilyl; silyl groups substituted with three alkyl groups having 1 to 6 carbon atoms, such as tert-butyldiphenylsilyl, diphenylmethylsilyl, butyldiphenylbutylsilyl, diphenylisopropylsilyl, and phenyldiisopropylsilyl; and triphenylsilyl.

[0188] In the present specification, the term "β-form" refers to a substance having a stereochemical structure in which the direction of substitution of the base part of the nucleic acid substituted at the 1' position of the ribose site of the nucleic acid is substituted in the same direction as the direction of substitution of the 5' side chain substituted at the 4' position of the ribose of the nucleic acid. In the case of a bridged artificial nucleic acid 2',4'-LNA, it refers to a compound having a configuration in which the direction of substitution of the base part of the nucleic acid substituted at the 1' position of the ribose site of the nucleic acid is substituted in the same direction as the direction of substitution of the 5' side chain substituted at the 4' position of the ribose of the nucleic acid that is not used for bridging.

[0189] In this specification, the term "β selectivity" means that the β form can be selectively obtained.

[0190] In this specification, the term "nucleic acid base portion" in the "nucleic acid base portion that can be substituted with one or more substituents" includes wild-type nucleic acid base portions and non-wild-type nucleic acid base portions, including aromatic heterocyclic groups, such as monocyclic groups, bicyclic groups, tricyclic groups, etc. Those skilled in the art should understand that the base portions of various nucleic acids that were previously considered to be "non-wild" were later found to exist in the wild. Therefore, the so-called "nucleic acid base" includes not only the known purine and pyrimidine heterocycles, but also their heterocyclic analogs and tautomers. Specific examples of the base portion of nucleic acids include adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N 6 -methyladenine, 7-deazaxanthine, 7-deazaguanine, N 4 ,N 4 -Ethylenediylcytosine, N 6 ,N 6 -Ethylidene-2,6-diaminopurine, 5-methylcytosine, 5-(C 3 ~C 6 )-alkynylcytosine, 5-fluorocytosine, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, inosine, N 6 -allylpurine, N6 -Acylpurine, N 6 -Benzylpurine, N 6 -Halogen purine, N 6 -vinylpurine, N 6 -acetylene purine, N 6 -Acylpurine, N 6 -Hydroxyalkylpurine, N 6 -Sulphoalkylpurine, N 2 -Alkyl purine, N 4 -Alkylpyrimidine, N 4 -Acylpyrimidine, N 4 -Benzylpurine, N 4 -Halogen pyrimidine, N 4 -vinylpyrimidine, N 4 -Ethylene pyrimidine, N 4 -acetylpyrimidine, N 4 -Hydroxyalkylpyrimidine, N 6 -thioalkylpyrimidine, 6-azapyrimidine, 6-azacytosine, 2- and / or 4-mercaptopyrimidine, uracil, C 5 -Alkylpyrimidine, C 5 -Benzylpyrimidine, C 5 -Halogen pyrimidine, C 5 -vinylpyrimidine, C 5 -Ethylene pyrimidine, C 5 -Acylpyrimidine, C 5 -Hydroxyalkylpurine, C 5 -amidopyrimidine, C 5 -Cyanopyrimidine, C 5 -Nitropyrimidine, C 5 -aminopyrimidine, N 2 -Alkyl purine, N 2 -alkyl-6-thiopurine, 5-cytidine, 5-azauracil, triazolopyridinyl, imidazopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl, but not limited to these. As the preferred base part of the nucleic acid, for example, adenine, guanine, 2,6-diaminopurine, thymine, 2-thiothymine, cytosine, 5-methylcytosine, uracil, 5-fluorocytosine, xanthine, 6-aminopurine, 2-aminopurine, 6-chloro-2-amino-purine, and 6-chloropurine can be mentioned. As the particularly preferred nucleic acid base part, for example, adenine, guanine, cytosine, 5-methylcytosine, thymine or uracil can be mentioned. The base part of these nucleic acids can be substituted with one or more substituents, and as the substituent, hydroxyl, C 1-6 Alkoxy, thiol, C 1-6 Alkylthio, amino, C 1-6 Alkyl-substituted amino, C 1-6Alkyl, C 1-6 The alkynyl and, oxo, thio, halogen atoms of the base moiety. As required or as desired, the functional oxygen, sulfur and nitrogen groups on the base moiety can be protected and / or deprotected. As for suitable protecting groups, it is well known to those skilled in the art, for example, including the aforementioned protecting groups of hydroxyl groups and protecting groups of amino groups, diphenylaminocarbonyl, silyl (for example, trimethylsilyl, dimethylhexylsilyl, tert-butyldimethylsilyl and tert-butyldiphenylsilyl), trityl, alkyl, acyl (for example, acetyl, propionyl, isobutyryl, benzoyl (Bz), phenoxyacetyl (Pac)), alkoxycarbonyl (for example, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), diphenylaminocarbonyl (DPC), cyanoethoxycarbonyl (Ceoc)), sulfonyl (for example, methylsulfonyl and p-toluenesulfonyl), dimethylaminomethylene etc. can be cited, but are not limited to these.

[0191] In this specification, the term "artificial nucleic acid" includes artificial nucleosides, artificial nucleotides (in this specification, one nucleoside or nucleotide is sometimes described as a monomer.), or artificial oligonucleotides. These artificial nucleic acids are not wild nucleic acids, and are nucleic acids that can only be artificially produced. Among these artificial nucleic acids, there can be cited artificial nucleic acids with non-wild bases in the nucleic acid base part, artificial nucleic acids with modified sugars in the sugar part, and / or artificial nucleic acids with non-wild phosphate groups in the phosphate part, but in the present invention, it refers to artificial nucleic acids with non-wild sugars in the sugar part, especially artificial nucleic acids with (deoxy) ribose bridged by carbon atoms at the 2' and 4' positions.

[0192] In this specification, the term "artificial oligonucleotide" refers to a product formed by bonding two or more identical or different "artificial nucleotides" with a phosphodiester bond, a thiophosphodiester bond, etc., preferably 2 to 100, more preferably 5 to 50, and most preferably 10 to 30 artificial nucleotides, or a product obtained by forming a double strand with their complementary strands. In this specification, an oligonucleotide formed by bonding two or more nucleotides is sometimes described as an oligomer.

[0193] Embodiments of the compounds of the present invention are described.

[0194] Compounds represented by general formula I

[0195] According to one method,

[0196] Provided is a compound represented by general formula (I) or a salt thereof.

[0197] [Chemical formula 7]

[0198]

[0199] [Wherein,

[0200] B is a base portion of a nucleic acid that may be substituted with one or more substituents;

[0201] R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl;

[0202] R5 and R6 are each independently a hydrogen atom, a protective group for a hydroxyl group, or a phosphate group which may be substituted;

[0203] m is 1 or 2;

[0204] X is a group represented by the following formula (II-1), (II-2), or (II-3);

[0205] [Chemical formula 8]

[0206]

[0207] Symbols described in formula (II-1), (II-2), or (II-3):

[0208] [Chemical formula 9]

[0209]

[0210] indicates the bonding site to the 2'-amino group;

[0211] R7 and R8 are each independently a hydrogen atom, a C 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, or an aromatic group which may be substituted with one or more substituents;

[0212] A is an aromatic group;

[0213] M is selected from C which may be substituted by one or more substituents 1-6 Sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.]

[0214] In one embodiment, the compound represented by the general formula (I) or a salt thereof is preferably a compound represented by the general formula Ia or a salt thereof,

[0215] [Chemical formula 10]

[0216]

[0217] (Wherein, R1, R2, R3, R4, R5, R6, B, X and m have the same meanings as in the general formula (I).)

[0218] In one embodiment, a compound represented by formula (I) or a salt thereof is provided, wherein ring B in formula (I) is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

[0219] In one embodiment, provided is a compound represented by formula (I) or a salt thereof, wherein ring B in formula (I) is 5-methylcytosyl which may have one or more protecting groups or 5-uracilyl which may have one or more protecting groups.

[0220] In one embodiment, provided is a compound represented by formula (I) or a salt thereof, wherein R1, R2, R3 and R4 in formula (I) are each independently a hydrogen atom, and m is 1.

[0221] In one embodiment, a compound represented by formula (I) or a salt thereof is provided, wherein R6 in formula (I) is a hydrogen atom or a DMTr group, and R5 is a hydrogen atom or -P(O(CH2)2CN)(N(iPr)2).

[0222] In one embodiment, a compound represented by formula (I) or a salt thereof is provided, wherein R6 in formula (I) is a DMTr group and R5 is -P(O(CH2)2CN)(N(iPr)2).

[0223] It is mainly classified into one embodiment described as formula (II-1), (II-2), or (II-3) and used.

[0224] First, there can be mentioned compounds in which X in the formula (I) is a group represented by the formula (II-1) (hereinafter, in the present specification, sometimes also referred to as “urea-type compounds”).

[0225] In one embodiment, X is a group represented by formula (II-1); and,

[0226] R7 and R8 are each independently a hydrogen atom, a C 1-6 An alkyl group or an aromatic group which may be substituted with one or more substituents, a compound represented by formula (I) or a salt thereof.

[0227] In one embodiment, X is a group represented by formula (II-1); and,

[0228] R7 and R8 are each independently a hydrogen atom, a C 1-3An alkyl group or an aromatic group which may be substituted with one or more substituents, a compound represented by formula (I) or a salt thereof.

[0229] In one embodiment, X is a group represented by formula (II-1); and,

[0230] R7 and R8 are each independently a hydrogen atom, a methyl group, an isopropyl group, or a phenyl group, and the compound represented by the formula (I) or a salt thereof.

[0231] In one embodiment, X is a group represented by formula (II-1); and,

[0232] The combination of R7 and R8 is a combination in which both R7 and R8 are hydrogen atoms, a combination in which both R7 and R8 are methyl groups, a combination in which R7 is a hydrogen atom and R8 is a methyl group, a combination in which R7 is a hydrogen atom and R8 is an isopropyl group, or a combination in which R7 is a hydrogen atom and R8 is a phenyl group, and is a compound represented by formula (I) or a salt thereof.

[0233] In one embodiment, X is a group represented by formula (II-1); and,

[0234] The combination of R7 and R8 is a combination in which both R7 and R8 are hydrogen atoms, a combination in which both R7 and R8 are methyl groups, a combination in which one of R7 and R8 is a hydrogen atom and the other is a methyl group, a combination in which one of R7 and R8 is a hydrogen atom and the other is an isopropyl group, or a combination in which one of R7 and R8 is a hydrogen atom and the other is a phenyl group, and is a compound represented by formula (I) or a salt thereof.

[0235] In one embodiment, X is a group represented by formula (II-1); and,

[0236] A compound represented by formula (I) or a salt thereof, wherein one of R7 and R8 is a hydrogen atom and the other is a methyl group.

[0237] In one embodiment, X is a group represented by formula (II-1); and,

[0238] A compound represented by formula (I) or a salt thereof, wherein one of R7 and R8 is a hydrogen atom and the other is an isopropyl group.

[0239] In addition, there can be mentioned compounds in which X in the formula (I) is a group represented by the formula (II-2) (hereinafter, in the present specification, sometimes also referred to as a "heteroaryl compound").

[0240] In one embodiment, X is a group represented by formula (II-2); and,

[0241] A is a compound represented by formula (I) or a salt thereof, wherein A is a heteroaryl group having a five-membered or six-membered ring and containing one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, which may be substituted with one or more substituents.

[0242] In one embodiment, X is a group represented by formula (II-2); and,

[0243] A is a compound represented by formula (I) or a salt thereof, wherein A is a heteroaryl group which may be substituted with one or more substituents and contains a five-membered or six-membered ring of two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms including at least two nitrogen atoms.

[0244] In one embodiment, X is a group represented by formula (II-2); and,

[0245] A is a heteroaryl group which may be substituted with one or more substituents and which contains one or more heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, including at least two nitrogen atoms, and which is a five-membered or six-membered ring (the substituents are each independently selected from the group consisting of C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A compound represented by formula (I) or a salt thereof.

[0246] In one embodiment, X is a group represented by formula (II-2); and,

[0247] A is a heteroaryl group which may be substituted with one or more substituents and which contains one or more heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, including at least two nitrogen atoms, and which is a five-membered or six-membered ring (the substituents are each independently selected from the group consisting of C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A compound represented by formula (I) or a salt thereof.

[0248] In one embodiment, X is a group represented by formula (II-2); and,

[0249] The five-membered or six-membered heteroaryl group as A is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl and pyrazinyl groups which may be substituted with one or more substituents, and is a compound represented by formula (I) or a salt thereof.

[0250] In one embodiment, X is a group represented by formula (II-2); and,

[0251] A compound represented by formula (I) or a salt thereof, wherein the triazolyl group which may be substituted with one or more substituents as A is 1,5-dimethyl-1,2,4-triazol-3-yl.

[0252] In one embodiment, X is a group represented by formula (II-2); and,

[0253] The oxadiazolyl group which may be substituted with one or more substituents as A is a 5-methyl-1,2,4-oxadiazol-3-yl group, and a compound represented by the formula (I) or a salt thereof.

[0254] In one embodiment, X is a group represented by formula (II-2); and,

[0255] The compound represented by the formula (I) or a salt thereof, wherein the thiadiazolyl group which may be substituted with one or more substituents as A is 3-methyl-1,2,4-thiadiazol-5-yl.

[0256] In one embodiment, X is a group represented by formula (II-3); and,

[0257] M is selected from C which may be substituted by one or more substituents 1-6 A compound represented by formula (I) or a salt thereof, which is a sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

[0258] In one embodiment, X is a group represented by formula (II-3); and,

[0259] A compound represented by formula (I) or a salt thereof, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group which may be substituted with one or more substituents and a phenyl group which may be substituted with one or more substituents.

[0260] In one embodiment, X is a group represented by formula (II-3); and,

[0261] A compound represented by formula (I) or a salt thereof, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

[0262] In one embodiment, as specific examples of the compound represented by formula (I) or a salt thereof, one or more compounds selected from the group consisting of the following compounds or salts thereof are provided.

[0263] The following compounds:

[0264] 3-[[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-6-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-methylsulfonyl-5-oxa-2-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 1 of the present invention);

[0265] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 2 of the present invention);

[0266] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 3 of the present invention);

[0267] N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-purin-6-yl]benzamide (Compound 4 of the present invention);

[0268] 3-[[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (compound 5 of the present invention);

[0269] N-[1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino)oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 6 of the present invention);

[0270] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 7 of the present invention);

[0271] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 8 of the present invention);

[0272] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(methylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 9 of the present invention);

[0273] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 10 of the present invention);

[0274] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 11 of the present invention);

[0275] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxopyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 12 of the present invention);

[0276] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(isopropylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 13 of the present invention);

[0277] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 14 of the present invention);

[0278] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 15 of the present invention);

[0279] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 16 of the present invention);

[0280] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 17 of the present invention);

[0281] 1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 18 of the present invention);

[0282] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-6-carboxamidine (Compound 19 of the present invention);

[0283] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 20 of the present invention);

[0284] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 21 of the present invention);

[0285] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 22 of the present invention);

[0286] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 23 of the present invention);

[0287] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 24 of the present invention);

[0288] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 25 of the present invention);

[0289] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-4-yl]benzamide (Compound 26 of the present invention);

[0290] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamine)phosphino]oxypropionitrile (Compound 27 of the present invention);

[0291] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[(6-dimethylamino)pyrimidin-4-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 28 of the present invention);

[0292] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)oxypropionitrile (Compound 29 of the present invention);

[0293] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 30 of the present invention);

[0294] 3-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 31 of the present invention);

[0295] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 32 of the present invention);

[0296] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 33 of the present invention);

[0297] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 34 of the present invention);

[0298] N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine (Compound 35 of the present invention);

[0299] N-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 36 of the present invention);

[0300] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 37 of the present invention);

[0301] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 38 of the present invention);

[0302] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 39 of the present invention);

[0303] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (compound 40 of the present invention);

[0304] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]dihydropyrimidin-2-one (Compound 41 of the present invention)

[0305] N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethylformamidine (compound 42 of the present invention);

[0306] N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide (compound 43 of the present invention); and

[0307] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide (compound 44 of the present invention).

[0308] Oligonucleotides

[0309] Compounds represented by general formula (I')

[0310] According to one method,

[0311] Provided is an oligonucleotide having one or more nucleosides represented by general formula (I') or a salt thereof.

[0312] [Chemical formula 11]

[0313]

[0314] [Wherein,

[0315] B is a base portion of a nucleic acid that may be substituted with one or more substituents;

[0316] R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl;

[0317] m is 1 or 2;

[0318] X is a group represented by the following formula (II'-1), (II'-2), or (II'-3);

[0319] [Chemical formula 12]

[0320]

[0321] Symbols described in formula (II'-1), (II'-2), or (II'-3):

[0322] [Chemical formula 13]

[0323]

[0324] indicates the bonding site to the 2'-amino group;

[0325] A is an aromatic group which may be substituted with one or more substituents and contains one or more heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom;

[0326] M is selected from C which may be substituted by one or more substituents 1-6 Sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.]

[0327] In one embodiment, an oligonucleotide compound represented by formula (I') or a salt thereof is provided, wherein ring B in formula (I') is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

[0328] In one embodiment, an oligonucleotide compound represented by formula (I') or a salt thereof is provided, wherein ring B in formula (I') is 5-methylcytosine group which may have one or more protecting groups or 5-uracil group which may have one or more protecting groups.

[0329] In one embodiment, an oligonucleotide compound represented by formula (I') or a salt thereof is provided, wherein R1, R2, R3 and R4 in formula (I') are each independently a hydrogen atom, and m is 1.

[0330] In one embodiment, a sulfurized oligonucleotide compound represented by formula (I') or a salt thereof is provided, wherein at least one of the nucleotides in formula (I') is a phosphorothioate bond.

[0331] Examples include compounds in which X in the formula (I') is a group represented by the formula (II'-1) (hereinafter, in the present specification, sometimes also referred to as "urea-type compounds").

[0332] In one embodiment, there is provided a formula (I') in which X is a group represented by the formula (II'-1); and

[0333] R7 and R8 are each independently a hydrogen atom, a C 1-6 An oligonucleotide compound represented by formula (I') or a salt thereof, which is an alkyl group or an aromatic group which may be substituted with one or more substituents.

[0334] In one embodiment, X is a group represented by formula (II'-1); and,

[0335] R7 and R8 are each independently a hydrogen atom, a C 1-6 An oligonucleotide compound represented by formula (I') or a salt thereof, which is an alkyl group or an aromatic group which may be substituted with one or more substituents.

[0336] In one embodiment, X is a group represented by formula (II'-1); and,

[0337] R7 and R8 are each independently a hydrogen atom, a C 1-3 An oligonucleotide compound represented by formula (I') or a salt thereof, which is an alkyl group or an aromatic group which may be substituted with one or more substituents.

[0338] In one embodiment, X is a group represented by formula (II'-1); and,

[0339] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein R7 and R8 are each independently a hydrogen atom, a methyl group, an isopropyl group, or a phenyl group.

[0340] In one embodiment, X is a group represented by formula (II'-1); and,

[0341] The combination of R7 and R8 is a combination in which both R7 and R8 are hydrogen atoms, a combination in which both R7 and R8 are methyl groups, a combination in which R7 is a hydrogen atom and R8 is a methyl group, a combination in which R7 is a hydrogen atom and R8 is an isopropyl group, or a combination in which R7 is a hydrogen atom and R8 is a phenyl group, and is an oligonucleotide compound represented by formula (I') or a salt thereof.

[0342] In one embodiment, X is a group represented by formula (II'-1); and,

[0343] The combination of R7 and R8 is a combination in which both R7 and R8 are hydrogen atoms, a combination in which both R7 and R8 are methyl groups, a combination in which one of R7 and R8 is a hydrogen atom and the other is a methyl group, a combination in which one of R7 and R8 is a hydrogen atom and the other is an isopropyl group, or a combination in which one of R7 and R8 is a hydrogen atom and the other is a phenyl group, and is an oligonucleotide compound represented by formula (I') or a salt thereof.

[0344] In one embodiment, X is a group represented by formula (II'-1); and,

[0345] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein one of R7 and R8 is a hydrogen atom and the other is a methyl group.

[0346] In one embodiment, X is a group represented by formula (II'-1); and,

[0347] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein one of R7 and R8 is a hydrogen atom and the other is an isopropyl group.

[0348] In addition, there can be mentioned compounds in which X in the formula (I') is a group represented by the formula (II'-2) (hereinafter, in the present specification, sometimes also referred to as "heteroaryl-type compound").

[0349] In one embodiment, X is a group represented by formula (II'-2); and,

[0350] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein A is a heteroaryl group having a five-membered or six-membered ring and containing one or more heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, which may be substituted with one or more substituents.

[0351] In one embodiment, X is a group represented by formula (II'-2); and,

[0352] A is an oligonucleotide compound represented by formula (I') or a salt thereof, wherein A is a heteroaryl group containing a five-membered or six-membered ring of two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms and including at least two nitrogen atoms, which may be substituted with one or more substituents.

[0353] In one embodiment, X is a group represented by formula (II'-2); and,

[0354] A is a heteroaryl group which may be substituted with one or more substituents and which contains one or more heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, including at least two nitrogen atoms, and which is a five-membered or six-membered ring (the substituents are each independently selected from the group consisting of C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 An oligonucleotide compound represented by formula (I') or a salt thereof.

[0355] In one embodiment, X is a group represented by formula (II'-2); and,

[0356] A is a heteroaryl group which may be substituted with one or more substituents and which contains one or more heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, including at least two nitrogen atoms, and which is a five-membered or six-membered ring (the substituents are each independently selected from the group consisting of C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 An oligonucleotide compound represented by formula (I') or a salt thereof.

[0357] In one embodiment, X is a group represented by formula (II'-2); and,

[0358] The five-membered or six-membered heteroaryl group as A is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl and pyrazinyl groups which may be substituted with one or more substituents; and the oligonucleotide compound represented by formula (I') or a salt thereof.

[0359] In one embodiment, X is a group represented by formula (II'-2); and,

[0360] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein the triazole group which may be substituted with one or more substituents as A is 1,5-dimethyl-1,2,4-triazol-3-yl.

[0361] In one embodiment, X is a group represented by formula (II'-2); and,

[0362] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein the oxadiazolyl group which may be substituted with one or more substituents as A is 5-methyl-1,2,4-oxadiazol-3-yl.

[0363] In one embodiment, X is a group represented by formula (II'-2); and,

[0364] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein the thiadiazolyl group which may be substituted with one or more substituents as A is 3-methyl-1,2,4-thiadiazol-5-yl.

[0365] In one embodiment, X is a group represented by formula (II'-3); and,

[0366] M is selected from C which may be substituted by one or more substituents 1-6 An oligonucleotide compound represented by formula (I') or a salt thereof, which is a sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

[0367] In one embodiment, X is a group represented by formula (II'-3); and,

[0368] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group which may be substituted with one or more substituents and a phenyl group which may be substituted with one or more substituents.

[0369] In one embodiment, X is a group represented by formula (II'-3); and,

[0370] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

[0371] In one embodiment, X is a group represented by formula (II'-3); and,

[0372] An oligonucleotide compound represented by formula (I') or a salt thereof, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

[0373] In one embodiment, the oligonucleotide or a salt thereof is a product obtained by bonding two or more nucleotides, preferably an oligonucleotide or a salt thereof containing 2 to 100 nucleotides, more preferably an oligonucleotide or a salt thereof containing 5 to 50 nucleotides, and most preferably a product formed by bonding 10 to 30 artificial nucleotides, or a product formed by forming a double strand with their complementary strands.

[0374] In the present specification, the term "salt" in the term "salt of a compound" includes alkali metal salts such as sodium salts, potassium salts and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, metal salts such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts and cobalt salts; inorganic salts such as ammonium salts, tert-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucamine (glucamine) salts, guanidine salts, diethylamine salts, triethylamine salts, hexylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenethylamine salts, piperazine salts, tetrakisone ... Amine salts such as organic salts such as methylammonium salts and tris(hydroxymethyl)aminomethane salts; inorganic acid salts such as hydrohalides such as hydrofluorides, hydrochlorides, hydrobromides, and hydroiodides, nitrates, perchlorates, sulfates, and phosphates; organic acid salts such as alkanesulfonates having 1 to 6 carbon atoms such as methanesulfonates, trifluoromethanesulfonates, and ethanesulfonates, arylsulfonates such as benzenesulfonates and p-toluenesulfonates, acetates, malates, fumarates, succinates, citrates, tartrates, oxalates, and maleates; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates, and aspartates, but are not limited to these. Pharmacologically acceptable salts are included.

[0375] Each compound represented by the general formula (I) described in this specification includes enantiomers or diastereomers or mixtures thereof. For example, the configuration of the sugar part in the structure of each compound includes α-body and β-body, preferably β-body. When the compound represented by the general formula (I) is obtained in the form of diastereomers or enantiomers, they can be separated by conventional methods known in the field of organic synthesis (e.g., sugar synthesis), such as chromatography or separate crystallization. For example, the configuration of the sugar part of the compound 2Td represented by the following formula is β-body.

[0376] [Chemical formula 14]

[0377]

[0378] Each compound represented by the general formula I described in this specification includes isotopes (e.g., 3 H. 13 C. 14 C. 15 N. 18 F. 32 P. 35 S. 125 I, etc.) and deuterated transformants.

[0379] For the oligonucleotides and analogs thereof described in this specification, for example, they can be prepared into parenteral preparations or liposome preparations by combining with adjuvants commonly used in the technical field of drug preparations such as excipients, adhesives, preservatives, oxidation stabilizers, disintegrants, lubricants, and flavoring agents. In addition, for example, they can be prepared into topical preparations such as liquids, creams, and ointments by combining with pharmaceutical carriers commonly used in the technical field.

[0380] (Manufacturing method)

[0381] The following describes a method for producing the compound of the present invention.

[0382] It should be noted that, in each of the starting compounds and intermediate compounds described below, an optically active form having an absolute configuration can also be produced by using an optically active substance in the starting raw material or by separating the isomers produced in the middle stage of the synthesis. In addition, for the nucleic acid base exchange reaction of replacing the nucleic acid base described below, β-selective transglycosylation is efficiently carried out, and the compound represented by the general formula I obtained can selectively obtain the desired β-form.

[0383] The compound of the present invention or a pharmacologically acceptable salt thereof can be produced by the following methods, but is not limited thereto.

[0384] Unless a specific production method is described for the raw material compounds, commercially available products may be used, or the raw material compounds may be produced by a known method or a method based on the known method.

[0385] It should be noted that the abbreviations used in this specification have the following meanings.

[0386] THF: Tetrahydrofuran

[0387] DMSO: dimethyl sulfoxide

[0388] MsCl: Methanesulfonyl chloride

[0389] DMAP: N,N-dimethyl-4-aminopyridine

[0390] iPr2NEt, and DIPEA: N,N-diisopropylethylamine

[0391] BSA: N,O-bis(trimethylsilyl)acetamide

[0392] TMSOTf: trimethylsilyl trifluoromethanesulfonate

[0393] TBSOTf: tert-Butyldimethylsilyl trifluoromethanesulfonate

[0394] Bn: benzyl

[0395] TMS: trimethylsilyl

[0396] TBDPS: tert-butyldiphenylsilyl

[0397] Ac:Acetyl

[0398] MOE: Methoxyethyl

[0399] CH2Cl2: dichloromethane

[0400] MeCN: Acetonitrile

[0401] DMTr: 4,4'-dimethoxytrityl

[0402] First, the method for producing the compound (monomer) of the present invention will be described in outline.

[0403] (Sulfonamide system compounds)

[0404] The present invention discloses a method for producing a compound of the so-called sulfonamide system, wherein X in the general formula I is a group represented by the formula (II-3). A typical example of the production synthesis route is shown in the following reaction synthesis route 1, but the present invention is not limited thereto.

[0405] Reaction synthesis route 1

[0406] [Chemical formula 15]

[0407]

[0408] (Process 1)

[0409] As a starting material, a starting compound 1 which is a sugar compound (for example, it can be produced according to the production method described in International Publication No. 2017 / 047816) is used, and a protective group for a hydroxyl group is introduced as the R5 group in the general formula (I) by a known method to produce an intermediate compound 2. Alternatively, a nucleic acid base portion (represented by the abbreviation B) in the starting compound 1 is subjected to a nucleic acid base exchange reaction with another nucleic acid base portion (represented by the abbreviation B') that can be protected, and at the same time, a protective group for a hydroxyl group is introduced to produce an intermediate compound 2.

[0410] The introduction of the protective group of the hydroxyl group can be carried out under reaction conditions well known in organic synthetic chemistry (e.g., nucleic acid synthesis) according to the type of the protective group. For example, when the protective group of the hydroxyl group is a silyl type protective group (e.g., TMS), a silylating agent (e.g., BSA, hexamethyldisilazane, TMS chloride) can be used. At this time, a Lewis acid (e.g., TMSOTf, TBSOTf, tin chloride) can be added.

[0411] The silylating agent may be used in an amount of about 1 to about 20 molar equivalents, and the Lewis acid may be used in an amount of a catalytic amount (about 0.05 molar equivalent) to 2 molar equivalents relative to the reaction substrate.

[0412] As a solvent, any solvent that does not affect the reaction can be used, and the reaction can be carried out in an appropriate solvent (for example, ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbonized hydrogens such as benzene and toluene, acetonitrile, water, or a mixed solvent thereof). As for the reaction temperature, it is preferably carried out at 0°C to high temperature, especially room temperature to about 60°C.

[0413] In addition, by using a nucleic acid base exchange reaction (transglycosylation reaction), the pyrimidine base portion of a nucleic acid base such as thymine (T) and uracil (U) is replaced with another nucleic acid base portion that can be protected (for example, adenine (A), guanine (G), uracil (U), thymine (T), cytosine (C), or 5-methylcytosine ( Me C)), thereby producing an intermediate compound 2 in which the nucleic acid base is partially exchanged. The base exchange reaction can be carried out in the presence of a Lewis acid (eg, TMSOTf, TBSOTf), and the reaction can be accelerated by reacting a silylating agent.

[0414] (Process 2)

[0415] Next, using the intermediate compound 2 as a starting material, an alkylsulfonyl halide or an aromatic sulfonyl halide is reacted with the intermediate compound 2 by a known method, thereby sulfonamidating the imino nitrogen atom to produce the intermediate compound 3.

[0416] Examples of the sulfonamidation reagent that can be used in the sulfonamidation reaction include alkynylsulfonyl halide reagents (e.g., methanesulfonyl chloride (MsCl)), alkylsulfonic acid anhydrides (e.g., methanesulfonic acid anhydride), aromatic sulfonyl halide reagents (e.g., benzenesulfonyl chloride), or aromatic sulfonic acid anhydrides (e.g., benzenesulfonic acid anhydride), which can be used in the presence of a base (e.g., triethylamine, DIPEA).

[0417] The sulfonamidation reagent can be used in an approximately equivalent molar amount to a slightly excess molar amount (eg, about 1.0 molar equivalent) relative to the reaction substrate.

[0418] As a solvent, any solvent that does not affect the reaction can be used, and the reaction can be carried out in an appropriate solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbonized hydrogens such as benzene and toluene, acetonitrile, water, or a mixed solvent thereof). As for the reaction temperature, it is preferably carried out at -25°C to room temperature, especially at 0°C to room temperature.

[0419] (Process 3)

[0420] Next, the intermediate compound 4 is produced by deprotecting the protective group of the hydroxyl group introduced in step 1 using the intermediate compound 3 as a starting material by a known method.

[0421] The deprotection reaction can be carried out under appropriate reaction conditions (e.g., reagents, etc.) according to the type of the protecting group. PRO ) is a silyl type protecting group (eg, TMS), it can be carried out by hydrolysis under acidic conditions (eg, acetic acid-THF-water) or by treatment with a reagent providing fluoride ions (eg, TBAF).

[0422] The reaction can be carried out in any suitable solvent (e.g., ethers such as THF, halogenated hydrocarbons such as dichloromethane, water, or a mixed solvent thereof). The reaction temperature is preferably -25°C to 100°C, particularly 0°C to 50°C.

[0423] (Process 4)

[0424] Furthermore, the intermediate compound 4 is used as a starting material and phosphoramidite reaction is carried out under reaction conditions (eg, reagents) generally known in organic synthesis (especially nucleic acid synthesis) to produce the desired sulfonamide system compound of the present invention.

[0425] As the phosphoramidite reagent, for example, the following formula can be mentioned:

[0426] [Chemical formula 16]

[0427] and

[0428] The phosphoramidite reaction may be carried out in the presence of a suitable base (eg, DIPEA) or a suitable acid (eg, diisopropylammonium tetrazolium salt, 4,5-dicyanoimidazole).

[0429] The phosphoramidite reagent can be used in an amount of 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents (eg, 3 molar equivalents) relative to the reaction substrate.

[0430] The reaction can be carried out in any suitable solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, acetonitrile, or a mixed solvent thereof). The reaction temperature is preferably -25°C to 60°C, particularly 0°C to room temperature.

[0431] It should be noted that the substituent on the nucleobase ring may be appropriately modified (for example, benzoylation or acetylation of the amino substituent on the cytosine ring) at any stage between before the implementation of step 1 and after the implementation of step 4.

[0432] In addition, among the above-mentioned steps (1) to (4), a plurality of steps (for example, step (1) and step (2), and step (2) and step (3)) may be performed continuously.

[0433] (Urea system compounds)

[0434] The present invention discloses a method for producing a so-called urea system compound in which X in the general formula I is a group represented by the formula (II-1). A typical example of the production synthesis route is shown in the following reaction synthesis route 2, but the present invention is not limited thereto.

[0435] Reaction synthesis route 2

[0436] [Chemical formula 17]

[0437]

[0438] (Process 1)

[0439] Before the ureidation reaction based on a known method using the aforementioned starting compound 1 as a starting material, a nucleic acid base exchange reaction may be carried out with another nucleic acid base part (represented by the abbreviation B') that can be protected, similarly to step 1 of the aforementioned reaction synthetic route 1, for the nucleic acid base part (represented by the abbreviation B) in the starting compound 1, and then a ureidation reaction may be carried out. In addition, similarly to the aforementioned reaction synthetic route, the nucleic acid base exchange reaction may be carried out, and then a protective group for the hydroxyl group may be appropriately introduced.

[0440] For the nucleic acid base exchange reaction (transglycosylation reaction), the pyrimidine base part of a nucleic acid base such as thymine (T) and uracil (U) is replaced with another nucleic acid base part that can be protected (for example, adenine (A), guanine (G), uracil (U), thymine (T), cytosine (C), or 5-methylcytosine ( Me C)), thereby producing an intermediate compound 5 in which the nucleic acid base is partially exchanged. The base exchange reaction can be carried out in the presence of a Lewis acid (eg, TMSOTf, TBSOTf), and the reaction can be accelerated by reacting a silylating agent (eg, BSA).

[0441] In addition, the introduction of the protective group of the hydroxyl group can be carried out under reaction conditions well known in organic synthetic chemistry (e.g., nucleic acid synthesis) according to the type of the protective group. For example, when the protective group of the hydroxyl group is a silyl type protective group (e.g., TMS), a silylating agent (e.g., BSA, hexamethyldisilazane, TMS chloride) can be used. At this time, a Lewis acid (e.g., TMSOTf, TBSOTf, tin chloride) can be added.

[0442] The silylating agent may be used in an amount of about 1 to about 20 molar equivalents relative to the reaction substrate, and the Lewis acid may be used in an amount of a catalytic amount (about 0.05 molar equivalent) to 2 molar equivalents.

[0443] As a solvent, any solvent that does not affect the reaction can be used, and the reaction can be carried out in an appropriate solvent (for example, ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbonized hydrogens such as benzene and toluene, acetonitrile, water, or a mixed solvent thereof). As for the reaction temperature, it is preferably carried out at 0°C to high temperature, especially room temperature to about 60°C.

[0444] (Process 2)

[0445] Next, starting compound 1 or intermediate compound 5 is used as a starting material and a ureidating agent is reacted with starting compound 1 or intermediate compound 5 by a known method, thereby ureidating the imino nitrogen atom to produce intermediate compound 6.

[0446] Examples of the ureidation reagent that can be used in the ureidation reaction include isocyanates, N-alkylcarbamoyl halide reagents (e.g., N-methylcarbamoyl chloride) or N,N-dialkylcarbamoyl halide reagents (e.g., N,N-dimethylcarbamoyl chloride), and they can be used in the presence or absence of a base (e.g., DIPEA).

[0447] The urea reagent can be used in approximately an equivalent molar amount to a slightly excess molar amount (for example, about 1.0 molar equivalent) relative to the reaction substrate.

[0448] The reaction can be carried out in any suitable solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, or mixed solvents thereof). The reaction temperature is preferably -25°C to room temperature, particularly 0°C to room temperature.

[0449] (Process 3)

[0450] Next, when a protective group for a hydroxyl group is introduced in the above step 1, the intermediate compound 7 is produced by deprotecting the introduced protective group for the hydroxyl group using the intermediate compound 6 as a starting material by a known method.

[0451] The deprotection reaction can be carried out in the same manner as step 3 of the above-mentioned reaction synthesis route 1 under appropriate reaction conditions (e.g., reagents, etc.) depending on the type of the protecting group. For example, the protecting group of the hydroxyl group (abbreviated as R PRO ) is a silyl type protecting group (eg, TMS), it can be carried out by hydrolysis under acidic conditions (eg, acetic acid-THF-water) or by treatment with a reagent providing fluoride ions (eg, TBAF).

[0452] The reaction can be carried out in any suitable solvent (e.g., ethers such as THF, halogenated hydrocarbons such as dichloromethane, water, or a mixed solvent thereof). The reaction temperature is preferably -25°C to 100°C, particularly 0°C to 50°C.

[0453] (Process 4)

[0454] Furthermore, similarly to step 4 of the above reaction synthesis route 1, intermediate compound 6 or intermediate compound 7 is used as a starting material and phosphoramidated by a known method to produce the desired urea system (e.g., methyl urea system and isopropyl urea system) compound of the present invention.

[0455] Examples of the phosphoramidite reagent include 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, which can be used in the presence of a base (eg, triethylamine, DIPEA).

[0456] The phosphoramidite reagent can be used in an amount of 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents (eg, 3 molar equivalents) relative to the reaction substrate.

[0457] The reaction can be carried out in any suitable solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, acetonitrile, or a mixed solvent thereof). The reaction temperature is preferably -25°C to 60°C, particularly 0°C to room temperature.

[0458] In addition, among the above-mentioned steps (1) to (4), a plurality of steps (for example, step (1) and step (2), step (2) and step (3), and step (1) to step (3)) may be performed continuously.

[0459] It should be noted that the substituent on the nucleobase ring may be appropriately modified (for example, benzoylation or acetylation of the amino substituent on the cytosine ring) at any stage between before the implementation of step 1 and after the implementation of step 4.

[0460] (Aryl System Compounds)

[0461] The present invention provides a method for producing a compound of the present invention in which X in the general formula I is a group represented by the formula (II-2), which is a so-called aryl system. An example of a production synthesis route is shown in the following reaction synthesis route 3.

[0462] Reaction synthesis route 3

[0463] [Chemical formula 18]

[0464]

[0465] (Process 1)

[0466] Before carrying out an arylation reaction based on a known method using the aforementioned starting compound 1 as a starting material, similarly to step 1 of the aforementioned reaction synthesis route 1, a nucleic acid base exchange reaction can be carried out with another nucleic acid base part that can be protected (represented by the abbreviation B') on the nucleic acid base part of the starting compound 1, and then an arylation reaction can be carried out.

[0467] For the nucleic acid base exchange reaction (transglycosylation reaction), the pyrimidine base portion of a nucleic acid base such as thymine (T) or uracil (U) is replaced with another nucleic acid base portion that can be protected (for example, adenine (A), guanine (G), uracil (U), thymine (T), cytosine (C), or 5-methylcytosine ( MeC)), thereby producing an intermediate compound 8 in which the nucleic acid base is partially exchanged. The base exchange reaction can be carried out in the presence of a Lewis acid (eg, TMSOTf, TBSOTf), and the reaction can be accelerated by reacting a silylating agent (eg, BSA).

[0468] In addition, the introduction of the protective group of the hydroxyl group can be carried out under reaction conditions well known in organic synthetic chemistry (e.g., nucleic acid synthesis) according to the type of the protective group. For example, when the protective group of the hydroxyl group is a silyl type protective group (e.g., TMS), a silylating agent (e.g., BSA, hexamethyldisilazane, TMS chloride) can be used. At this time, a Lewis acid (e.g., TMSOTf, TBSOTf, tin chloride) can be added.

[0469] The silylating agent may be used in an amount of about 1 to about 20 molar equivalents relative to the reaction substrate, and the Lewis acid may be used in an amount of a catalytic amount (about 0.05 molar equivalent) to 2 molar equivalents.

[0470] As a solvent, any solvent that does not affect the reaction can be used, and the reaction can be carried out in an appropriate solvent (for example, ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbonized hydrogens such as benzene and toluene, acetonitrile, water, or a mixed solvent thereof). As for the reaction temperature, it is preferably carried out at 0°C to high temperature, especially room temperature to about 60°C.

[0471] (Process 2)

[0472] Next, using the starting compound 1 or the intermediate compound 8 as a starting material, an arylating agent is reacted with the starting compound 1 or the intermediate compound 8 by a known method, thereby aromatizing the imino nitrogen atom to produce the intermediate compound 9.

[0473] Examples of the arylating agent that can be used in the aromatization reaction include a halide compound of a desired aryl group (e.g., chloropyrimidine, dichloropyrimidine, fluoropyrazine, chlorotriazole, chlorooxadiazole, or chlorothiadiazole) in the presence of a base (e.g., DIPEA).

[0474] The arylating agent can be used in about 1 to about 10 molar equivalents, preferably about 1 to about 5 molar equivalents (for example, about 3 molar equivalents) relative to the reaction substrate.

[0475] As a solvent, any solvent that does not affect the reaction can be used, and the reaction can be carried out in an appropriate solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, aprotic polar solvents such as DMSO, or mixed solvents thereof). As for the reaction temperature, it is preferably carried out at room temperature to high temperature, especially high temperature (for example, 120 to 130°C).

[0476] (Process 3)

[0477] Furthermore, similarly to step 4 of the above reaction synthesis route 1, intermediate compound 9 or intermediate compound 8 is used as a starting material and phosphoramidated by a known method to produce the compound of the present invention having a desired aryl system (e.g., aromatic system and heteroaryl system).

[0478] Examples of the phosphoramidite reagent include 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, which can be used in the presence of a base (eg, triethylamine, DIPEA).

[0479] The phosphoramidite reagent can be used in an amount of 1 to 10 molar equivalents, preferably 1 to 5 molar equivalents (eg, 3 molar equivalents) relative to the reaction substrate.

[0480] The reaction can be carried out in any suitable solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, acetonitrile, or a mixed solvent thereof). The reaction temperature is preferably -25°C to 60°C, particularly 0°C to room temperature.

[0481] In addition, among the above steps (1) to (3), a plurality of steps (for example, step (1) and step (2)) may be performed continuously.

[0482] It should be noted that, at any stage from before the implementation of the above-mentioned step 1 to after the implementation of step 3, the substituent on the ring of the nucleic acid base can be appropriately modified (for example, benzoylation or acetylation of the amino substituent of the cytosine ring), or the substituent on the aromatic ring of the introduced aromatic group can be modified (for example, conversion of a chloro group to an amino group), or both of the above modifications can be performed.

[0483] (Other production methods for nucleic acid base exchange)

[0484] Instead of the nucleic acid base exchange reaction described in step 1, a series of reactions shown in the following reaction synthesis scheme 4 can be used to partially return the nucleic acid base. The series of reactions can be carried out according to the method described in the literature (for example, CH Kim et al., J. Med. Chem. 1987, 30, 862).

[0485] Reaction synthesis route 4

[0486] [Chemical formula 19]

[0487]

[0488] (Process A)

[0489] An intermediate compound 9' (e.g., intermediate compound 2 obtained in step 2) whose nucleic acid base portion is thymine is used as a starting material, and an acetylating agent (e.g., acetic anhydride) is reacted in the presence of a base (e.g., pyridine) to produce an intermediate compound A in which the hydroxyl group is acylated. A catalytic amount of DMAP may be added as a suitable reaction activating agent.

[0490] The acetylating agent may be used in an amount of about 1 to 3 molar equivalents (eg, about 1.5 molar equivalents) relative to the reaction substrate.

[0491] The reaction can be carried out in an appropriate solvent (ethers such as THF, or pyridine used as a base). The reaction temperature is preferably 0°C to a high temperature (eg, room temperature).

[0492] (Process B)

[0493] Next, using intermediate compound A as a starting material, the thymine moiety is activated with a chlorinating agent such as phosphoryl chloride, and then 1,2,4-triazole is reacted in the presence of a base (eg, DIPEA) to produce intermediate compound B in which the nucleic acid base moiety is substituted with a 1,2,4-triazole group.

[0494] 1,2,4-triazole may be used in an excess molar amount (about 5 to about 20 molar equivalents (for example, about 9 to 10 molar equivalents)) relative to the reaction substrate.

[0495] The reaction can be carried out in any suitable solvent (ethers such as THF, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, acetonitrile, or a mixed solvent thereof). The reaction temperature is preferably -25°C to room temperature, particularly 0°C to room temperature.

[0496] (Process C)

[0497] Alternatively, intermediate compound B is used as a starting material and reacted with a base (eg, aqueous ammonia) to remove the acetyl group introduced in step A and the 1,2,4-triazole group modified in step B, thereby producing intermediate compound C in which the nucleic acid base portion is 5-methylcytosine.

[0498] Aqueous ammonia may be used in excess molar equivalent relative to the reaction substrate (eg, 28% aqueous ammonia).

[0499] The reaction can be carried out in any suitable solvent (ethers such as THF, acetonitrile, or a mixed solvent thereof). The reaction temperature is preferably 0°C to room temperature, particularly room temperature.

[0500] Using the obtained intermediate compound C as a starting material, the substituents on the ring of the nucleic acid base are appropriately modified (for example, benzoylation or acetylation of the amino substituent of the cytosine ring), or the substituents on the aromatic ring of the introduced aryl group are modified (for example, conversion of a chloro group to an amino group), and then phosphoramidation is performed to produce the compound of the present invention having the desired aryl system (for example, an aromatic system and a heteroaryl system).

[0501] (Other production methods 1 for aromatization)

[0502] Furthermore, instead of the aromatization using an arylating agent described in step 2, aromatization can be performed using a series of reactions shown in the following reaction synthesis scheme 5.

[0503] Reaction Synthesis Pathway 5

[0504] [Chemical formula 20]

[0505]

[0506] (Process D)

[0507] The starting compound 1 is reacted with a thiourea reagent (eg, 1,1-thiocarbonyldiimidazole), and then treated with aqueous ammonia to produce an intermediate compound D in which the imino nitrogen atom is thiourea-formed.

[0508] The thiourea reagent may be used in an amount of about 1 to 5 molar equivalents, particularly about 2 molar equivalents, relative to the reaction substrate.

[0509] The reaction can be carried out in an appropriate solvent (such as ethers such as THF) as long as the solvent does not affect the reaction. The reaction temperature is preferably 0°C to room temperature (for example, room temperature).

[0510] (Process E)

[0511] Next, the intermediate compound D is used as a starting material and reacted with a methylating agent (eg, methyl iodide), thereby producing an intermediate compound E that has been S-methylated and carboximidized.

[0512] The methylating agent may be used in an amount of about 1 to 5 molar equivalents, particularly about 3 molar equivalents, relative to the reaction substrate.

[0513] The reaction can be carried out in an appropriate solvent (such as ethers such as THF) as long as the solvent does not affect the reaction. The reaction temperature is preferably 0°C to room temperature (for example, room temperature).

[0514] (Process F)

[0515] Alternatively, intermediate compound E is used as a starting material and reacted in the presence of an acetylating agent (e.g., acetic anhydride) and a base (e.g., pyridine) to produce intermediate compound F in which the carbonyl imide group and the hydroxyl group are acylated. A catalytic amount of DMAP may be added as a suitable reaction activating agent.

[0516] The acetylating agent may be used in about 1 to 5 molar equivalents (eg, about 3 molar equivalents) relative to the reaction substrate.

[0517] The reaction can be carried out in an appropriate solvent (ethers such as THF, or pyridine used as a base). The reaction temperature is preferably 0°C to a high temperature (eg, room temperature).

[0518] (Process G)

[0519] Alternatively, the intermediate compound F was used as a starting material and subjected to a ring-closing reaction with methylhydrazine to produce the intermediate compound G having a 1,2,4-triazole ring.

[0520] Methylhydrazine may be used in an excess molar amount (about 5 to 20 molar equivalents (for example, about 10 molar equivalents)) relative to the reaction substrate.

[0521] The reaction can be carried out in any suitable solvent (such as an alcohol solvent such as ethanol). The reaction temperature is preferably 0°C to a high temperature (for example, room temperature).

[0522] Using the obtained intermediate compound G as a starting material, the substituents on the ring of the nucleic acid base are appropriately modified (for example, benzoylation of the amino substituent of the cytosine ring), or the substituents on the aromatic ring of the introduced aryl group are modified (for example, conversion of a chloro group to an amino group), and then phosphoramidation is performed to produce the compound of the present invention having the desired aryl system (for example, an aromatic system and a heteroaryl system).

[0523] (Preparation method of oligomer)

[0524] [Chemical formula 21]

[0525]

[0526] The compound of the present invention or its salt can be used as a monomer starting material for producing oligonucleotides. Oligonucleotides can be synthesized by carrying out an oligomerization reaction using the compound represented by general formula (I) or its salt and then, if necessary, deprotecting the amino protecting group and the hydroxy protecting group.

[0527] The oligomerization reaction is not particularly limited, and can be carried out by any method generally known in synthetic chemistry (especially nucleic acid synthesis), for example, by the phosphoramidite phosphoramidite method. As the phosphoramidite phosphoramidite method, for example, it can be carried out according to a method based on the method described in WO 2014 / 046212A1.

[0528] By this oligomerization reaction, an oligonucleotide having one or more nucleotides represented by the general formula (I) can be produced.

[0529] That is, the method for producing the oligonucleotide represented by general formula (I') comprises the following steps:

[0530] a) Using a compound represented by the general formula (I) or a salt thereof, an oligomerization reaction is carried out, and then, if necessary, the amino protecting group and the hydroxy protecting group are deprotected.

[0531] In addition, the method for producing the compound represented by the general formula (I) or a salt thereof may include at least one of the following steps among the steps described in the present specification.

[0532] A process for producing the compound of the present invention or a salt thereof.

[0533] For example, a step of preparing a compound represented by the general formula (I') or a salt thereof by subjecting the compound represented by the intermediate compound 4, 7 or 9 or a salt thereof to a phosphamidite reaction.

[0534] For example, a step of producing a compound represented by the intermediate compound 4, 7 or 9 by deprotecting the protective group of the hydroxyl group of the compound represented by the intermediate compound 3 or 6.

[0535] (Preparation method of phosphorothioate oligomer)

[0536] In the synthesis of oligonucleotides based on the phosphoramidite method, an oxidant can be used when converting a phosphite group to a phosphate group. If DDTT (((dimethylamino-methylene (methylidene))amino)-3H-1,2,4-dithiazoline-3-thione) or Beaucage reagent (3H-1,2-benzodithiol-3-one-1,1-dioxide) is used instead of the oxidant used at this time, a phosphorothioate oligomer having a protective group can be obtained in which the oxygen atom in the P=O of the phosphate group is replaced with sulfur in the form of P=S to form a phosphorothioate group.

[0537] Example

[0538] The following examples are given to further illustrate the present invention, but the present invention is not limited to these examples. It should be noted that the identification of the compound is carried out by mass spectrometry, high performance liquid chromatography mass spectrometry; LCMS, NMR spectroscopy, high performance liquid chromatography (HPLC), etc. In NMR, in hydrogen nuclear magnetic resonance ( 1 In the phosphorus nuclear magnetic resonance (H-NMR), a resonance frequency of 400 MHz was used. 31 In P-NMR), a resonance frequency of 161.8 MHz is used. As symbols used in NMR, s represents a singlet, d represents a doublet, dd represents a doublet of a doublet, t represents a triplet, td represents a triplet of a doublet, q represents a quartet, quin represents a quintet, sept represents a septet, m represents a multiplet, br represents a broad peak, brs represents a broad singlet, brd represents a broad doublet, brt represents a broad triplet, and J represents a coupling constant.

[0539] The structure and abbreviation (in this specification, abbreviations are used as appropriate) of each artificial nucleic acid are shown in the following structural formula.

[0540] The structures and abbreviations of artificial nucleic acids

[0541] [Chemical formula 22]

[0542]

[0543] Synthesis of ALNA[Ms]-T

[0544] [Chemical formula 23]

[0545]

[0546] Example 1 Synthesis of Compound 2Ta

[0547] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidine-2,4-dione

[0548] BSA (13 mL, 53.17 mmol) was added to a mixed solution of 1-[(1R, 3R, 4R, 7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidine-2,4-dione (1a) (12.35 g, 21.61 mmol) synthesized by the method described in International Publication No. 2017 / 047816 in dichloromethane (61 mL), and the mixture was stirred at room temperature for 8 hours. BSA (5.2 mL, 21 mmol) and TMSOTf (200 μL, 1.0 mmol) were added thereto, and the mixture was stirred at room temperature for 15 hours again. A 5% sodium bicarbonate aqueous solution (50 mL) was added to the reaction solution, stirred, and extracted with dichloromethane. The aqueous layer was mixed with dichloromethane (61 mL) for extraction, and the organic layers of dichloromethane were combined and mixed. The solvent of the organic layer was distilled off, and then the residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 98 / 2) to obtain compound 2Ta (10.49 g, yield 75%).

[0549] MS (ESI): m / z = 644 (M + H) +

[0550] Example 2 Synthesis of Compound 2Tb

[0551] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-methylsulfonyl-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidine-2,4-dione

[0552] To a mixed solution of compound 2Ta (10.19 g, 15.83 mmol) in dichloromethane (50 mL) was added DIPEA (5.4 mL, 31 mmol), and methanesulfonyl chloride (1.4 mL, 18 mmol) was added under an ice bath, and the mixture was stirred for 1.5 hours under an ice bath. A 5% aqueous sodium bicarbonate solution (20 mL) was added to the reaction solution, stirred, and extracted with dichloromethane. The aqueous layer was mixed with dichloromethane (20 mL), extracted, and the organic layers of dichloromethane were combined and mixed. The solvent of the organic layer was distilled off, and then the residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 98 / 2), thereby obtaining compound 2Tb (6.56 g, yield was 57%).

[0553] MS (ESI): m / z = 720 (MH) -

[0554] Example 3 Synthesis of Compound 2Tc

[0555] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidine-2,4-dione

[0556] Under ice bath, add TBAF (1.35 mL, 4.58 mmol, 1 M tetrahydrofuran solution) to a mixture of compound 2Tb (3.02 g, 4.13 mmol) in tetrahydrofuran (15 mL), and stir the mixture for 30 minutes. Add 10% aqueous ammonium chloride solution (20 mL) and dichloromethane (20 mL) to the reaction solution, stir, and extract with dichloromethane. Mix the aqueous layer with dichloromethane (20 mL), extract, and mix the organic layer with dichloromethane. Distill off the solvent of the organic layer, and then purify the obtained residue by silica gel column chromatography (chloroform / methanol, 100 / 0 to 98 / 2), thereby obtaining compound 2Tc (2.47 g, yield 92%).

[0557] MS (ESI): m / z = 648 (MH) -

[0558] Example 4 Compound 2Td

[0559] 3-[[(1R,4R,6R,7S)-4-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-6-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-methylsulfonyl-5-oxa-2-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 1 of the present invention)

[0560] Under ice cooling, DIPEA (2.00 mL, 12.0 mmol) and 2-cyanoethyl N,N,N',N'-diisopropylchlorophosphoramidite (2.10 mL, 9.40 mmol) were added to a solution of compound 2Tc (2.47 g, 3.80 mmol) in dichloromethane (12.5 mL), and the mixture was stirred at room temperature for 5 hours. Under ice cooling, 5% aqueous sodium bicarbonate solution (15 mL) and dichloromethane (10 mL) were added thereto, stirred at room temperature, and then extracted with dichloromethane. The aqueous layer was extracted with dichloromethane (10 mL), and the organic layers of dichloromethane were combined and mixed. Under reduced pressure, the solvent was distilled off, and then purified by silica gel column chromatography (hexane / ethyl acetate, 60 / 40 to 40 / 60), thereby obtaining compound 2Td (2.13 g, yield 66%) as compound 1 of the present invention.

[0561] MS (ESI): m / z = 850 (M + H) +

[0562] 31 P-NMR(CDCl3)δ:150.30, 149.12

[0563] Synthesis of ALNA[Ms]-mC

[0564] [Chemical formula 24]

[0565]

[0566] Example 5 Synthesis of Compound 2mCc

[0567] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0568] BSA (44 mL, 180 mmol) was added to a suspension of compound 1a (10.33 g, 18.1 mmol) and N-(5-methyl-2-oxo-1H-pyrimidin-4-yl)benzamide (12.42 g, 54.2 mmol) in toluene (180 mL), and the mixture was stirred at room temperature for 15 minutes. TMSOTf (0.52 mL, 2.71 mmol) was added thereto, and stirred at room temperature for 2 hours. The reaction solution was added to a mixture of IPE (100 mL), saturated aqueous sodium bicarbonate solution (50 mL), and water (50 mL), and the mixture was stirred for 10 minutes, filtered through diatomaceous earth, and the insoluble matter was removed. The water layer was removed from the filtrate, and the organic layer was washed with water (50 mL) and saturated brine (50 mL) in turn. The solvent was distilled off through a phase separator. Dichloromethane (90 mL) was added to the residue to dissolve it, triethylamine (5.0 mL, 36.0 mmol) and methanesulfonic anhydride (3463 mg, 19.9 mmol) were added, and the mixture was stirred at room temperature for 40 minutes. Methanesulfonic anhydride (944 mg, 5.42 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. Methanesulfonic anhydride (944 mg, 5.42 mmol) and triethylamine (1.3 mL, 9.06 mmol) were further added, and the mixture was stirred at room temperature for 20 minutes. Dilute with ethyl acetate (80 mL), add water (40 mL) and saturated sodium bicarbonate aqueous solution (40 mL), and stir the mixture. The aqueous layer was removed, and the organic layer was washed with saturated brine (50 mL), and then the solvent was distilled off through a phase separator and vacuum dried. THF (90 mL) was added to the residue to prepare a solution, and TBAF (0.1 M THF solution, 21.7 mL, 21.7 mmol) was added under ice cooling, and the mixture was stirred for 15 minutes under ice cooling. Dilute with ethyl acetate (90 mL), add saturated aqueous ammonium chloride solution (40 mL) and water (40 mL), and stir. The aqueous layer was removed, and the solvent was distilled off through a phase separator. The obtained residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 95 / 5), thereby obtaining compound 2mCc (5702 mg, 38% yield in 3 steps).

[0569] MS (ESI): m / z = 753 (M + H) +

[0570] Example 6 Synthesis of Compound 2mCd

[0571] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 2 of the present invention)

[0572] In the same manner as in Example 4, compound 2mCd (6809 mg, yield: 72%), which is compound 2 of the present invention, was obtained from compound 2mCc (8099 mg, 9.89 mmol).

[0573] MS (APCI): m / z = 954 (M + H) +

[0574] Synthesis of ALNA[Ms]-G

[0575] [Chemical formula 25]

[0576]

[0577] Example 7 Synthesis of Compound 2Ga

[0578] [9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0579] To a solution of compound 1a (5040 mg, 8.817 mmol) and [2-(2-methylpropionylamino)-9H-purin-6-yl] N,N-diphenylcarbamate (5400 mg, 12.97 mmol) in 1,2-dichloroethane (24.7 mL), BSA (14.8 mL, 60.46 mmol) was added, and the mixture was stirred at 64°C for 1 hour. Next, while maintaining the internal temperature at 60°C, TMSOTf (0.167 mL, 0.864 mmol) was slowly added thereto, and the mixture was stirred for 1 hour. After cooling, the reaction solution was slowly added to a mixed solution of chloroform (40 mL) and saturated aqueous sodium bicarbonate solution (40 mL) prepared separately, and the mixture was stirred. After the insoluble matter was filtered off, the filtrate was extracted with ethyl acetate (50 mL). For the organic layer, it was washed with saturated brine (50 mL) and dried over sodium sulfate. Next, the filtrate was removed by distillation under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3) to obtain Compound 2Ga (6350 mg, yield: 79%).

[0580] MS (ESI): m / z = 935 (M + H) +

[0581] Example 8 Synthesis of Compound 2Gb

[0582] [9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-methylsulfonyl-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0583] To a solution of compound 2Ga (2370 mg, 2.537 mmol) in dichloromethane (24.9 mL), triethylamine (0.692 mL, 4.984 mmol) was added, and the mixture was stirred at room temperature for 5 minutes. Next, methanesulfonyl chloride (0.193 mL, 2.488 mmol) was added thereto under ice cooling, and the mixture was stirred for 1 hour. Under ice cooling, dichloromethane (30 mL) and saturated aqueous sodium bicarbonate solution (30 mL) were added to the reaction solution, stirred, and separated. The organic layer was washed with saturated brine (30 mL) and dried over sodium sulfate. Next, the filtrate was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate, 67 / 33 to 50 / 50), thereby obtaining compound 2Gb (2210 mg, yield 88%).

[0584] MS (ESI): m / z = 1013 (M + H) +

[0585] Example 9 Synthesis of Compound 2Gc [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0586] Under ice cooling, TBAF (2.4 mL, 3.407 mmol) was added to a solution of compound 2Gb (2200 mg, 2.173 mmol) in THF (11 mL), and the mixture was stirred at room temperature for 5 hours. Under ice cooling, ethyl acetate (30 mL) and saturated aqueous ammonium chloride solution (30 mL) were added to the reaction solution, stirred, and separated. The organic layer was washed with saturated brine (30 mL) and dried over sodium sulfate. Next, the filtrate was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate, 60 / 40 to 50 / 50). In order to remove the raw material, it was purified again by silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3), thereby obtaining compound 2Gc (1070 mg, yield 52%).

[0587] MS (ESI): m / z = 941 (M + H) +

[0588] Example 10 Synthesis of Compound 2Gd

[0589] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 3 of the present invention)

[0590] Under ice cooling, DIPEA (0.590 mL, 3.407 mmol) and 2-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.510 mL, 2.282 mmol) were added to a solution of compound 2Gc (1070 mg, 1.139 mmol) in dichloromethane (5.690 mL), and the mixture was stirred at room temperature for 22 hours. Under ice cooling, dichloromethane (20 mL) and saturated aqueous sodium bicarbonate solution (20 mL) were added to the reaction solution, stirred, and separated. The aqueous layer was removed and the organic layer was passed through a phase separator. The filtrate was removed by distillation under reduced pressure, and then the residue was purified by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 40 / 60), thereby obtaining compound 2Gd (548 mg, 42% yield) as compound 3 of the present invention.

[0591] MS (ESI): m / z = 1141 (M + H) +

[0592] Synthesis of ALNA[Ms]-A

[0593] [Chemical formula 26]

[0594]

[0595] Example 11 Synthesis of Compound 2Ac

[0596] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-purin-6-yl]benzamide

[0597] BSA (30 mL, 123 mmol) was added dropwise to a suspension of compound 1a (10.0 g, 17.6 mmol) and N-(9H-purine-6-yl)benzamide (5.04 g, 21.1 mmol) in toluene (176 mL), and the mixture was heated to 60 ° C and stirred for 30 minutes. TMSOTf (1.03 mL, 5.34 mmol) was added thereto, and the mixture was stirred at 60 ° C for 15 minutes. Under ice cooling, the reaction solution was added to a mixture of IPE (100 mL) and saturated sodium bicarbonate aqueous solution (100 mL) while stirring, the mixture was stirred for 20 minutes, and the insoluble matter was removed by filtration. The filter cake was washed twice with Et2O (20 mL), and then the filtrate was separated and washed with saturated brine (50 mL). After passing through a phase separator, it was concentrated under reduced pressure. Dichloromethane (24.9 mL) was added to the residue to dissolve it, pyridine (4.57 mL, 56.5 mmol) and methanesulfonic anhydride (3614 mg, 20.75 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Saturated sodium bicarbonate aqueous solution (50 mL) and water (50 mL) were added, stirred, and liquid separation was performed. After washing the organic layer with saturated brine (50 mL), the solvent was distilled off under reduced pressure through a phase separator. THF (88 mL) was added to the residue to prepare a solution, and TBAF (1M THF solution, 21.1 mL, 21.1 mmol) was added under ice cooling, and the mixture was stirred for 30 minutes under ice cooling. Dilute with ethyl acetate (80 mL), add saturated ammonium chloride aqueous solution (50 mL) and water (50 mL), and the mixture was stirred at room temperature. Liquid separation was performed, the organic layer was washed with saturated brine (50 mL), and then the solvent was distilled off through a phase separator. The resulting residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 95 / 5) to obtain Compound 2Ac (10.6 g, yield in 3 steps: 75%).

[0598] MS (ESI): m / z = 763 (M + H) +

[0599] Example 12 Synthesis of Compound 2Ad

[0600] N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-purin-6-yl]benzamide (Compound 4 of the present invention)

[0601] Under ice cooling, DIPEA (4.8 mL, 28.0 mmol) and 2-cyanoethyl-N, N-diisopropylchlorophosphoramidite (4.7 mL, 21.0 mmol) were added to a solution of compound 2Ac (5.60 g, 7.01 mmol) in dichloromethane (40 mL), and the mixture was stirred at room temperature for 4 hours. Under ice cooling, ethanol (1.2 mL, 21.0 mmol) was added, and the mixture was stirred at room temperature for 5 minutes. Under ice cooling again, saturated sodium bicarbonate aqueous solution (20 mL) and saturated brine (20 mL) were added thereto, stirred, and the organic layer was passed through a phase separator. The filtrate was removed by distillation under reduced pressure, and then the residue was purified by silica gel column chromatography (hexane / ethyl acetate, 67 / 33-10 / 90), thereby obtaining compound 2Ad (5.44 g, yield 77%) as compound 4 of the present invention.

[0602] MS (ESI): m / z = 964 (M + H) +

[0603] Synthesis of ALNA[Bs]-T

[0604] [Chemical formula 27]

[0605]

[0606] Example 13 Synthesis of Compound 3Tb

[0607] 1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0608] Toluene was added to compound 2Ta (1.00 g, 1.56 mmol) for azeotropy. Dichloromethane (5 mL) and triethylamine (0.43 mL, 3.1 mmol) were added to the residue to completely dissolve it. The mixed solution was ice-cooled, benzenesulfonyl chloride (0.21 mL, 1.6 mmol) was added, and the mixture was stirred for 4 hours under ice-cooling. A 5% aqueous potassium carbonate solution (20 mL) was added to the reaction solution, stirred, and extracted with dichloromethane (5 mL). The aqueous layer was mixed with dichloromethane (5 mL), extracted, and the organic layers of dichloromethane were combined and mixed. The solvent of the organic layer was distilled off, and then the residue was purified by silica gel column chromatography (hexane / ethyl acetate, 40 / 60 to 20 / 80), thereby obtaining compound 3Tb (0.78 g, yield was 64%).

[0609] MS (ESI): m / z = 782 (MH) -

[0610] Example 14 Synthesis of Compound 3Tc

[0611] 1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0612] In the same manner as in Example 3, compound 3Tc (0.59 g, yield: 84%) was synthesized from compound 3Tb (0.78 g, 0.99 mmol).

[0613] MS (ESI): m / z = 710 (MH) -

[0614] Example 15 Synthesis of Compound 3Td

[0615] 3-[[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 5 of the present invention)

[0616] To a solution of compound 3Tc (599 mg, 0.765 mmol) in acetonitrile (3 mL), diisopropylammonium tetrazolium salt (171 mg, 0.996 mmol) and 3-bis(diisopropylamino)phosphinooxypropionitrile (0.36 mL, 1.1 mmol) were added, and the mixture was stirred at room temperature for 19 hours. Ethyl acetate (10 mL) and water (5 mL) were added to the reaction solution, and the aqueous layer was separated after stirring. Ethyl acetate (10 mL) was added to the aqueous layer, and the organic layer was separated after mixing. The organic layers were combined, mixed, and concentrated under reduced pressure at 40°C. The residue was purified by silica gel column chromatography (hexane / ethyl acetate, 67 / 33 to 10 / 90), thereby synthesizing compound 3Td (0.65 g, yield 86%) as compound 5 of the present invention.

[0617] MS (ESI): m / z = 912 (M + H) +

[0618] 31 P-NMR(CDCl3)δ:149.68, 149.22

[0619] Synthesis of ALNA[Bs]-mC

[0620] [Chemical formula 28]

[0621]

[0622] Example 16 Synthesis of Compound 3Cb

[0623] N-[1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0624] In the same manner as in Example 13, compound 3mCb (0.85 g, yield: 71%) was synthesized from compound 1b (1.00 g, 1.34 mmol) synthesized by the method described in International Publication No. 2017 / 047816.

[0625] MS (ESI): m / z = 887 (M + H) +

[0626] Example 17 Synthesis of Compound 3mCb

[0627] N-[1-[(1R,3R,4R,7S)-5-(Benzenesulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0628] In the same manner as in Example 14, compound 3mCc (0.78 g, yield: 99%) was synthesized from compound 3mCb (0.85 g, 0.96 mmol).

[0629] MS (ESI): m / z = 813 (M + H) +

[0630] Example 18 Synthesis of Compound 3mCd

[0631] N-[1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino)oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 6 of the present invention)

[0632] In the same manner as in Example 15, compound 3mCd (0.53 g, yield: 55%), which is compound 6 of the present invention, was synthesized from compound 3mCc (0.78 g, 0.89 mmol).

[0633] MS (ESI): m / z = 1015 (M + H) +

[0634] 31 P-NMR(CDCl3)δ:149.94, 149.34

[0635] Synthesis of ALNA[mU]-T

[0636] [Chemical formula 29]

[0637]

[0638] Example 19 Synthesis of Compound 4Tc

[0639] (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0640] Compound 1a (1.20 g, 2.10 mmol) was azeotroped with toluene, and N-diisopropyl-N-ethylamine (0.61 mL, 3.5 mmol) was added to a mixed solution of the residue and tetrahydrofuran (6 mL). A tetrahydrofuran solution (1 mL) of N-methylcarbamoyl chloride (0.20 g, 2.2 mmol) was added thereto under an ice bath, and the mixture was stirred for 3 hours under an ice bath. A 5% aqueous sodium bicarbonate solution (20 mL) and ethyl acetate (10 mL) were added to the reaction solution, stirred, and extracted with ethyl acetate. Extraction was performed twice with ethyl acetate (10 mL), and the organic layers were combined and mixed. The solvent of the organic layer was distilled off, and then the residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3), thereby obtaining compound 4Tc (1.28 g, yield 97%).

[0641] MS (ESI): m / z = 627 (MH) -

[0642] Example 20 Synthesis of Compound 4Td

[0643] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 7 of the present invention)

[0644] In the same manner as in Example 15, compound 4Td (0.56 g, yield: 37%), which is compound 7 of the present invention, was synthesized from compound 4Tc (1.16 g, 1.8 mmol).

[0645] MS (ESI): m / z = 828 (MH) -

[0646] 31 P-NMR(CDCl3)δ:149.31, 147.44

[0647] Synthesis of ALNA[mU]-mC

[0648] [Chemical formula 30]

[0649]

[0650] Example 21 Synthesis of Compound 4mCa

[0651] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0652] After 18 minutes, BSA (584 mL, 2390 mmol) was added dropwise to a mixture of compound 1a (105.0 g, 184 mmol), 5-methylcytosine (69.0 g, 551 mmol), and 1,2-dichloroethane (918 mL). The mixture was heated to 60°C and stirred for 20 minutes. After ice cooling, the internal temperature was cooled to 19.5 degrees, TMSOTf (10 mL, 55.2 mmol) was added thereto, and the mixture was heated to 60°C. After stirring for 40 minutes, the reaction solution was ice-cooled, and a 5% aqueous sodium bicarbonate solution (525 mL) was added dropwise. Next, chloroform (1050 mL) and a 15% aqueous sodium chloride solution (525 mL) were added thereto. After filtering the obtained slurry with diatomaceous earth, the filter cake was washed with chloroform (525 mL), thereby obtaining a residue. 1 and filtrate 1 To the residue 1 Ethyl acetate (2100 mL) and water (2100 mL) were added, and the mixture was stirred for 1 hour. After filtering the mixture through celite, the residue was washed with ethyl acetate (1050 mL) to obtain a filtrate. 2 . The filtrate 2 The organic layer was separated and washed twice with water (525 mL). 1 The liquid was separated, and the aqueous layer was extracted with chloroform (525 mL). The organic layers were combined and washed twice with 1050 mL of water. The obtained organic layer was concentrated under reduced pressure to obtain a light yellow solid (125.6 g). THF (550 mL) was added thereto, stirred, and 1M TBAF / THF solution (276 mL, 276 mmol) was added. After stirring at room temperature for 3 hours, water (550 mL) was added to the reaction solution to quench it, and chloroform (550 mL) was added to separate the liquids. The aqueous layer was extracted again with chloroform (275 mL), and the organic layers were combined. After washing the organic layer with water, it was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform / methanol, 20 / 1 to 4 / 1), thereby obtaining compound 4mCa (69.62 g, yield 62%).

[0653] MS (ESI): m / z = 593 (M + Na) +

[0654] Example 22 Synthesis of Compound 4mCb

[0655] (1R,3R,4R,7S)-3-(4-amino-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0656] Compound 4mCa (1.00 g, 1.75 mmol) was azeotroped with toluene, triethylamine (0.49 mL, 3.5 mmol) was added to a mixed solution of tetrahydrofuran (5 mL) of the residue, and a tetrahydrofuran solution (1 mL) of N-methylcarbamoyl chloride (0.17 g, 1.8 mmol) was added under an ice bath, and the mixture was stirred for 3 hours under an ice bath. Tap water (15 mL), ethyl acetate (1 mL), and chloroform (15 mL) were added to the reaction solution, stirred, and extracted with an organic solvent. The aqueous layer was extracted with chloroform (5 mL), and the organic layers were combined and mixed. The organic layer was dried with magnesium sulfate and the solid was filtered. The solvent of the filtrate was distilled off to obtain compound 4mCb (1.18 g, yield quant.). The residue was not purified and used in the next reaction.

[0657] MS (ESI): m / z = 627 (MH) -

[0658] Example 23 Synthesis of Compound 4mCc

[0659] (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0660] Compound 4mCb (1.18 g) was azeotroped with toluene, and benzoic anhydride (0.51 g, 2.27 mmol) and methanol (0.01 mL, 0.25 mmol) were added to a mixed solution of the residue in tetrahydrofuran (5 mL) at room temperature, and the mixture was stirred for 4 hours in an external bath at 70°C. A 5% aqueous sodium bicarbonate solution (10 mL) and ethyl acetate (10 mL) were added thereto, stirred, and extracted with an organic solvent. The aqueous layer was extracted with ethyl acetate (15 mL), and the organic layers were combined and mixed. The solvent of the organic layer was distilled off, and the residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3), thereby obtaining compound 4mCc (0.99 g, yield 77%).

[0661] MS (ESI): m / z = 731 (MH) -

[0662] Example 24 Synthesis of Compound 4mCd

[0663] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 8 of the present invention)

[0664] In the same manner as in Example 15, compound 4mCd (0.96 g, yield: 77%), which is compound 8 of the present invention, was synthesized from compound 4mCc (0.98 g, 1.34 mmol).

[0665] MS (ESI): m / z = 933 (M + H) +

[0666] Synthesis of ALNA[mU]-G

[0667] [Chemical formula 31]

[0668]

[0669] Example 25 Synthesis of Compound 4Ga

[0670] [9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0671] BSA (91 mL, 372 mmol) was added dropwise to a suspension of compound 1a (30.5 g, 53.4 mmol) and [2-(2-methylpropionylamino)-9H-purin-6-yl] N,N-diphenylcarbamate (26.7 g, 64.1 mmol) in toluene (267 mL) over about 20 minutes, and the mixture was heated to 60°C and stirred for 5 minutes. Toluene (100 mL) was added, and the mixture was further stirred at 60°C for 10 minutes. TMSOTf (1.03 mL, 5.34 mmol) was added thereto, and the mixture was stirred at 60°C for 20 minutes. The reaction solution was added to a mixture of IPE (100 mL), a saturated aqueous sodium bicarbonate solution (50 mL), and water (50 mL) while stirring under ice cooling, and the mixture was stirred for 2 hours, and the insoluble matter was removed by filtration. The residue was washed twice with Et2O (20 mL), and the filtrate was separated, and the organic layer was washed with water (50 mL) and saturated brine (50 mL) in sequence, and then concentrated under reduced pressure through a phase separator and dried in vacuo to obtain 4Ga (48.67 g) as a crude product.

[0672] MS (ESI): m / z = 954 (M + H) +

[0673] Example 26 Synthesis of Compound 4Gc

[0674] [9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0675] THF (100 mL) was added to compound 4Ga (17.4 g, 18.6 mmol) to dissolve it. DIPEA (4.87 mL, 28.0 mmol) and N-methylcarbamoyl chloride (1830 mg, 19.6 mmol) were added under ice cooling, and the mixture was stirred for 30 minutes. Saturated sodium bicarbonate aqueous solution (100 mL) and ethyl acetate (100 mL) were added thereto in sequence, and the mixture was brought to room temperature and stirred for 5 minutes. After separation, the organic layer was washed with water (50 mL) and saturated brine (50 mL) in sequence, and the solvent was distilled off through a phase separator and vacuum dried. THF (90 mL) was added to the residue to prepare a solution, and TBAF (1M THF solution, 4.54 mL, 4.54 mmol) was added under ice cooling, and the mixture was stirred for 20 minutes under ice cooling. Dilute with ethyl acetate (100 mL), add saturated aqueous ammonium chloride solution (50 mL) and water (50 mL), bring the mixture to room temperature, and stir for 5 minutes. Separate the liquids, pass the organic layer through a phase separator, and distill off the solvent. Purify the obtained residue by silica gel column chromatography (chloroform / methanol, 100 / 0 to 95 / 5), thereby obtaining compound 4Gc (9030 mg, 54% yield in 3 steps).

[0676] MS (ESI): m / z = 919 (M + H) +

[0677] Example 27 Synthesis of Compound 4Gd

[0678] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(methylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 9 of the present invention)

[0679] In the same manner as in Example 12, compound 4Cd (8700 mg, yield: 79%), which is compound 9 of the present invention, was synthesized from compound 4Gc (9020 mg, 9.82 mmol).

[0680] MS (ESI): m / z = 1197 (M + H) +

[0681] Synthesis of ALNA[mU]-A

[0682] [Chemical formula 32]

[0683]

[0684] Example 28 Synthesis of Compound 4Aa

[0685] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide

[0686] BSA (90 mL, 368 mmol) was added dropwise to a suspension of compound 1a (30.0 g, 52.5 mmol) and N-(9H-purine-6-yl)benzamide (15.0 g, 62.7 mmol) in toluene (500 mL), and the mixture was heated to 80°C and stirred for 20 minutes. TMSOTf (1.0 mL, 5.17 mmol) was added thereto under ice cooling, and the mixture was stirred at 60°C for 20 minutes. Under ice cooling, the reaction solution was added to a stirred mixture of IPE (200 mL) and saturated aqueous sodium bicarbonate solution (200 mL), the mixture was stirred for 20 minutes, and the insoluble matter was removed by filtration. After washing the filter cake twice with Et2O (40 mL), the filtrate was separated and washed with saturated brine. After drying the organic layer with sodium sulfate, the insoluble matter was removed by filtration, concentrated under reduced pressure, and vacuum dried, thereby obtaining 4Aa (40.5 g) as a crude product.

[0687] MS (ESI): m / z = 757 (M + H) +

[0688] Example 29 Synthesis of Compound 4Ab

[0689] (1R,3R,4R,7S)-3-(6-Benzamidopurin-9-yl)-1[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-N-methyl-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0690] THF (87 mL) was added to the crude product 4Aa (8.20 g) to dissolve it, and DIPEA (3.00 mL, 17.2 mmol) and N-methylcarbamoyl chloride (970 mg, 10.4 mmol) were added thereto in sequence at room temperature, and the mixture was stirred for 30 minutes. Ethyl acetate (100 mL), saturated sodium bicarbonate aqueous solution (50 mL), and water (50 mL) were added thereto, and after separation, the organic layer was washed with saturated brine (50 mL), and the solvent was distilled off by a phase separator, and vacuum drying was performed to obtain a crude product 4Ab (8.70 g).

[0691] MS (ESI): m / z = 813 (MH) -

[0692] Example 30 Synthesis of Compound 4Ac

[0693] (1R,3R,4R,7S)-3-(6-Benzamidopurin-9-yl)-1[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0694] THF (100 mL) was added to the crude product 4Ab (8.00 g) to prepare a solution, and TBAF (1M THF solution, 5.00 mL, 5.00 mmol) was added under ice cooling, and the mixture was stirred for 1 hour under ice cooling. The mixture was diluted with ethyl acetate (80 mL), saturated aqueous ammonium chloride solution (50 mL) and water (50 mL) were added, and stirred at room temperature. The liquid was separated, and the organic layer was washed with saturated brine (50 mL), and then the solvent was distilled off through a phase separator. The residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3), thereby obtaining compound 4Ac (6100 mg, 84% yield in 3 steps).

[0695] MS (ESI): m / z = 742 (M + H) +

[0696] Example 31 Synthesis of Compound 4Ad

[0697] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 10 of the present invention)

[0698] In the same manner as in Example 12, 4Ad (3830 mg, yield: 48%) as the compound 10 of the present invention was obtained from 4Ac (6100 mg, 8.20 mmol).

[0699] MS (APCI): m / z = 942 (M + H) +

[0700] Synthesis of ALNA[ipU]-T

[0701] [Chemical formula 33]

[0702]

[0703] Example 32 Synthesis of Compound 5Tc

[0704] (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-N-isopropyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0705] Under ice cooling, 2-isocyanate propane (0.27 ml, 2.7 mmol) was added to a solution of compound 1a (1500 mg, 2.624 mmol) in dichloromethane (26 mL), and the mixture was stirred at room temperature for 1 hour. A mixture of ethyl acetate (10 mL) and saturated sodium bicarbonate aqueous solution (20 mL) was added thereto, and after separation, the aqueous layer was extracted twice with 10 mL of ethyl acetate, and the combined organic layer was washed with 10 mL of saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off. Purification was performed by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 0 / 100), thereby obtaining compound 5Tc (1904 mg, yield quant.).

[0706] MS (ESI): m / z = 656 (MH) -

[0707] Example 33 Synthesis of Compound 5Td

[0708] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 11 of the present invention)

[0709] In the same manner as in Example 4, compound 5Td (1272.9 mg, yield: 52%), which is compound 11 of the present invention, was obtained from compound 5Tc (2020 mg, 2.85 mmol).

[0710] MS (ESI): m / z = 855 (MH) -

[0711] Synthesis of ALNA[ipU]-mC

[0712] [Chemical formula 34]

[0713]

[0714] Example 34 Synthesis of Compound 5mCc

[0715] (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxopyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-hydroxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0716] Compound 5mCc (1168 mg, 93% yield) was obtained from compound 1c (1300 mg, 1.657 mmol) synthesized by the method described in International Publication No. 2017 / 047816.

[0717] MS (ESI): m / z = 761 (M + H) +

[0718] Example 35 Synthesis of Compound 5mCd

[0719] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxopyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 12 of the present invention)

[0720] In the same manner as in Example 4, compound 5mCd (1002.8 mg, yield: 75%), which is compound 12 of the present invention, was obtained from compound 5mCc (1168 mg, 1.378 mmol).

[0721] MS (ESI): m / z = 961 (M + H) +

[0722] Synthesis of ALNA[ipU]-G

[0723] [Chemical formula 35]

[0724]

[0725] Example 36 Synthesis of Compound 5Gc

[0726] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-(isopropylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate

[0727] Under ice cooling, isopropyl isocyanate (0.31 mL, 3.09 mmol) was added to a dichloromethane (28 mL) solution of compound 1d (2.42 g, 2.81 mmol) synthesized according to the method described in the example of International Publication No. 2017 / 047816, and the mixture was stirred for 3 hours at room temperature. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, stirred, and the solvent was distilled off after passing through a phase separator. The residue was purified by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 20 / 80) to obtain compound 5Gc (1.41 g, 53% yield).

[0728] MS (ESI): m / z = 948 (M + H) +

[0729] Example 37 Synthesis of Compound 5Gd

[0730] [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(isopropylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate (Compound 13 of the present invention)

[0731] In the same manner as in Example 4, compound 5Gd (1.20 g, yield: 70%), which is compound 13 of the present invention, was obtained from compound 5Gc (1.41 g, 1.49 mmol).

[0732] MS (ESI): m / z = 1148 (M + H) +

[0733] 31 P-NMR (CDCl3)δ:149.42,149.39

[0734] Synthesis of ALNA[ipU]-A

[0735] [Chemical formula 36]

[0736]

[0737] Example 38 Synthesis of Compound 5Ac

[0738] (1R,3R,4R,7S)-3-(6-Benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-carboxamide

[0739] To a suspension of compound 1a (10.0 g, 17.5 mmol) and N-(9H-purine-6-yl)benzamide (5.0 g, 21.0 mmol) in toluene (175 mL), BSA (30 mL, 122 mmol) was added dropwise, the mixture was heated to 60°C, stirred for 10 minutes, TMSOTf (0.34 mL, 1.8 mmol) was added thereto, and stirred at 60°C for 15 minutes. Under ice cooling, the reaction solution was added to a mixture of IPE (100 mL) and saturated aqueous sodium bicarbonate solution (100 mL) while stirring, the mixture was stirred for 20 minutes, and the insoluble matter was removed by filtration. After washing the filter cake with Et2O (10 mL), the filtrate was separated and washed with saturated brine. After drying the organic layer with sodium sulfate, the insoluble matter was removed by filtration and concentrated under reduced pressure. Dichloromethane (162mL) was added to the residue to dissolve it, and isopropyl isocyanate (1.8mL, 18mmol) was added at room temperature, and the mixture was stirred for 60 minutes. Ethyl acetate (100mL), saturated sodium bicarbonate aqueous solution (50mL), and water (50mL) were added thereto, and after separation, the organic layer was washed with saturated brine (50mL), dried with sodium sulfate, filtered, and the solvent was distilled off. THF (162mL) was added to the residue to make a solution, and TBAF (1M THF solution, 2.39mL, 8.11mmol) was added under ice cooling, and the mixture was stirred for 24 hours at room temperature. Dilute with ethyl acetate (80mL), add saturated ammonium chloride aqueous solution (50mL) and water (50mL), and stir the mixture at room temperature. Separate the liquid, wash the organic layer with saturated brine (50mL), then, dry with sodium sulfate, filter, and distill off the solvent. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 0 / 100) to obtain Compound 5Ac (10.1 g, yield in 3 steps: 77%).

[0740] MS (ESI): m / z = 770 (M + H) +

[0741] Example 39 Synthesis of Compound 5Ad

[0742] (1R,3R,4R,7S)-3-(6-benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 14 of the present invention)

[0743] In the same manner as in Example 4, compound 5d (4.6 g, yield: 51%), which is compound 14 of the present invention, was obtained from compound 5c (7.0 g, 9.09 mmol).

[0744] MS (ESI): m / z = 970 (M + H) +

[0745] 31 P-NMR (CDCl3) δ: 149.4

[0746] Synthesis of ALNA[dmU]-T

[0747] [Chemical formula 37]

[0748]

[0749] Example 40 Synthesis of Compound 6Tc

[0750] (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N,N-dimethyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0751] To a solution of compound 1a (1512 mg, 2.645 mmol) in tetrahydrofuran (26 mL), diisopropylethylamine (0.483 ml, 2.773 mmol) was added, and after ice cooling, N,N-dimethylcarbamoyl chloride (0.255 mL, 2.77 mmol) was added thereto. After the mixture was warmed to room temperature, N,N-dimethylformamide (1 mL, 12.9 mmol) was added, and the mixture was stirred for 4 hours. A mixed solution of ethyl acetate (10 mL) and saturated sodium bicarbonate aqueous solution (20 mL) was added thereto, stirred, and after separation, the aqueous layer was extracted twice with 10 mL of ethyl acetate, and the combined organic layer was washed with 10 mL of saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off. Purification by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 0 / 100) was performed, thereby obtaining compound 6Tc1 (1705 mg, yield quant.).

[0752] MS (ESI): m / z = 642 (MH) -

[0753] Example 41 Synthesis of Compound 6Td

[0754] (1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 15 of the present invention)

[0755] In the same manner as in Example 4, compound 6Td (1565 mg, yield: 68%), which is compound 15 of the present invention, was obtained from compound 6Tc (1758 mg, 2.735 mmol).

[0756] MS (ESI): m / z = 842 (MH) -

[0757] Synthesis of ALNA[dmU]-mC

[0758] [Chemical formula 38]

[0759]

[0760] Example 42 Synthesis of Compound 6mCc

[0761] (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-N,N-dimethyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide

[0762] To a solution of compound 1c (1300 mg, 1.657 mmol) in tetrahydrofuran (16.6 mL), diisopropylethylamine (0.317 mL, 1.820 mmol) was added, and after ice cooling, N,N-dimethylcarbamoyl chloride (0.168 mL, 1.83 mmol) was added thereto, and the mixture was stirred at room temperature for 10 minutes. After heating the mixture under reflux for 2 hours, it was added to a mixed solution of ethyl acetate (10 mL) and saturated sodium bicarbonate aqueous solution (20 mL) at room temperature, and after separation, the aqueous layer was extracted twice with 10 mL of ethyl acetate, and the combined organic layer was washed with 10 mL of saturated brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off. Purification by silica gel column chromatography (hexane / ethyl acetate, 70 / 30 to 30 / 70) was performed to obtain compound 6mCc (1705 mg, yield 79%).

[0763] MS (ESI): m / z = 747 (M + H) +

[0764] Example 43 Synthesis of Compound 6mCd

[0765] (1R,3R,4R,7S)-3-(4-benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide (Compound 16 of the present invention)

[0766] In the same manner as in Example 4, compound 6mCd (936.5 mg, yield: 76%), which is compound 16 of the present invention, was obtained from compound 6mCc (1019 mg, 1.312 mmol).

[0767] MS (ESI): m / z = 947 (M + H) +

[0768] Synthesis of ALNA[2Pym]-T

[0769] [Chemical formula 39]

[0770]

[0771] Example 44 Synthesis of Compound 7Tc

[0772] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0773] Under nitrogen atmosphere, a mixture of compound 1a (2.00 g, 3.50 mmol), 2-chloropyrimidine (1.20 g, 10.5 mmol), DIPEA (3.05 mL, 17.5 mmol), and DMSO (17.5 mL) was stirred at 130°C for 6 hours. Ethyl acetate was added to the reaction solution, and the mixture was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and then concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 7Tc (1.74 g, yield 77%).

[0774] HRMS(MALDI):C 36 H 35 Calculated value for N5O7 [M+Na] + :672.2429, measured value:672.2427

[0775] Example 45 Synthesis of Compound 7Td

[0776] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 17 of the present invention)

[0777] Under ice cooling, 2-cyanoethyl N, N-diisopropyl chlorophosphamide (1.19 mL, 5.32 mmol) was added to a mixture of compound 7Tc (1.73 g, 2.66 mmol), dichloromethane (13 mL), and DIPEA (1.39 mL, 7.98 mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off under reduced pressure. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 60 / 40 to 10 / 90, diol: hexane / ethyl acetate = 70 / 30 to 20 / 80, NH: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 7Td (1.53 g, yield 68%) as compound 17 of the present invention.

[0778] HRMS(FAB):C 45 H 52 Calculated value for N7O8P [M+H] + :850.3693, measured value:850.3699

[0779] 31 P-NMR(CDCl3)δ:148.72, 148.83

[0780] Synthesis of ALNA[2Pym]-mC

[0781] [Chemical formula 40]

[0782]

[0783] Example 46 Synthesis of Compound 7mCa

[0784] Acetate [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]

[0785] To a mixture of compound 7Ta (3.68 g, 5.67 mmol), DMAP (69.3 mg, 0.567 mmol) and pyridine (28 mL), acetic anhydride (0.804 mL, 8.51 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered out, and concentrated under reduced pressure. After azeotroping pyridine with ethyl acetate, it was crushed with diisopropyl ether to obtain compound 7mCa (3.49 g, yield was 89%).

[0786] HRMS(FAB):C 38 H 38 Calculated value [M+H]+ for N5O8: 692.2720, found: 692.2713

[0787] Example 47 Synthesis of Compound 7mCb

[0788] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[5-methyl-2-oxo-4-(1,2,4-triazol-1-yl)pyrimidin-1-yl]-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] acetate

[0789] Under ice cooling, phosphorus oxychloride (0.792 mL, 8.50 mmol) was added to a mixture of compound 7mCa (3.46 g, 5.00 mmol), 1,2,4-triazole (3.11 g, 45.0 mmol), DIPEA (8.71 mL, 50.0 mmol) and acetonitrile (50 mL), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and concentrated under reduced pressure. It was crushed with diisopropyl ether to obtain compound 7mCb1 (3.40 g, yield was 92%).

[0790] HRMS(FAB):C 40 H 38 Calculated for N8O7 [M+H] + :743.2942, measured value:743.2945

[0791] Example 48 Synthesis of Compound 7mCc

[0792] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidin-2-one

[0793] To a mixture of compound 7mCb (3.40 g, 4.58 mmol) and acetonitrile (46 mL), 28% aqueous ammonia (31 mL) was added, and the mixture was stirred at room temperature for 3 days. Water was added to the reaction solution and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and concentrated under reduced pressure. The compound 7mCc (2.65 g, yield was 89%) was obtained by crushing with diisopropyl ether and a small amount of ethyl acetate.

[0794] HRMS(FAB):C 36 H 36 Calculated for N6O6 [M+H] + :649.2775, measured value:649.2766

[0795] Example 49 Synthesis of Compound 7mCd

[0796] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0797] To a mixture of compound 7mCc (2.62 g, 4.04 mmol) and DMF (20 mL), anhydrous benzoic acid (959 mg, 4.24 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 7mCd (1.42 g, yield 47%).

[0798] HRMS(FAB):C 43 H 40 Calculated for N6O7 [M+H] + :753.3037, measured value:753.3035

[0799] Example 50 Synthesis of Compound 7mCe

[0800] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 18 of the present invention)

[0801] To a mixture of compound 7mCd (1.40 g, 1.86 mmol), dichloromethane (9 mL), and DIPEA (0.972 mL, 5.58 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphoramide (0.830 mL, 3.72 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 80 / 20-30 / 70, NH: hexane / ethyl acetate = 50 / 50-0 / 100) to obtain compound 7mCe (1.01 g, 57% yield) as compound 18 of the present invention.

[0802] HRMS(FAB):C 52 H 57 Calculated value [M+Na] obtained from N8O8P + :975.3935, measured value:975.3931

[0803] 31 P-NMR(CDCl3)δ:149.17, 149.23

[0804] Synthesis of ALNA[2Pym]-G

[0805] [Chemical formula 41]

[0806]

[0807] Example 51 Synthesis of Compound 7Gc

[0808] N'-[9-(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine

[0809] To a solution of compound 1d (3.00 g, 3.50 mmol) in methanol (20 mL) and THF (20 mL) was added 28% aqueous ammonia (40 mL). Methanol (20 mL) and THF (20 mL) were added, and the mixture was allowed to stand at room temperature for 16 hours. A 40% methanol solution of methylamine (40 mL) was added, and the mixture was allowed to stand at room temperature for 4 hours. After the solvent was distilled off, it was azeotroped with toluene and dried under reduced pressure. DMSO (35 mL) was added to the residue to dissolve it, and DIPEA (4.8 mL, 28.0 mmol) and 2-fluoropyrimidine (0.66 mL, 10.5 mmol) were added thereto, and the mixture was stirred at 80°C for 2 hours, and then stirred at 100°C for 2 hours. 2-Fluoropyrimidine (0.66 mL, 10.5 mmol) was added thereto, and the mixture was further stirred at 100°C for 2 hours. 2-Fluoropyrimidine (0.22 mL, 3.5 mmol) and DIPEA (1.6 mL, 9.3 mmol) were added again, and the mixture was stirred at 100 ° C for 2 hours. N, N-dimethylformamide dimethyl acetal (2.3 mL, 17.0 mmol) was added to the reaction solution and stirred at room temperature. After 1 hour, ethyl acetate (200 mL), saturated sodium bicarbonate aqueous solution (20 mL), and water (80 mL) were added to separate the liquids. The organic layer was washed 3 times with water (50 mL), and then washed with saturated brine. After drying with sodium sulfate, the insoluble matter was filtered out, and the solvent was distilled off under reduced pressure. The aqueous layer during separation was further extracted 3 times with chloroform (100 mL), and washed with water (100 mL) and saturated brine. After drying the chloroform layer over sodium sulfate, the insoluble matter was filtered out, and the solvent was distilled off under reduced pressure. The mixture was combined with the previous extract and purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 92 / 8) to obtain compound 7Gc (1.66 g, 65% yield in 3 steps).

[0810] MS (ESI): m / z = 731 (M + H) +

[0811] Example 52 Synthesis of Compound 7Gd

[0812] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-6-carboxamidine (Compound 19 of the present invention)

[0813] In the same manner as in Example 4, compound 7Gd (1.07 g, yield: 53%), which is compound 19 of the present invention, was obtained from compound 7Gc (1.58 g, 2.16 mmol).

[0814] MS (ESI): m / z = 931 (M + H) +

[0815] Synthesis of ALNA[2Pym]-A

[0816] [Chemical formula 42]

[0817]

[0818] Example 53 Synthesis of Compound 7Aa

[0819] N-[9-(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide

[0820] Under a nitrogen atmosphere, a mixture of compound 1e (500 mg, 0.730 mmol), 2-fluoropyrimidine (215 mg, 2.19 mmol), DIPEA (0.509 mL, 2.92 mmol), and DMSO (7 mL) synthesized by the method described in International Publication No. 2017 / 047816 was stirred at 130 ° C for 7 hours. Ethyl acetate was added to the reaction solution and washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered out, the solvent was distilled off under reduced pressure, and concentrated. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 7Aa (207 mg, yield 37%).

[0821] HRMS(MALDI):C 43 H 38 Calculated value for N8O6 [M+Na] + :785.2807, measured value:785.2807

[0822] Example 54 Synthesis of Compound 7Ab

[0823] N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 20 of the present invention)

[0824] To a mixture of compound 7Aa (126 mg, 0.165 mmol), dichloromethane (3 mL), and DIPEA (86.2 μL, 0.495 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (73.6 μL, 0.330 mmol) was added, and the mixture was stirred for 5 hours at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (NH: hexane / ethyl acetate = 50 / 50 to 0 / 100, SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100, diol: hexane / ethyl acetate = 60 / 40 to 10 / 90) to obtain compound 7Ab (110 mg, 69% yield) as compound 20 of the present invention.

[0825] HRMS(MALDI):C 52 H 55 N 10 Calculated value [M+Na] obtained by O7P + :985.3885, measured value:985.3878

[0826] 31 P-NMR(CDCl3)δ:149.33, 149.47

[0827] Synthesis of ALNA[4Pym]-T

[0828] [Chemical formula 43]

[0829]

[0830] Example 55 Synthesis of Compound 8Ta 1-[(1R,3R,4R,7S)-7-benzyloxy-1-(benzyloxymethyl)-5-(6-chloropyrimidin-4-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0831] A mixture (2 batches) of compound 1f (1.00 g, 2.22 mmol), 4,6-dichloropyrimidine (398 mg, 2.66 mmol), DIPEA (1.16 mL, 6.66 mmol), and EtOH (20 mL) synthesized by the method described in International Publication No. 2017 / 047816 was stirred at 120° C. for 5 hours for each batch under microwave irradiation. The batches were combined, the insoluble matter in the reaction solution was filtered out, and washed with EtOH, thereby obtaining compound 8Ta (1.54 g, yield 62%).

[0832] HRMS(FAB):C29 H 28 Calculated value for ClN5O5 [M+H] + :562.1857, measured value:562.1859

[0833] Example 56 Synthesis of Compound 8Tb

[0834] 1-[(1R,3R,4R,7S)-5-(6-chloropyrimidin-4-yl)-7-hydroxy-1-(hydroxymethyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0835] Under nitrogen atmosphere, trichloroborane (1.0 mol / L dichloromethane solution, 62 mL, 62.1 mmol) was added to a mixture of compound 8Ta (3.49 g, 6.21 mmol) and dichloromethane (62 mL) at -78 °C, and the mixture was slowly warmed to room temperature while stirring overnight. Under ice cooling, MeOH (62 mL) was slowly added to the reaction solution and stirred at room temperature for a while. After the reaction solution was concentrated, it was crushed with ethyl acetate to obtain compound 8Tb (3.27 g) as a crude product.

[0836] HRMS(FAB):C 15 H 16 Calculated value for ClN5O5 [M+H] + :382.0918, measured value:382.0919

[0837] Example 57 Synthesis of Compound 8Tc

[0838] 1-[(1R,3R,4R,7S)-7-Hydroxy-1-(hydroxymethyl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0839] 20% palladium hydroxide (654 mg, 20 wt%) was added to compound 8Tb (3.27 g, 6.21 mmol, in bold) and MeOH (62 mL), and the mixture was stirred overnight at room temperature under a hydrogen atmosphere. Water (31 mL) was added to the reaction solution to dissolve the insoluble matter, and the palladium was filtered through celite. The filtrate was concentrated, and water and toluene were azeotroped. The residue was crushed with MeOH to obtain compound 8Tc (1.75 g, 81% yield in 2 steps).

[0840] HRMS(MALDI):C 15 H 17 Calculated for N5O5 [M+H] +:348.1302, measured value:348.1308

[0841] Example 58 Synthesis of Compound 8Td

[0842] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0843] To a mixture of compound 8Tc (444 mg, 1.28 mmol) and pyridine (13 mL), 4,4-dimethoxytrityl chloride (520 mg, 1.54 mmol) was added, and the mixture was stirred overnight at room temperature. Under ice cooling, the reaction solution was added dropwise to a saturated sodium bicarbonate aqueous solution, and ethyl acetate was added thereto. The organic layer was washed with a saturated sodium bicarbonate aqueous solution, water, and saturated saline. The organic layer was dried over anhydrous magnesium sulfate and concentrated. Pyridine was azeotropically removed with ethyl acetate, and the residue was crushed with diisopropyl ether, thereby obtaining compound 8Td (652 mg, yield 78%).

[0844] HRMS(MALDI):C 36 H 35 Calculated for N5O7 [M+H] + :650.2609, measured value:650.2600

[0845] Example 59 Synthesis of Compound 8Te

[0846] 3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 21 of the present invention)

[0847] Under ice cooling, 2-cyanoethyl N, N-diisopropylchlorophosphoramide (309 μL, 1.39 mmol) was added to a mixture of compound 8Td (300 mg, 0.462 mmol), dichloromethane (5 mL), and DIPEA (322 μL, 1.85 mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0-90 / 10, diol: hexane / ethyl acetate = 50 / 50-0 / 100) to obtain compound 8Te (263 mg, 67% yield) as compound 21 of the present invention.

[0848] HRMS(FAB):C 45 H 52 Calculated value for N7O8P [M+H] + :850.3693, measured value:850.3685

[0849] 31 P-NMR(CDCl3)δ:148.93, 149.47

[0850] Synthesis of ALNA[4Pym]-mC

[0851] [Chemical formula 44]

[0852]

[0853] Example 60 Synthesis of Compound 8Ca

[0854] Acetate [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]

[0855] To a mixture of compound 8Td (234 mg, 0.360 mmol), DMAP (4.4 mg, 0.0360 mmol) and pyridine (3.6 mL), acetic anhydride (51.1 μL, 0.540 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with 5% aqueous copper sulfate, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was crushed with diisopropyl ether to obtain compound 8Ca (219 mg, yield 88%).

[0856] HRMS(FAB):C 38 H 37Calculated for N5O8 [M+H] + :692.2720, measured value:692.2720

[0857] Example 61 Synthesis of Compound 8Cb

[0858] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-[5-methyl-2-oxo-4-(1,2,4-triazol-1-yl)pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]acetate

[0859] Under ice cooling, phosphorus oxychloride (46.1 μL, 0.494 mmol) was added to a mixture of compound 8Ca (201 mg, 0.291 mmol), 1,2,4-triazole (181 mg, 2.62 mmol), DIPEA (507 μL, 2.91 mmol) and acetonitrile (3 mL), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. It was crushed with diisopropyl ether to obtain compound 8Cb (211 mg, 98% yield).

[0860] HRMS(FAB):C 40 H 38 Calculated for N8O7 [M+H] + :743.2942, measured value:743.2939

[0861] Example 62 Synthesis of Compound 8Cc

[0862] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0863] To a mixture of compound 8Cb (613 mg, 0.825 mmol) and acetonitrile (8.3 mL), 28% aqueous ammonia (5.5 mL) was added, and the mixture was stirred overnight at room temperature. The acetonitrile of the reaction solution was concentrated. The insoluble matter was filtered out and washed with water. The crude product was crushed again with ethyl acetate to obtain compound 8Cc (380 mg, yield 71%).

[0864] HRMS(FAB):C 36 H 36 Calculated for N6O6 [M+H] +:649.2775, measured value:649.2773

[0865] Example 63 Synthesis of Compound 8Cd

[0866] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0867] To a mixture of compound 8Cc (378 mg, 0.583 mmol) and pyridine (6 mL), anhydrous benzoic acid (198 mg, 0.875 mmol) was added, and the mixture was stirred at room temperature for 3 days. The reaction solution was concentrated, and the residue was purified by column chromatography (diol: 0.5% triethylamine-chloroform / methanol = 100 / 0 to 90 / 10, SiO2: 0.5% triethylamine-chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 8Cd (247 mg, yield 56%).

[0868] HRMS(FAB):C 43 H 40 Calculated for N6O7 [M+H] + :753.3037, measured value:753.3040

[0869] Example 64 Synthesis of Compound 8Ce

[0870] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 22 of the present invention)

[0871] To a mixture of compound 8Cd (135 mg, 0.179 mmol), dichloromethane (2 mL), and DIPEA (125 μL, 0.716 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (120 μL, 0.537 mmol) was added, and the mixture was stirred at room temperature for 2 days under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100, diol: hexane / ethyl acetate = 60 / 40 to 10 / 90, NH: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 8Ce (61.9 mg, 36% yield) as compound 22 of the present invention.

[0872] HRMS(FAB):C 52 H 57 Calculated value for N8O8P [M+H] + :953.4115, measured value:953.4109

[0873] 31 P-NMR(CDCl3)δ:149.65, 150.24

[0874] Synthesis of ALNA[4-CF3-2Pym]-T

[0875] [Chemical formula 45]

[0876]

[0877] Example 65 Synthesis of Compound 9Ta

[0878] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0879] Under microwave irradiation, a mixture of compound 1a (500 mg, 0.875 mmol), 2-chloro-4-trifluoropyrimidine (239 mg, 1.31 mmol), DIPEA (457 μL, 2.63 mmol), and EtOH (4.4 mL) was stirred at 120°C for 30 minutes. 2-Chloro-4-trifluoropyrimidine (239 mg, 1.31 mmol) and DIPEA (457 μL, 2.63 mmol) were added to the reaction solution, and the mixture was stirred at 120°C for 1 hour under microwave irradiation. The reaction solution was concentrated, ethyl acetate was added, and the mixture was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 9Ta (545 mg, yield 87%).

[0880] HRMS(FAB):C 37 H 34 Calculated value for F3N5O7 [M+H] + :718.2489, measured value:718.2491

[0881] Example 66 Synthesis of Compound 9Tb

[0882] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 23 of the present invention)

[0883] Under ice cooling, 2-cyanoethyl N, N-diisopropyl chlorophosphamide (328 μL, 1.47 mmol) was added to a mixture of compound 9Ta (527 mg, 0.734 mmol), dichloromethane (7 mL), and DIPEA (384 μL, 2.20 mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 80 / 20-30 / 70, diol: hexane / ethyl acetate = 70 / 30-20 / 80) to obtain compound 9Tb (530 mg, 79% yield) as compound 23 of the present invention.

[0884] HRMS(FAB):C 46 H 51 Calculated value for F3N7O8P [M+H] +:918.3567, measured value:918.3568

[0885] 31 P-NMR(CDCl3)δ:149.04,149.12,149.20,149.47

[0886] Synthesis of ALNA[4-CF3-2Pym]-G

[0887] [Chemical formula 46]

[0888]

[0889] Example 67 Synthesis of Compound 9Ca

[0890] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidin-2-one

[0891] Under microwave irradiation, a mixture of compound 4Ca (500 mg, 0.876 mmol), 2-chloro-4-trifluoropyrimidine (317 μL, 2.63 mmol), DIPEA (610 μL, 3.50 mmol), and EtOH (4.4 mL) was stirred at 150°C for 1 hour. The reaction solution was concentrated, ethyl acetate was added, and washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 9Ca (186 mg, yield 30%).

[0892] HRMS(FAB):C 37 H 35 Calculated value for F3N6O6 [M+H] + :717.2648, measured value:717.2651

[0893] Example 68 Synthesis of Compound 9Cb N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0894] To a mixture of compound 9Ca (395 mg, 0.551 mmol) and DMF (5.5 mL), anhydrous benzoic acid (131 mg, 0.579 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and the mixture was washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 15) to obtain compound 9Cb (335 mg, yield 74%).

[0895] HRMS(FAB):C 44 H 39 Calculated value for F3N6O7 [M+H] + :821.2911, measured value:821.2932

[0896] Example 69 Synthesis of Compound 9Cc

[0897] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 24 of the present invention)

[0898] To a mixture of compound 9Cb (316 mg, 0.385 mmol), dichloromethane (4 mL), and DIPEA (201 μL, 1.16 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphoramide (172 μL, 0.770 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 100 / 0 to 50 / 50, diol: hexane / ethyl acetate = 100 / 0 to 50 / 50) to obtain compound 9Cc (227 mg, 58% yield) as compound 24 of the present invention.

[0899] HRMS(FAB):C 53 H 56 Calculated value for F3N8O8P [M+H] + :1021.3989, measured value:1021.3993

[0900] 31 P-NMR(CDCl3)δ:149.15,149.28,149.36,149.60

[0901] Synthesis of ALNA[5-Cl-2Pym]-G

[0902] [Chemical formula 47]

[0903]

[0904] Example 70 Synthesis of Compound 10Ta

[0905] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0906] Under microwave irradiation, a mixture of compound 1a (500 mg, 0.875 mmol), 2,5-dichloropyrimidine (196 mg, 1.31 mmol), DIPEA (457 μL, 2.63 mmol), and EtOH (4.4 mL) was stirred at 150°C for 1 hour. The insoluble matter in the reaction solution was dissolved with chloroform and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 10Ta (263 mg, yield 44%).

[0907] HRMS(FAB):C 36 H 34 Calculated value for ClN5O7 [M+H] + :684.2225, measured value:684.2226

[0908] Example 71 Synthesis of Compound 10Tb

[0909] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 25 of the present invention)

[0910] Under ice cooling, to a mixture of compound 10Ta (240 mg, 0.351 mmol), dichloromethane (3.5 mL), and DIPEA (183 μL, 1.05 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (157 μL, 0.702 mmol) was added, and the mixture was stirred for 4 days at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 70 / 30 to 20 / 80, diol: hexane / ethyl acetate = 70 / 30 to 20 / 80) to obtain compound 10Tb (201 mg, 65% yield) as compound 25 of the present invention.

[0911] HRMS(FAB):C 45 H 51 Calculated value for ClN7O8P [M+H] + :884.3304, measured value:884.3303

[0912] 31 P-NMR (CDCl3) δ: 149.12

[0913] Synthesis of ALNA[5-Cl-2Pym]-mC

[0914] [Chemical formula 48]

[0915]

[0916] Example 72 Synthesis of Compound 10mCa

[0917] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0918] For a mixture (2 batches) of compound 4Ca (500 mg, 0.876 mmol), 2,5-dichloropyrimidine (391 mg, 2.63 mmol), DIPEA (610 μL, 3.50 mmol), and EtOH (4.4 mL), each batch was stirred for 1 hour at 150°C under microwave irradiation. The reaction solution was concentrated, water was added, and extracted with chloroform. The combined organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 10mCa (381 mg, yield 32%).

[0919] HRMS(FAB):C 36 H 35 Calculated value for ClN6O6 [M+H] + :683.2385, measured value:683.2389

[0920] Example 73 Synthesis of Compound 10mCb

[0921] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0922] To a mixture of compound 10mCa (375 mg, 0.549 mmol) and DMF (5.5 mL), anhydrous benzoic acid (130 mg, 0.576 mmol) was added, and the mixture was stirred overnight at room temperature. Anhydrous benzoic acid (24.8 mg, 0.110 mmol) was added to the reaction solution, and then stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 10mCb (422 mg, yield 98%).

[0923] HRMS(MALDI):C 43 H 39 Calculated value for ClN6O7 [M+Na] + :809.2461, measured value:809.2463

[0924] Example 74 Synthesis of Compound 10mCc

[0925] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-4-yl]benzamide (Compound 26 of the present invention)

[0926] To a mixture of compound 10mCb (409 mg, 0.520 mmol), dichloromethane (5 mL), and DIPEA (272 μL, 1.56 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphamide (232 μL, 1.04 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 100 / 0 to 50 / 50, diol: hexane / ethyl acetate = 100 / 0 to 50 / 50) to obtain compound 10mCc (264 mg, 51% yield) as compound 26 of the present invention.

[0927] HRMS(MALDI):C 52 H 56 Calculated value for ClN8O8P [M+Na] + :1009.3540, measured value:1009.3521

[0928] 31 P-NMR (CDCl3) δ: 149.28

[0929] Synthesis of ALNA[6-NMe2-4Pym]-T

[0930] [Chemical formula 49]

[0931]

[0932] Example 75 Synthesis of Compound 11Ta

[0933] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(6-chloropyrimidin-4-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0934] Under microwave irradiation, a mixture of compound 1a (1.00 g, 1.75 mmol), 4,6-2-dichloropyrimidine (391 mg, 2.63 mmol), DIPEA (914 μL, 5.25 mmol), and EtOH (18 mL) was stirred for 1 hour at 120° C. The reaction solution was concentrated, and the residue was purified by column chromatography (SiO2: chloroform / methanol=100 / 0 to 95 / 5) to obtain compound 11Ta (1.00 g, yield 84%).

[0935] HRMS(FAB):C 36 H 34Calculated value for ClN5O7 [M+H] + :684.2225, measured value:684.2214

[0936] Example 76 Synthesis of Compound 11Tb

[0937] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0938] To a mixture of compound 11Ta (500 mg, 0.731 mmol), DIPEA (637 μL, 3.66 mmol) and EtOH (5 mL) was added dimethylamine hydrochloride (179 mg, 2.19 mmol), and stirred at 150° C. for 30 minutes under microwave irradiation. The insoluble matter was filtered off to obtain compound 11Tb (386 mg, yield 76%).

[0939] HRMS(FAB):C 38 H 40 Calculated for N6O7 [M+H] + :693.3037, measured value:693.3030

[0940] Example 77 Synthesis of Compound 11Tc

[0941] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamine)phosphino]oxypropionitrile (Compound 27 of the present invention)

[0942] Under ice cooling, 2-cyanoethyl N, N-diisopropyl chlorophosphamide (216 μL, 0.968 mmol) was added to a mixture of compound 11Tb (335 mg, 0.484 mmol), dichloromethane (5 mL), and DIPEA (253 μL, 1.45 mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. DMF (2 mL) was added to the reaction solution, and stirred overnight at room temperature under a nitrogen atmosphere. DIPEA (253 μL, 1.45 mmol) and 2-cyanoethyl N, N-diisopropyl chlorophosphamide (216 μL, 0.968 mmol) were added to the reaction solution, and the mixture was stirred for 2 days at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and washed with a saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10, diol: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain Compound 11Tc (189 mg, yield 44%) as Compound 27 of the present invention.

[0943] HRMS(FAB):C 47 H 57 Calculated value for N8O8P [M+H] + :893.4115, measured value:893.4115

[0944] 31 P-NMR (CDCl3)δ:148.83,148.99

[0945] Synthesis of ALNA[6-NMe2-4Pym]-mC

[0946] [Chemical formula 50]

[0947]

[0948] Example 78 Synthesis of Compound 11mCa

[0949] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(6-chloropyrimidin-4-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0950] A mixture of compound 4mCa1 (2.00 g, 3.50 mmol), 4,6-dichloropyrimidine (626 mg, 4.20 mmol), DIPEA (1.83 mL, 10.5 mmol), and EtOH (17.5 mL) was stirred at 100°C for 4 hours. The reaction solution was concentrated, water was added, and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 11mCa (1.34 g, yield 56%).

[0951] HRMS(FAB):C 36 H 35 Calculated value for ClN6O6 [M+H] + :683.2385, measured value:683.2384

[0952] Example 79 Synthesis of Compound 11mCb

[0953] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0954] Under microwave irradiation, a mixture of compound 11mCa (1.12 g, 1.64 mmol), dimethylamine (50% aqueous solution, 863 μL, 8.20 mmol), and EtOH (11 mL) was stirred for 30 minutes at 150° C. The reaction solution was concentrated, and the residue was purified by column chromatography (NH: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 11mCb (1.09 g, yield 96%).

[0955] HRMS(MALDI):C 38 H 41 Calculated value for N7O6 [M+Na] + :714.3011, measured value:714.3003

[0956] Example 80 Synthesis of Compound 11mCc

[0957] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0958] To a mixture of compound 11mCb (1.08 g, 1.56 mmol) and DMF (8 mL), anhydrous benzoic acid (389 mg, 1.72 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 11mCc (1.02 g, yield 82%).

[0959] HRMS(MALDI):C 45 H 45 Calculated for N7O7 [M+H] + :796.3453, measured value:796.3466

[0960] Example 81 Synthesis of Compound 11mCd

[0961] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[(6-dimethylamino)pyrimidin-4-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 28 of the present invention)

[0962] To a mixture of compound 11mCc (972 mg, 1.22 mmol), dichloromethane (12 mL), and DIPEA (637 μL, 3.66 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (545 μL, 2.44 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100, NH: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 11mCd (788 mg, 65% yield) as compound 28 of the present invention.

[0963] HRMS(MALDI):C 54 H 62 Calculated value for N9O8P [M+H] + :996.4532, measured value:996.4513

[0964] 31 P-NMR (CDCl3)δ:149.06,149.17

[0965] Synthesis of ALNA[2-NMe2-4Pym]-T

[0966] [Chemical formula 51]

[0967]

[0968] Example 82 Synthesis of Compound 12Ta

[0969] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(2-chloropyrimidin-4-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0970] A mixture of compound 1a (2.00 g, 3.50 mmol), 2,4-dichloropyrimidine (782 mg, 5.25 mmol), DIPEA (1.83 mL, 10.5 mmol), and EtOH (17.5 mL) was stirred at 100°C for 4.5 hours. The reaction solution was concentrated, water was added, and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 12Ta (1.86 g, yield 78%).

[0971] HRMS(FAB):C 36 H 34 Calculated value for ClN5O7 [M+H] + :684.2225, measured value:684.2223

[0972] Example 83 Synthesis of Compound 12Tb

[0973] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[0974] To a mixture of compound 12Ta (500 mg, 0.731 mmol), DIPEA (637 μL, 3.66 mmol) and EtOH (5 mL), dimethylamine hydrochloride (179 mg, 2.19 mmol) was added, and stirred at 150°C for 30 minutes under microwave irradiation. The reaction solution was concentrated, and the residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5). The mixture was crushed with diisopropyl ether to obtain compound 12Tb (648 mg) as a crude product.

[0975] HRMS(FAB):C 38 H 40 Calculated for N6O7 [M+H] + :693.3037, measured value:693.3041

[0976] Example 84 Synthesis of Compound 12Tc

[0977] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)oxypropionitrile (Compound 29 of the present invention)

[0978] Under ice cooling, 2-cyanoethyl N, N-diisopropylchlorophosphoramide (326 μL, 1.46 mmol) was added to a mixture of compound 12Tb (638 mg, 0.731 mmol, bold), dichloromethane (7 mL), and DIPEA (382 μL, 2.19 mmol), and the mixture was stirred for 5 days at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10, diol: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 12Tc (304 mg, 47% yield in 2 steps) as compound 29 of the present invention.

[0979] HRMS(FAB):C 47 H 57 Calculated value for N8O8P [M+H] + :893.4115, measured value:893.4128

[0980] 31 P-NMR (CDCl3)δ:148.91,149.33

[0981] Synthesis of ALNA[2-NMe2-4Pym]-mC

[0982] [Chemical formula 52]

[0983]

[0984] Example 85 Synthesis of Compound 12mCa

[0985] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(2-chloropyrimidin-4-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0986] A mixture of compound 4mCa (2.00 g, 3.50 mmol), 2,4-dichloropyrimidine (627 mg, 4.20 mmol), DIPEA (1.83 mL, 10.5 mmol), and EtOH (17.5 mL) was stirred at 100°C for 3 hours. The reaction solution was concentrated, water was added, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 12mCa (1.28 g, yield 54%).

[0987] HRMS(MALDI):C 36 H 35 Calculated value for ClN6O6 [M+Na] + :705.2199, measured value:705.2194

[0988] Example 86 Synthesis of Compound 12mCb

[0989] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[0990] Under microwave irradiation, a mixture of compound 12mCa (941 mg, 1.38 mmol), dimethylamine (50% aqueous solution, 725 μL, 6.90 mmol), and EtOH (14 mL, 0.1 M) was stirred for 30 minutes at 150° C. The reaction solution was concentrated, and the residue was purified by column chromatography (NH: chloroform / methanol=100 / 0 to 90 / 10) to obtain compound 12mCb (784 mg, yield 82%).

[0991] HRMS(MALDI):C 38 H 41 Calculated for N7O6 [M+H] + :692.3191, measured value:692.3167

[0992] Example 87 Synthesis of Compound 12mCc

[0993] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[0994] To a mixture of compound 12mCb (754 mg, 1.09 mmol) and DMF (5.5 mL), anhydrous benzoic acid (271 mg, 1.20 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 12mCc (731 mg, yield 84%).

[0995] HRMS(MALDI):C 45 H 45 Calculated for N7O7 [M+H] + :796.3453, measured value:796.3440

[0996] Example 88 Synthesis of Compound 12mCd

[0997] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 30 of the present invention)

[0998] To a mixture of compound 12mCc (709 mg, 0.891 mmol), dichloromethane (9 mL), and DIPEA (466 μL, 2.67 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphamide (397 μL, 1.78 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100, NH: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 12mCd (482 mg, 54% yield) as compound 30 of the present invention.

[0999] HRMS(MALDI):C54 H 62 Calculated value for N9O8P [M+H] + :996.4532, measured value:996.4526

[1000] 31 P-NMR(CDCl3)δ:149.19,149.46,149.65

[1001] Synthesis of ALNA[Prz]-T

[1002] [Chemical formula 53]

[1003]

[1004] Example 89 Synthesis of Compound 13Ta

[1005] [1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[1006] A mixture of compound 1a (500 mg, 0.875 mmol), 2-fluoropyrazine (201 μL, 2.63 mmol), DIPEA (610 μL, 3.50 mmol), and DMSO (8.8 mL) was stirred at 140°C for 1.5 hours and at 150°C for 4.5 hours under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10, SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 13Ta (227 mg, 40% yield).

[1007] HRMS(MALDI):C 36 H 35 Calculated value for N5O7 [M+Na] + :672.2429, measured value:672.2409

[1008] Example 90 Synthesis of Compound 13Tb

[1009] 3-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 31 of the present invention)

[1010] To a mixture of compound 13Ta (214 mg, 0.329 mmol), dichloromethane (6.6 mL), and DIPEA (172 μL, 0.987 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (147 μL, 0.658 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50-0 / 100, NH: ethyl acetate / methanol = 100 / 0-90 / 10) to obtain compound 13Tb (204 mg, 73% yield) as compound 31 of the present invention.

[1011] HRMS(MALDI):C 45 H 52 Calculated value [M+Na] for N7O8P + :872.3507, measured value:872.3507

[1012] 31 P-NMR (CDCl3)δ:149.12,149.31

[1013] Synthesis of ALNA[Prz]-mC

[1014] [Chemical formula 54]

[1015]

[1016] Example 91 Synthesis of Compound 13mCb

[1017] Acetate [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]

[1018] To a mixture of compound 13Ta (746 mg, 1.15 mmol), DMAP (14.0 mg, 0.115 mmol) and pyridine (5.8 mL), acetic anhydride (163 μL, 1.73 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. Pyridine was azeotropically removed with ethyl acetate, and the residue was crushed with diisopropyl ether to obtain compound 13mCb (712 mg, yield was 90%).

[1019] HRMS(MALDI):C 38 H 37 Calculated value for N5O8 [M+Na] + :714.2534, measured value:714.2520

[1020] Example 92 Synthesis of Compound 13mCc

[1021] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2-oxo-(4-1,2,4-triazol-1-yl)pyrimidin-1-yl]-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] acetate

[1022] Under ice cooling, phosphorus oxychloride (158 μL, 1.70 mmol) was added to a mixture of compound 13mCb (692 mg, 1.00 mmol), 1,2,4-triazole (622 mg, 9.00 mmol), DIPEA (1.74 mL, 10.0 mmol) and acetonitrile (10 mL), and the mixture was stirred for 1 hour at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 13mCc (753 mg) as a crude product.

[1023] HRMS(MALDI):C 40 H 38 Calculated value for N8O7 [M+Na] + :765.2756, measured value:765.2750

[1024] Example 93 Synthesis of Compound 13mCd

[1025] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[1026] To a mixture of compound 13mCc (744 mg, 1.00 mmol, in bold) and acetonitrile (10 mL), 28% aqueous ammonia (6.7 mL) was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, and extraction was performed with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain compound 13mCd (638 mg, yield 98%, 2 steps).

[1027] HRMS(MALDI):C 36 H 36 Calculated value for N6O6 [M+Na] + :671.2589, measured value:671.2591

[1028] Example 94 Synthesis of Compound 13mCe

[1029] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[1030] To a mixture of compound 13mCd (625 mg, 0.963 mmol) and DMF (4.8 mL), anhydrous benzoic acid (327 mg, 1.44 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 13mCe (245 mg, yield 34%).

[1031] HRMS(MALDI):C 43 H 40 Calculated value for N6O7 [M+Na] + :775.2851, measured value:775.2845

[1032] Example 95 Synthesis of Compound 13mCf

[1033] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 32 of the present invention)

[1034] To a mixture of compound 13mCe (565 mg, 0.751 mmol), dichloromethane (7.5 mL), and DIPEA (392 μL, 2.25 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphamide (335 μL, 1.50 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 70 / 30 to 20 / 80, NH: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 13mCf (369 mg, 52% yield) as compound 32 of the present invention.

[1035] HRMS(MALDI):C 50 H 44 Calculated value for N6O8 [M+Na] + :975.3929, measured value:975.3923

[1036] 31 P-NMR (CDCl3)δ:149.25,149.49

[1037] Synthesis of ALNA[Trz]-T

[1038] [Chemical formula 55]

[1039]

[1040] Example 96 Synthesis of Compound 14Ta

[1041] (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbothioamide

[1042] To a mixture of compound 1a (2.00 g, 3.50 mmol) and THF (17.5 mL), 1,1-thiocarbonyldiimidazole (1.25 g, 7.00 mmol) was added, and the mixture was stirred overnight at room temperature. 28% ammonia water (17.5 mL) was added to the reaction solution, and stirred overnight at room temperature. The reaction solution was concentrated and the insoluble matter was filtered out. The insoluble matter was washed with water, thereby obtaining compound 14Ta (2.35 g) as a crude product.

[1043] HRMS(MALDI):C 33 H 34 Calculated value for N4O7 [M+Na] + :653.2040, measured value:653.2026

[1044] Example 97 Synthesis of Compound 14Tb

[1045] (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboximidothioic acid methyl ester

[1046] To a mixture of compound 14Ta (2.35 g, 3.50 mmol, in bold) and THF (17.5 mL), iodomethane (654 μL, 10.5 mmol) was added, and the mixture was stirred at room temperature for 2 days. A saturated aqueous sodium bicarbonate solution was added to the reaction solution, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and then concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 80 / 20) to obtain compound 14Tb (1.88 g, 83% yield in 2 steps).

[1047] HRMS(MALDI):C 34 H 36 Calculated for N4O7 [M+H] + :645.2377, measured value:645.2374

[1048] Example 98 Synthesis of Compound 14Tc

[1049] Acetate [(1R,3R,4R,7S)-5-[(Z)-N-acetyl-C-methylsulfanyl-carboimidolyl]-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] ester

[1050] To a mixture of compound 14Tb (1.87 g, 2.90 mmol), DMAP (35.4 mg, 0.290 mmol), and pyridine (14.5 mL), acetic anhydride (822 μL, 8.70 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and the mixture was washed with a 5% aqueous copper sulfate solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and then concentrated under reduced pressure to obtain compound 14Tc (2.11 g, yield 100%).

[1051] HRMS(MALDI):C 38 H 40 Calculated value [M+Na]+ obtained by N4O9S: 751.2408, measured value: 751.2398

[1052] Example 99 Synthesis of Compound 14Td

[1053] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[1054] Methylhydrazine (1.20 mL, 22.8 mmol) was added to a mixture of compound 14Tc (1.66 g, 2.28 mmol) and EtOH (23 mL), and the mixture was stirred overnight at room temperature. The reaction solution was concentrated, and the residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 14Td (985 mg, yield 65%).

[1055] HRMS(MALDI):C 36 H 38 Calculated value for N6O7 [M+Na] + :689.2694, measured value:689.2684

[1056] Example 100 Synthesis of Compound 14Te

[1057] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 33 of the present invention)

[1058] To a mixture of compound 14Td (576 mg, 0.864 mmol), dichloromethane (8.6 mL), and DIPEA (451 μL, 2.59 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (385 μL, 1.73 mmol) was added, and the mixture was stirred for 2 days at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50 to 0 / 100, diol: hexane / ethyl acetate = 50 / 50 to 0 / 100) to obtain compound 14Te (517 mg, 69% yield) as compound 33 of the present invention.

[1059] HRMS(MALDI):C 45 H 55 Calculated value [M+Na] obtained from N8O8P + :889.3773, measured value:889.3778

[1060] 31 P-NMR (CDCl3) δ: 148.40, 148.45

[1061] Synthesis of ALNA[Trz]-mC

[1062] [Chemical formula 56]

[1063]

[1064] Example 101 Synthesis of Compound 14Ca

[1065] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]acetate

[1066] To a mixture of compound 14Td (918 mg, 1.38 mmol), DMAP (16.9 mg, 0.138 mmol), and pyridine (6.9 mL), acetic anhydride (196 μL, 2.07 mmol) was added, and the mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and the mixture was washed with saturated sodium bicarbonate aqueous solution, water, and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and then concentrated under reduced pressure to obtain compound 14Ca (955 mg, yield 98%).

[1067] HRMS(MALDI):C 38 H 40 Calculated value for N6O8 [M+Na] + :731.2800, measured value:731.2791

[1068] Example 102 Synthesis of Compound 14Cb

[1069] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2-oxo-4-(1,2,4-triazol-1-yl)pyrimidin-1-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] acetate

[1070] Under ice cooling, phosphorus oxychloride (204 μL, 2.19 mmol) was added to a mixture of compound 14Ca (915 mg, 1.29 mmol), 1,2,4-triazole (802 mg, 11.6 mmol), DIPEA (2.25 mL, 12.9 mmol), and acetonitrile (12.9 mL), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was removed by filtration, and then concentrated under reduced pressure to obtain compound 14Cb (1.08 g) as a crude product.

[1071] HRMS(MALDI):C 40 H 41 Calculated value for N9O7 [M+Na] + :782.3021, measured value:782.3019

[1072] Example 103 Synthesis of Compound 14Cc

[1073] 4-Amino-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidin-2-one

[1074] To a mixture of compound 14Cb (1.07 g, 1.29 mmol, in bold) and acetonitrile (12.9 mL), 28% aqueous ammonia (8.6 mL) was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, and it was extracted with chloroform. The organic layer was passed through a phase separator and concentrated to obtain compound 14Cc (748 mg, 87% yield in two steps).

[1075] HRMS(MALDI):C 36 H 39 Calculated value for N7O6 [M+Na] + :688.2854, measured value:688.2857

[1076] Example 104 Synthesis of Compound 14Cd

[1077] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[1078] To a mixture of compound 14Cc (733 mg, 1.10 mmol) and pyridine (5.5 mL), anhydrous benzoic acid (374 mg, 1.65 mmol) was added, and the mixture was stirred overnight at room temperature. 2 equivalents of sodium hydroxide aqueous solution (5.5 mL) was added to the reaction solution, and the mixture was stirred for 1 hour at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 14Cd (744 mg, yield 88%).

[1079] HRMS(MALDI):C 43 H 43 Calculated value for N7O7 [M+Na] + :792.3116, measured value:792.3111

[1080] Example 105 Synthesis of Compound 14Ce

[1081] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 34 of the present invention)

[1082] Under ice cooling, 2-cyanoethyl N, N-diisopropylchlorophosphoramide (0.423mL, 1.90mmol) was added to a mixture of compound 14Cd (730mg, 0.948mmol), dichloromethane (9.5mL), and DIPEA (0.495mL, 2.84mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 50 / 50-0 / 100, NH: hexane / ethyl acetate = 50 / 50-0 / 100) to obtain compound 14Ce (672mg, 73% yield) as compound 34 of the present invention.

[1083] HRMS(MALDI):C 52 H 60 Calculated value for N9O8P [M+Na] + :992.4195, measured value:992.4186

[1084] 31 P-NMR (CDCl3)δ:148.50,148.58

[1085] Synthesis of ALNA[Trz]-G

[1086] [Chemical formula 57]

[1087]

[1088] Example 106 Synthesis of Compound 14Ga

[1089] (1R,3R,4R,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbothioamide

[1090] 1,1-Carbonyldiimidazole (21.0 g, 118 mmol) was added to a THF (270 mL) solution of 1 g (55.0 g, 58.9 mmol) of the compound synthesized by the method described in International Publication No. 2017 / 047816, and the mixture was stirred at room temperature for 2 hours. 28% aqueous ammonia (270 mL) was added to the reaction solution, and the mixture was stirred at room temperature for 30 minutes and then stirred at 50°C for 46 hours. Chloroform (700 mL) was added to the reaction solution, and after stirring for a while, the organic layer was separated and dried over anhydrous sodium sulfate. After filtering out the insoluble matter, the solvent was removed by distillation under reduced pressure, and the residue was roughly purified by silica gel column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10). The obtained residue was dissolved in ethyl acetate (250 mL) and toluene (250 mL) was added. About 300 mL of the solvent was distilled off under reduced pressure (solid precipitated), diisopropyl ether (IPE) (50 mL) was added to the obtained suspension, and the mixture was stirred at room temperature for 30 minutes. The precipitate was filtered out, washed with IPE (50 mL), and then dried under reduced pressure to obtain compound 14Ga (27.9 g, yield 72%).

[1091] MS (ESI): m / z = 656 [M+H] +

[1092] Example 107 Synthesis of Compound 14Gb

[1093] (1R,3R,4R,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboximidothioic acid methyl ester

[1094] Under ice cooling, iodomethane (4.24 mL, 68.1 mmol) was added dropwise to a solution of compound 14Ga (27.9 g, 42.5 mmol) in THF (400 mL), and the mixture was stirred at room temperature for 24 hours. While stirring, the reaction solution was added to a mixture of an aqueous sodium bicarbonate solution (prepared from a saturated aqueous sodium bicarbonate solution (400 mL) and water (400 mL)) and chloroform (1400 mL). After stirring for a while, the organic layer was separated and dried over anhydrous sodium sulfate. Filtered with diatomaceous earth, the filtrate was concentrated under reduced pressure, and then azeotroped with toluene to obtain compound 14Gb (26.9 g, yield 82%).

[1095] MS (ESI): m / z = 670 [M+H] +

[1096] Example 108 Synthesis of Compound 14Gc

[1097] Acetate [(1R,3R,4R,7S)-5-(N-acetyl-C-methylsulfanyl-carboximido)-3-(2-amino-6-oxo-1H-purin-9-yl)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]

[1098] To a pyridine (100 mL) solution of compound 14Gb (26.9 g, 34.7 mmol), acetic anhydride (9.83 mL, 104 mmol) and DMAP (424 mg, 3.47 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Ethyl acetate (400 mL) and saturated sodium bicarbonate aqueous solution (200 mL) were added to the reaction solution, and after vigorous stirring for 20 minutes, the organic layer was separated. The organic layer was washed with water (2×200 mL) and saturated brine (200 mL), and then dried over anhydrous sodium sulfate. After filtering to remove the insoluble matter, the solvent was removed by distillation under reduced pressure, and the obtained residue was azeotroped with toluene, thereby obtaining compound 14Gc (30.5 g). It was not purified and was directly supplied to the next step.

[1099] MS (ESI): m / z = 754 [M+H] +

[1100] Example 109 Synthesis of Compound 14Gd

[1101] N'-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine

[1102] Methylhydrazine (18.9 mL, 359 mmol) was added to a solution of compound 14Gc (30.5 g, 35.9 mmol) in 1,4-dioxane (300 mL), and the mixture was stirred at room temperature for 2 hours and then at 50°C for 3 hours. Water (100 mL) was added to the reaction solution and distilled under reduced pressure. Chloroform (250 mL) was added and stirred slowly for a while, and the mixture was passed through a phase separator to separate the organic layer. After distillation under reduced pressure to remove the solvent, it was azeotroped with toluene. The residue obtained by suspending it with IPE (100 mL) was placed in an ultrasonic bath for 20 minutes, and the precipitate was filtered out, air-dried, and dried under reduced pressure.

[1103] To a DMF (75 mL, 970 mmol) solution of the obtained residue, N,N-dimethylformamide dimethyl acetal (50 mL, 375 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solvent was removed by distillation under reduced pressure, and the concentrated residue obtained was purified by silica gel column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10, SiO2: ethyl acetate / methanol = 90 / 10 to 72 / 28) for crude purification. The crude product was suspended in ethyl acetate (200 mL), filtered, and dried under reduced pressure to obtain compound 14Gd (11.2 g, yield 40%).

[1104] MS (ESI): m / z = 748 [M+H] +

[1105] Example 110 Synthesis of Compound 14Ge

[1106] N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine (Compound 35 of the present invention)

[1107] Under ice cooling, DIPEA (5.30 mL, 30.6 mmol) was added to a solution of compound 14Gd (6.00 g, 7.60 mmol) in dichloromethane (60 mL), followed by dropwise addition of 2-cyanoethyl N,N-diisopropylchlorophosphoramide (5.12 mL, 23.0 mmol), and the mixture was stirred at room temperature for 6 hours. The reaction solution was ice-cooled, saturated sodium bicarbonate aqueous solution (120 mL) and chloroform (160 mL) were added, and after vigorous stirring for 15 minutes, the organic layer was separated and dried over anhydrous sodium sulfate. After filtering to remove insoluble matter, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (SiO2: ethyl acetate / methanol = 100 / 0 to 84 / 16) to obtain compound 14Ge (5.59 g, yield 74%) as compound 35 of the present invention.

[1108] MS (ESI): m / z = 948 [M + H] +

[1109] 31 P-NMR (CDCl3)δ:148.52,148.59

[1110] Synthesis of ALNA[Trz]-A

[1111] [Chemical formula 58]

[1112]

[1113] Example 111 Synthesis of Compound 14Aa

[1114] Benzotriazol-1-yl (benzotriazol-2-yl)methanimine [Chemical Formula 59]

[1115]

[1116] Under ice cooling, to a solution of benzotriazole (7.70 g, 64.6 mmol) in EtOH (135 mL), a solution of cyanogen bromide (3.41 g, 32.2 mmol) in acetone (15 mL) was slowly added dropwise, followed by slowly adding 2 equivalents of sodium hydroxide aqueous solution (16.2 mL, 32.4 mmol). After stirring for 30 minutes under ice cooling, the precipitate was filtered out and washed with cold ethanol (80 mL). After air drying, the precipitate was dried under reduced pressure to obtain compound 14Aa (5.14 g, yield 61%).

[1117] 1 H NMR (400 MHz, CHLOROFORM- d )δppm 6.92-6.98(m,1H)7.46-7.55(m,2H)7.58-7.65(m,1H)7.77(ddd,J=8.35,7.06 ,1.03Hz,1H)8.17-8.22(m,1H)8.22-8.27(m,1H)8.31-8.37(m,1H)9.67(s,1H)

[1118] MS(ESI): Not detected

[1119] Example 112 Synthesis of Compound 14Ae

[1120] (1R,3R,4R,7S)-3-(6-aminopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-7-ol

[1121] Compound 1a (10.3 g, 17.9 mmol) was added little by little to a suspension of N-(9H-purine-6-yl)benzamide (5.15 g, 21.5 mmol) in toluene (200 mL). Next, BSA (38 mL, 120 mmol) was added and the mixture was stirred vigorously at 60 ° C for 30 minutes. TMSOTf (0.324 mL, 1.79 mmol) was added at the same temperature, and the mixture was stirred at 60 ° C for 15 minutes. The reaction solution was cooled with ice water, and then, under vigorous stirring, the reaction solution was added to a mixture of ice-cooled IPE (100 mL), water (100 mL) and saturated sodium bicarbonate aqueous solution (100 mL). After vigorous stirring for 20 minutes, diatomaceous earth filtration was performed to remove insoluble matter. The organic layer of the filtrate was separated, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain a residue of crude compound 14Gb.

[1122] Compound 14Aa (4.72 g, 17.9 mmol) was added to a THF (200 mL) solution of the obtained residue, and the mixture was stirred at room temperature for 92 hours and further stirred at 50° C. for 9 hours. Ethyl acetate (400 mL) and saturated sodium bicarbonate aqueous solution (200 mL) were added to the reaction solution, and after stirring for 20 minutes, the organic layer was separated. The organic layer was washed with water (300 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered to remove insoluble matter, and then the solvent was distilled off to obtain a residue of crude compound 14Gc.

[1123] To the obtained residue in pyridine (65 mL) solution, acetic anhydride (5.08 mL, 53.8 mmol) and DMAP (219 mg, 1.79 mmol) were added, and the mixture was stirred at room temperature for 3 hours. Ethyl acetate (400 mL) and saturated sodium bicarbonate aqueous solution (200 mL) were added to the reaction solution, and after stirring for 20 minutes, the organic layer was separated. The organic layer was washed with water (300 mL) and saturated brine (100 mL), and then dried over anhydrous sodium sulfate. After filtering to remove insoluble matter, the mixture was distilled under reduced pressure, and after removing the solvent, it was azeotroped with toluene to obtain the residue of crude compound 14Gd.

[1124] Under cooling with cold water, methylhydrazine (9.44 mL, 179 mmol) was added dropwise to a solution of the obtained residue in 1,4-dioxane (100 mL), and the mixture was stirred at room temperature for 3 hours. The temperature was raised to 50°C and stirred for 10 hours. After adding water (100 mL) to the reaction solution, it was removed by distillation under reduced pressure, and the residue was subjected to liquid extraction with chloroform (2×150 mL). The organic layers were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. After filtering to remove the insoluble matter, the solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (NH silica: chloroform / methanol=100 / 0~99 / 1) to obtain compound 14Ae (4.91 g, yield was 41%).

[1125] MS (ESI): m / z = 675 [MH] -

[1126] Example 113 Synthesis of Compound 14Af

[1127] N-[9-(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide

[1128] Under ice cooling, to a mixture of compound 14Ae (4.80 g, 7.10 mmol) and pyridine (10 mL), benzoyl chloride (2.48 mL, 21.3 mmol) was added, and the mixture was stirred for 3 hours under ice cooling. 2 equivalents of sodium hydroxide aqueous solution (25 mL, 50 mmol) was added to the reaction solution, and the mixture was stirred for 2 hours at room temperature. The reaction solution was extracted 4 times with chloroform (50 mL), and the organic layer was passed through a phase separator and dried over anhydrous sodium sulfate. The solution was filtered through diatomaceous earth and concentrated. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 93 / 7) to obtain compound 14Af (4.60 g, yield was 83%).

[1129] MS (ESI): m / z = 781 [M+H] +

[1130] Example 114 Synthesis of Compound 14Ag

[1131] N-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide (Compound 36 of the present invention)

[1132] Under ice cooling, DIPEA (3.78 mL, 21.8 mmol) and 2-cyanoethyl N, N-diisopropylchlorophosphoramide (3.66 mL, 16.4 mmol) were added to a mixture of compound 14Af (4.26 g, 5.46 mmol) and dichloromethane (50 mL), and the mixture was stirred at room temperature for 2 hours. The reaction solution was ice-cooled, saturated aqueous sodium bicarbonate solution (100 mL) was added, and extracted with chloroform (100 mL). After drying the organic layer with anhydrous sodium sulfate, the insoluble matter was filtered off and the solvent was distilled off. The residue was purified by column chromatography (SiO2: ethyl acetate / methanol = 100 / 0 to 94 / 6, NH silica: ethyl acetate / methanol = 100 / 0 to 93 / 7) to obtain compound 14Ag (3.88 g, yield 67%) as compound 36 of the present invention.

[1133] MS (ESI): m / z = 980 [M + H] +

[1134] 31 P-NMR (CDCl3)δ:148.84,149.04

[1135] Synthesis of ALNA[Oxz]-T

[1136] [Chemical formula 60]

[1137]

[1138] Example 115 Synthesis of Compound 15Ta

[1139] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[1140] Hydroxylamine (50% aqueous solution, 1.90 mL, 28.8 mmol) was added to a mixture of compound 14Tc (2.10 g, 2.88 mmol) and EtOH (14.4 mL), and the mixture was stirred at room temperature for 2 days. The reaction solution was concentrated, and the residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 15Ta (1.34 g, yield 71%).

[1141] HRMS(MALDI):C 35 H 35 Calculated value for N5O8 [M+Na] + :676.2378, measured value:676.2363

[1142] Example 116 Synthesis of Compound 15Tb

[1143] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 37 of the present invention)

[1144] To a mixture of compound 15Ta (300 mg, 0.459 mmol), dichloromethane (4.6 mL), and DIPEA (240 μL, 1.38 mmol), 2-cyanoethyl N, N-diisopropyl chlorophosphamide (205 μL, 0.918 mmol) was added, and the mixture was stirred for 5 days at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 60 / 40 to 10 / 90, diol: hexane / ethyl acetate = 70 / 30 to 20 / 80, NH: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 15Tb (214 mg, 55% yield) as compound 37 of the present invention.

[1145] HRMS(MALDI):C 44 H 52 Calculated value [M+Na] obtained from N7O9P + :876.3456, measured value:876.3441

[1146] 31 P-NMR (CDCl3)δ:148.83,149.09

[1147] Synthesis of ALNA[Oxz]-mC

[1148] [Chemical formula 61]

[1149]

[1150] Example 117 Synthesis of Compound 15Ca

[1151] Acetate [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]

[1152] To a mixture of compound 15Ta (999 mg, 1.53 mmol), DMAP (18.7 mg, 0.153 mmol), and pyridine (7.7 mL), acetic anhydride (217 μL, 2.30 mmol) was added, and the mixture was stirred at room temperature for 2 days. Ethyl acetate was added to the reaction solution, and the mixture was washed with saturated sodium bicarbonate aqueous solution, water, and saturated saline. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and then concentrated under reduced pressure to obtain compound 15Ca (1.10 g, quantitatively).

[1153] HRMS(MALDI):C 37 H 37 Calculated value for N5O9 [M+Na] + :718.2483, measured value:718.2470

[1154] Example 118 Synthesis of Compound 15Cb

[1155] [(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(5-methyl-1,2,4-oxadiazol-3-yl)-3-[5-methyl-2-oxo-4-(1,2,4-triazol-1-yl)pyrimidin-1-yl]-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] acetate

[1156] Under ice cooling, phosphorus oxychloride (239 μL, 2.57 mmol) was added to a mixture of compound 15Ca (1.05 g, 1.51 mmol), 1,2,4-triazole (939 mg, 13.6 mmol), DIPEA (2.63 mL, 15.1 mmol), and acetonitrile (15 mL), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was removed by filtration, and the mixture was concentrated under reduced pressure to obtain compound 15Cb (1.32 g) as a crude product.

[1157] HRMS(MALDI):C 39 H 38 Calculated value for N8O8 [M+Na] + :769.2705, measured value:769.2707

[1158] Example 119 Synthesis of Compound 15Cc

[1159] 4-Amino-1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[1160] To a mixture of compound 15Cb (1.30 g, 1.51 mmol, in bold) and acetonitrile (15.1 mL), 28% aqueous ammonia (10.1 mL) was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, and extraction was performed with chloroform. The organic layer was passed through a phase separator and concentrated to obtain compound 15Cc (0.96 g, 97% yield in two steps).

[1161] HRMS(MALDI):C 35 H 36 Calculated value for N6O7 [M+Na] + :675.2538, measured value:675.2539

[1162] Example 120 Synthesis of Compound 15Cd

[1163] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-hydroxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[1164] To a mixture of compound 15Cc (0.93 g, 1.42 mmol) and pyridine (7.1 mL), anhydrous benzoic acid (482 mg, 2.13 mmol) was added, and the mixture was stirred overnight at room temperature. 2 equivalents of sodium hydroxide aqueous solution (7.1 mL) was added to the reaction solution, and stirred at room temperature for 1 hour. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 15Cd (958 mg, yield 89%).

[1165] HRMS(MALDI):C 42 H 40 Calculated value for N6O8 [M+Na] + :779.2800, measured value:779.2794

[1166] Example 121 Synthesis of Compound 15Ce

[1167] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 38 of the present invention)

[1168] Under ice cooling, 2-cyanoethyl N, N-diisopropylchlorophosphoramide (0.559 mL, 2.50 mmol) was added to a mixture of compound 15Cd (949 mg, 1.25 mmol), dichloromethane (12.5 mL), and DIPEA (0.653 mL, 3.75 mmol), and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 80 / 20-30 / 70, NH: hexane / ethyl acetate = 50 / 50-0 / 100) to obtain compound 15Ce (834 mg, 70% yield) as compound 38 of the present invention.

[1169] HRMS(MALDI):C 51 H 57 Calculated value [M+Na] obtained from N8O9P + :979.3878, measured value:979.3876

[1170] 31 P-NMR (CDCl3)δ:148.98,149.27

[1171] Synthesis of ALNA[Tdz]-T

[1172] [Chemical formula 62]

[1173]

[1174] Example 122 Synthesis of Compound 16Ta

[1175] 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidine-2,4-dione

[1176] A mixture of compound 1a (3.00 g, 5.25 mmol), 5-chloro-3-methyl-1,2,4-thiadiazole (848 mg, 6.30 mmol), DIPEA (2.72 mL, 15.7 mmol), and DMSO (26 mL) was stirred at 120°C for 2 hours. Ethyl acetate was added to the reaction solution, and the mixture was washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and then concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 95 / 5) to obtain compound 16TaAB37420-001 (3.30 g, yield 94%).

[1177] MS (ESI): m / z = 670 [M+H] +

[1178] Example 123 Synthesis of Compound 16Tb

[1179] 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile (Compound 39 of the present invention)

[1180] To a mixture of compound 16Ta (2.26 g, 3.37 mmol), dichloromethane (17 mL), and DIPEA (1.75 mL, 10.1 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphoramide (1.51 mL, 6.77 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. A saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 70 / 30 to 20 / 80, diol: hexane / ethyl acetate = 70 / 30 to 20 / 80) to obtain compound 16Tb (2.45 g, 84% yield) as compound 39 of the present invention.

[1181] MS (ESI): m / z = 870 [M+H] +

[1182] 31 P-NMR(CDCl3)δ:149.23, 149.51

[1183] Synthesis of ALNA[Tdz]-mC

[1184] [Chemical formula 63]

[1185]

[1186] Example 124 Synthesis of Compound 16mCa

[1187] [[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]acetate

[1188] To a mixture of compound 16Ta (5.92 g, 8.84 mmol), DMAP (120 mg, 0.982 mmol) and pyridine (18 mL), acetic anhydride (1.25 mL, 13.2 mmol) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated, ethyl acetate was added to the residue, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, insoluble matter was removed by filtration, and concentrated under reduced pressure to obtain compound 16mCa (5.69 g, yield 90%).

[1189] MS (ESI): m / z = 712 [M+H] +

[1190] Example 125 Synthesis of Compound 16mCb

[1191] [[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-[5-methyl-2-oxo-4-(1,2,4-thiadiazol-1-yl)pyrimidin-1-yl]-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl] acetate

[1192] Under ice cooling, phosphorus oxychloride (1.23 mL, 13.2 mmol) was added to a mixture of compound 16mCa (5.52 g, 7.75 mmol), 1,2,4-triazole (4.82 g, 69.8 mmol), DIPEA (13.4 mL, 77.5 mmol), and acetonitrile (39 mL), and the mixture was stirred for 2 hours at room temperature under a nitrogen atmosphere. Ethyl acetate was added to the reaction solution, and the mixture was washed with a saturated aqueous sodium bicarbonate solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, the insoluble matter was filtered off, and then concentrated under reduced pressure to obtain compound 16mCb (6.18 g, containing impurities) as a crude product.

[1193] Example 126 Synthesis of Compound 16mCc

[1194] 4-Amino-1-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[1195] To a mixture of compound 16mCb (6.18 g, 7.75 mmol, containing impurities) and acetonitrile (39 mL), 28% aqueous ammonia (39 mL) was added, and the mixture was stirred at room temperature for 4 days. Water was added to the reaction solution and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and then concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 16mCc (4.50 g, 87% yield in 2 steps).

[1196] MS (ESI): m / z = 667 [MH] -

[1197] Example 127 Synthesis of Compound 16mCd

[1198] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide

[1199] At room temperature, a mixture of compound 16mCc (4.37 g, 6.53 mmol), anhydrous benzoic acid (2.22 g, 9.81 mmol), and pyridine (13 mL) was stirred overnight. 2 equivalents of sodium hydroxide aqueous solution (13 mL, 26 mmol) was added to the reaction solution, and the mixture was stirred for 1.5 hours at room temperature. Ethyl acetate was added to the reaction solution, and washed with saturated sodium bicarbonate aqueous solution and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered to remove insoluble matter, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2: chloroform / methanol = 100 / 0 to 90 / 10) to obtain compound 16mCdAB37471-001 (4.76 g, yield 94%).

[1200] MS (ESI): m / z = 773 [M+H] +

[1201] Example 128 Synthesis of Compound 16mCe

[1202] N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (Compound 40 of the present invention)

[1203] To a mixture of compound 16mCd (4.62 g, 5.98 mmol), dichloromethane (12 mL), and DIPEA (3.10 mL, 17.9 mmol), 2-cyanoethyl N, N-diisopropylchlorophosphoramide (2.67 mL, 12.0 mmol) was added, and the mixture was stirred overnight at room temperature under a nitrogen atmosphere. Saturated aqueous sodium bicarbonate solution was added to the reaction solution and extracted with chloroform. The organic layer was passed through a phase separator and the solvent was distilled off. The residue was purified by column chromatography (SiO2: hexane / ethyl acetate = 80 / 20 to 30 / 70, NH: hexane / ethyl acetate = 70 / 30 to 20 / 80) to obtain compound 16mCe (3.57 g, 61% yield) as compound 40 of the present invention.

[1204] MS (ESI): m / z = 974 [M+H] +

[1205] 31 P-NMR(CDCl3)δ:149.45, 149.78

[1206] ALNA[Ms]-mC can also be synthesized by converting the nucleobase portion of the ALNA[Ms]-T nucleoside as described below.

[1207] Synthesis of compound 2Cf

[1208] [Chemical formula 64]

[1209]

[1210] Example 129 Synthesis of Compound 2Cd

[1211] 3-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-methylsulfonyl-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-6-(1,2,4-triazol-1-yl)-1,6-dihydropyrimidin-2-one

[1212] 2Tb (14.1 g, 0.019 mol) was dissolved in acetonitrile (310 mL), triethylamine (97.29 mL, 0.961 mol) was added, and the mixture was stirred at 0°C for 15 minutes. 1,2,4-triazole (30.36 g, 0.439 mol) was added to the reaction solution, and the mixture was stirred at 0°C for 15 minutes. Phosphorus oxychloride (4.44 mL, 0.028 mol) was added, and the mixture was stirred at 0°C for 15 minutes. The mixture was heated to room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and ethyl acetate (200 mL) and water (100 mL) were added to separate the liquids. The organic layer was washed twice with sodium carbonate (100 mL), dried with sodium sulfate, and concentrated under reduced pressure to obtain a crude product 2Cd (11.8 g).

[1213] Example 130 Synthesis of Compound 2Ce

[1214] 6-Amino-3-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidin-2-one

[1215] The crude product 2Cd (11.8 g) was dissolved in 1,4-dioxane (118 mL), 25% aqueous ammonia (118 mL) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane / methanol, 95 / 5 to 94 / 6). The mixture was stirred in a mixture of dichloromethane / hexane (10 / 90), and the precipitate was filtered to obtain compound 2Ce (8.3 g, 64% yield in 2 steps).

[1216] MS (ESI): m / z = 649.3 (M+H) +

[1217] Example 131 Synthesis of Compound 2Cf

[1218] N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]dihydropyrimidin-2-one

[1219] To a solution of compound 2Ce (8.3 g, 0.012 mol) in DMF (63 mL), add benzoic anhydride (2.57 g, 0.011 mol) and stir at room temperature for 24 hours. Add ethyl acetate (200 mL) to the reaction solution, dilute it, and wash it twice with water (100 mL). Wash the organic layer with sodium carbonate water (100 mL) and saturated brine (100 mL) in turn, and dry it with sodium sulfate. Concentrate it under reduced pressure, and purify the residue by silica gel column chromatography (dichloromethane / methanol, 99.5 / 0.5 to 99 / 1). Stir it in a mixed solution of dichloromethane / hexane (10 / 90), and filter out the precipitate to obtain compound 2Cf (4.0 g, yield 47%).

[1220] MS (ESI): m / z = 753.1 (M+H) +

[1221] Alternatively, ALNA[Ms]-mC nucleoside can also be synthesized as follows.

[1222] Synthesis of compound 2Cj

[1223] [Chemical formula 65]

[1224]

[1225] Example 132 Synthesis of Compound 2Cg

[1226] 1-[(1R,3R,4R,7S)-7-Benzyloxy-1-(benzyloxymethyl)-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidine-2,4-dione

[1227] To a mixed solution of 1-[(1R,3R,4R,7S)-7-benzyloxy-1-(benzyloxymethyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methylpyrimidine-2,4-dione (1h) (20.00 g, 21.61 mmol) in dichloromethane (200 mL) synthesized by the method described in International Publication No. 2017 / 047816, triethylamine (15.5 mL, 111 mmol) was added, and methanesulfonyl chloride (4.15 mL, 53.4 mmol) was added under ice bath, and the mixture was stirred for 4.5 hours under ice bath. A 5% aqueous sodium bicarbonate solution (60 mL) was added to the reaction solution, stirred, and separated. The aqueous layer was extracted with dichloromethane (40 mL), and the organic layers of dichloromethane were combined and mixed. The organic layer was washed with 15% brine (60 mL), and the solvent was distilled off. Methanol (90 mL) was added to the concentrated residue to suspend it. The generated precipitate was filtered and vacuum dried to obtain Compound 2Cg (21.94 g, yield 94%).

[1228] MS (ESI): m / z = 528 (M + H) +

[1229] Example 133 Synthesis of Compound 2Ch

[1230] 1-[(1R,3R,4R,7S)-7-Benzyloxy-1-(benzyloxymethyl)-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2-one

[1231] In the same manner as in Example 129, compound 2Ch (3.4 g) was obtained as a crude product from 2Cg (3.0 g, 5.6 mmol).

[1232] Example 134 Synthesis of Compound 2Ci

[1233] 4-Amino-1-[(1R,3R,4R,7S)-7-benzyloxy-1-(benzyloxymethyl)-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidin-2-one

[1234] In the same manner as in Example 130, compound 2Ci (2.6 g, 87% yield) was obtained from compound 2Ch (3.4 g, 5.8 mmol).

[1235] MS (ESI): m / z = 527.2 (M+H) +

[1236] Example 135 Synthesis of Compound 2Cj

[1237] 4-Amino-1-[(1R,3R,4R,7S)-7-hydroxy-1-(hydroxymethyl)-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-2-one

[1238] Compound 2Ci (2.6 g, 4.9 mmol) was dissolved in acetic acid (28.6 mL), 20% palladium hydroxide / carbon (0.35 g) was added, and the mixture was stirred at room temperature for 16 hours under a hydrogen atmosphere. After filtering out the insoluble matter, the mixture was concentrated under reduced pressure. 1-Butanol and IPE were added to the residue, stirred, and the precipitate was filtered out. The obtained solid was recrystallized from methanol to obtain compound 2Cj (1.0 g, 58% yield).

[1239] MS (ESI): m / z = 346.9 (M+H) +

[1240] For ALNA[Ms]-G, a monomer in which the guanine position is protected by dimethylaminomethylene can be synthesized in the following manner. It should be noted that when a monomer having such a protection method is used for oligomer synthesis, the generation of byproducts that may be generated when synthesizing oligomers using 2Gd in which the 6-position of guanine is protected by DPC can be controlled.

[1241] [Chemical formula 66]

[1242]

[1243] Example 136 Synthesis of Compound 2Ge

[1244] 2-Amino-9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-1H-purin-6-one

[1245] To a solution of compound 2Gc (1000 mg, 1.1 mmol) in tetrahydrofuran (10 mL) was added 28% aqueous ammonia (5 ml) at room temperature, and the mixture was stirred overnight at room temperature. Furthermore, 28% aqueous ammonia (15 ml) was added, and the mixture was stirred at 70°C for 8 hours. Water and dichloromethane were added at room temperature, and the mixture was stirred. The organic layer was recovered and dried over sodium sulfate. The residue was filtered, and the solvent was distilled off, and then purified by silica gel column chromatography (chloroform / methanol, 97 / 3 to 92 / 8). Thus, compound 2Ge (620 mg, yield 86%) was obtained.

[1246] MS (ESI): m / z = 675 (M + H) +

[1247] Example 137 Synthesis of Compound 2Gf

[1248] N'-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethylformamidine

[1249] Compound 2Ge (150 mg, 0.22 mmol) was dissolved in tetrahydrofuran (2.22 mL), and N,N-dimethylformamide dimethyl acetal (132 mg, 1.11 mmol) was added at room temperature, and stirred for 1 hour. Added at room temperature, extracted once with ethyl acetate (2 mL). The obtained organic layer was washed with brine and dried over sodium sulfate. The residue was filtered, and the solvent was distilled off, and then purified by silica gel column chromatography (chloroform / methanol=99 / 1, chloroform / methanol=93 / 7), thereby obtaining compound 2Gf (145 mg, yield 89%).

[1250] MS (ESI): m / z = 728 (MH) -

[1251] Example 138 Synthesis of Compound 2Gg

[1252] N'-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethylformamidine

[1253] Compound 2Gf (900 mg, 1.2 mmol) was dissolved in dichloromethane (15 mL), and N,N-diisopropylethylamine (747 mg, 5.8 mmol) and 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1061 mg, 4.5 mmol) were added at room temperature, and stirred overnight. At room temperature, saturated sodium bicarbonate aqueous solution and dichloromethane were added to separate the organic layer. The obtained organic layer was dried over sodium sulfate, and the residue was filtered. After the solvent was distilled off, amino silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3) and diol silica gel column chromatography (chloroform / methanol, 100 / 0 to 97 / 3) were performed to obtain compound 2Gg (690 mg, yield 60%).

[1254] MS (ESI): m / z = 930 (M + H) +

[1255] For ALNA[Ms]-G, a monomer in which the guanine site is only protected by an isobutyryl group can be synthesized in the following manner. It should be noted that when a monomer having such a protection method is used for oligomer synthesis, the generation of byproducts that may be generated when 2Gd in which the 6-position of guanine is protected by DPC is controlled for oligomer synthesis.

[1256] [Chemical formula 67]

[1257]

[1258] Example 139 Synthesis of Compound 2Gh

[1259] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1260] Compound 2Ge (100 mg, 0.15 mmol) was dissolved in pyridine (1.4 mL), and N,N-dimethyl-4-aminopyridine (29 mg, 0.24 mmol) and 2-methylpropionyl 2-methyl ester (100 μL, 0.6 mmol) were added at room temperature, and stirred at 100°C for 4 hours. Further, 2-methylpropionyl 2-methyl ester (100 μL, 0.6 mmol) was added, and stirred at 100°C for 2 hours. Saturated sodium bicarbonate aqueous solution and sodium acetate were added at room temperature to separate the organic layer. The obtained organic layer was dried over sodium sulfate. The residue was filtered, and after the solvent was distilled off, it was purified by silica gel column chromatography (hexane / ethyl acetate, 50 / 50 to 20 / 80). Further, the compound was dissolved in tetrahydrofuran (1 mL), 0.1N sodium hydroxide aqueous solution (1 mL) was added, and stirred at 0°C for 40 minutes. Water and ethyl acetate were added to the reaction solution, the organic layer was separated, washed with saturated aqueous ammonium chloride solution, separated again, dried over sodium sulfate, and the residue was filtered, and the solvent was distilled off to obtain Compound 2Gh (56 mg, yield 50%).

[1261] MS (ESI): m / z = 745 (M + H) +

[1262] Example 140 Synthesis of Compound 2Gi

[1263] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1264] Molecular sieve 3A was added to dichloromethane (3.6 mL), and after stirring for 1 hour, compound 2Gh (500 mg, 0.67 mmol), 1-methylimidazole (10.9 mg, 0.1 mol), tetrazole (84 mg, 1.2 mmol), and 3-bis(diisopropylamino)phosphoalkyloxypropionitrile (949 mg, 3.1 mmol) were added at room temperature and stirred for 6 hours. Saturated aqueous sodium bicarbonate solution was added at room temperature, and the mixture was extracted twice with dichloromethane. The obtained organic layer was dried over sodium sulfate, and the residue was filtered. After the solvent was distilled off, silica gel column chromatography was performed for purification (hexane / ethyl acetate, 50 / 50 to 25 / 75), thereby obtaining compound 2Gi (500 mg, yield 79%).

[1265] MS (ESI): m / z = 946 (M + H) +

[1266] Alternatively, the ALNA[Ms]-G monomer in which the guanine site is protected only by an isobutyryl group can also be directly synthesized from compound 1a by transglycosylation in the following manner.

[1267] [Chemical formula 68]

[1268]

[1269] Example 141 Synthesis of Compound 2Gj

[1270] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1271] To a mixture of compound 1a (5.0 g, 8.75 mmol) and 2-methyl-N-(6-oxo-1,9-dihydropurin-2-yl)propionamide (3.87 g, 17.5 mmol) in 1,2-dichloroethane (30 mL), add BSA (21.4 mL, 87.5 mmol) and stir at 60°C for 30 minutes. Next, add TMSOTf (0.254 mL, 1.31 mmol) and stir for 1.5 hours. After cooling, add chloroform (50 mL) and saturated aqueous sodium bicarbonate solution (50 mL) to the reaction solution and stir. After filtering the insoluble matter, wash the organic layer with water and saturated brine, dry with magnesium sulfate, and concentrate. The residue obtained was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 90 / 10) to obtain compound 2Gj (3.83 g, yield 59%).

[1272] MS (ESI): m / z = 739.5 (M+H) +

[1273] Example 142 Synthesis of Compound 2Gk

[1274] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-methylsulfonyl-7-trimethylsilyloxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1275] Under ice cooling, methanesulfonic anhydride (284 mg, 1.63 mmol) was added to a solution of compound 2Gj (1.0 g, 1.35 mmol) and pyridine (0.327 mL, 4.06 mmol) in dichloromethane (7 mL), and stirred for 45 minutes under ice cooling. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, and extracted with chloroform. The organic layer was passed through a phase separator and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 90 / 10), thereby obtaining compound 2Gk (657 mg, yield 59%).

[1276] MS (ESI): m / z = 817.4 (M+H) +

[1277] Example 143 Synthesis of Compound 2Gh

[1278] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1279] To a solution of compound 2Gk (3.16 g, 3.87 mmol) in THF (8 mL), TBAF (1 mol / L THF solution, 4.6 mL, 4.6 mmol) was added and stirred at room temperature for 1 hour. The reaction solution was concentrated, and ethyl acetate and water were added, and the organic layer was washed with saturated brine. The organic layer was dried over magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 90 / 10) to obtain compound 2Gh (2.57 g, yield 89%).

[1280] MS (ESI): m / z = 745.5 (M+H) +

[1281] Alternatively, compound 2Gh can also be synthesized from compound 2Gb in the following manner.

[1282] [Chemical formula 69]

[1283]

[1284] Example 144 Synthesis of Compound 2Gh

[1285] N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide

[1286] Compound 2Gb (1010 mg, 1.0 mmol) was dissolved in tetrahydrofuran (10 mL), and tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution, 3 mL, 3.0 mmol) was added at room temperature, and stirred at 70°C for 24 hours. Furthermore, tetrabutylammonium fluoride (1 mol / L tetrahydrofuran solution, 9 mL, 9.0 mmol) was added at room temperature, and stirred at 80°C for 8 hours. After the solvent was distilled off, it was purified by silica gel column chromatography (chloroform / methanol, 98 / 2 to 93 / 7). Furthermore, it was purified by silica gel column chromatography (chloroform / methanol, 100 / 0 to 94 / 6), thereby obtaining compound 2Gh (570 mg, yield 77%).

[1287] MS (ESI): m / z = 745 (M + H) +

[1288] Example 145 Synthesis and purification of oligonucleotide analogs (in vitro)

[1289] Using the various amidites (compounds 1 to 44 of the present invention) obtained in the above-mentioned examples, the oligonucleotide analog compounds described in Tables 1 to 4 below were synthesized using a DNA / RNA oligonucleotide automatic synthesizer ns-8II (manufactured by GeneDesign, Inc.) at a scale of 0.2 or 1.0 μmol using CPG or polystyrene carriers. All the amidites were prepared as 0.1M acetonitrile solutions, and the coupling time in non-wild-type nucleosides was 10 minutes. The other steps were carried out under the standard conditions of ns-8II. Activator 42 (Sigma-Aldrich) was used as the activator, and Sulfurizing Reagent II (Gren Research Corporation) was used for sulfurization. For the synthesized oligonucleotides, a 28% ammonia solution was added and the reaction was carried out at 60-65°C for 8 hours, thereby excision from the carrier and deprotection of the base portion. After concentrating and distilling to remove ammonia, reverse phase HPLC purification was performed.

[1290] Example 146 Synthesis and purification of oligonucleotide analogs (in vivo)

[1291] Using the various amidates obtained in the above-mentioned examples (compounds 1 to 44 of the present invention), the oligonucleotide analog compounds described in the following Table 5 were synthesized using a DNA / RNA oligonucleotide automatic synthesizer AKTA oligopilot plus 10 (manufactured by GE Healthcare Japan Co., Ltd.) at a scale of 20 μmol and a polystyrene carrier. The DNA amidate was prepared as a 0.1 M acetonitrile solution, and the non-wild-type amidate was prepared as a 0.05 M acetonitrile solution. The coupling cycle time for the non-wild-type nucleoside was 20 minutes. When the first base was introduced into the universal carrier, the coupling, sulfurization, and capping steps were performed twice in succession. The other steps were performed under the standard conditions of AKTA oligopilot plus 10. Activator 42 (Sigma-Aldrich) was used as the activator, and Sulfurizing Reagent II (Gren Research Corporation) was used for sulfurization. For the synthesized oligonucleotide, 28% ammonia solution was added and reacted at 60-65°C for 8 hours to perform excision from the carrier and deprotection of the base portion. After the ammonia was removed by concentration and distillation, it was purified using an anion exchange column. The remaining salt contained after the anion exchange was removed using a desalting column.

[1292] Purification and purity confirmation of the synthesized oligonucleotide analogs were performed using reverse phase HPLC under the following conditions.

[1293] Reversed Phase HPLC

[1294] Mobile Phase:

[1295] Solution A: 20 mM hexylamine acetate aqueous solution

[1296] Solution B: Acetonitrile

[1297] Gradient: A:B = 90:10 → 50:50 (40 min) or A:B = 90:10 → 40:60 (45 min)

[1298] Use column:

[1299] Analyze Waters XBridge@Oligonucleotide BEH C18 Column, 2.5μm, 4.6mm*50mm

[1300] IsolationWaters XBridge@Oligonucleotide BEH C18 OBDTM Prep Column, 2.5μm, 10mm*50mm

[1301] Flow Rate:

[1302] Analysis 1ml / min

[1303] Separation 4ml / min

[1304] Column temperature: 60°C

[1305] Detection: UV (260nm)

[1306] Anion exchange purification

[1307] Mobile Phase:

[1308] Solution A: 20 mM Tris-HCl (pH 8.0) aqueous solution

[1309] Solution B: 20 ​​mM Tris-HCl (pH 8.0), 1 M NaBr aqueous solution

[1310] Use column:

[1311] GE HiTrap CaptQ ImpRes(Anion exchange)5ml

[1312] Flow rate: 5ml / min

[1313] Column temperature: room temperature

[1314] Detection: UV (260nm)

[1315] Desalting columns

[1316] Mobile Phase:

[1317] Liquid A: H2O

[1318] Liquid B: H2O

[1319] Use column:

[1320] GE HiPrep 26 / 10 Desalting

[1321] Flow rate: 10ml / min

[1322] Column temperature: room temperature

[1323] The molecular weights of the synthesized oligonucleotide analogs were measured using Waters ZQ under the following conditions.

[1324] Mobile Phase:

[1325] Solution A: 400mM hexafluoroisopropanol, 15mM triethylamine aqueous solution

[1326] Liquid B: Methanol

[1327] Gradient: A:B = 80:20 → 70:30 (2.5 min) or A:B = 90:10 → 40:60 (45 min)

[1328] Use column:

[1329] Analyze Waters ACQUITY UPLC@Oligonucleotide BEH C18Column, 1.7μm, 2.1mm*100mm

[1330] Flow rate: 0.2ml / min

[1331] Column temperature: 60°C

[1332] Detection: UV (260nm)

[1333] Table 1 Mass spectrometry results of each Tm sequence

[1334] gcgttT(X)tttgct(sequence number 1)

[1335] (Here, lowercase letters represent the nucleic acid bases of DNA, T(X) represents the artificial nucleic acid species with thymine, and all phosphate bonds are phosphodiester)

[1336] [Table 1]

[1337]

[1338] Table 2 Mass spectrometry results of each SRB1(2-10-2) sequence

[1339] T(X)C(X)agtcatgactT(X)C(X)(Serial number 2)

[1340] (Here, lowercase letters represent the nucleic acid bases of DNA, T(X) and C(X) represent the artificial nucleic acid species with thymine and the artificial nucleic acid species with 5-methylcytosine, respectively, and all phosphate bonds are phosphorothioates)

[1341] [Table 2]

[1342]

[1343] Table 3 Mass spectrometry results of each SRB1(3-10-3) sequence

[1344] T(X)T(X)C(X)agtcatgactT(X)C(X)C(X)(Serial number 3)

[1345] (Here, lowercase letters represent the nucleic acid bases of DNA, T(X) and C(X) represent artificial nucleic acid species with thymine and artificial nucleic acid species with 5-methylcytosine, respectively, and all phosphate bonds are phosphorothioates)

[1346] [Table 3]

[1347]

[1348] Table 4 Mass spectrometry results of antimiR-21 sequences

[1349] A(m)C(X)atC(X)agtC(X)tgaT(X)aagC(X)tA(m)(Serial No. 4)

[1350] (Here, A(m) represents 2'-MOE adenine nucleoside, lowercase letters represent the nucleic acid bases of DNA, T(X) and C(X) represent the artificial nucleic acid species having thymine and the artificial nucleic acid species having 5-methylcytosine, respectively, and all phosphate bonds are phosphorothioates)

[1351] [Table 4]

[1352]

[1353] Table 5 Mass spectrometry results of Malat1 sequences

[1354] G(X)T(X)T(X)cactgaatG(X)C(X)(Serial No. 5)

[1355] (Here, lowercase letters represent the nucleic acid bases of DNA, T(X), C(X), and G(X) represent artificial nucleic acid species with thymine, artificial nucleic acid species with 5-methylcytosine, and artificial nucleic acid species with guanine, respectively, and all phosphate bonds are phosphorothioates)

[1356] [Table 5]

[1357]

[1358] Example 147 Evaluation of Binding Ability to Target Chain and Mismatch Selectivity

[1359] The antisense strands (herein, the sequence is gcgttT(X)tttgct (SEQ ID NO. 1), lowercase letters represent the nucleic acid bases of DNA, and T(X) represents the artificial nucleic acid species having thymine) comprising various artificial nucleic acid species, and the sense strand, i.e., the DNA strand having a sequence complementary to the antisense strand (herein, the sequence is agcaaaaaacgc (SEQ ID NO. 6), lowercase letters represent the nucleic acid bases of DNA), and the RNA strand having a complementary sequence (herein, the sequence is AGCAAA AAACGC (sequence number 7), capital letters represent each nucleic acid base of RNA), and RNA chains having three complementary sequences containing one base mismatch (here, the sequence represents AGCAAANAACGC (sequence number 8), capital letters represent each nucleic acid base of RNA, and N represents uracil (U), guanine (G), and cytosine (C) respectively) are annealed to form a double strand, and then the temperature of 50% deviation of the double strand, i.e., the Tm value, is measured to examine the double-stranded formation ability of the oligonucleotide. Specifically, a sample solution (150 μL) containing 100 mmol / L of sodium chloride aqueous solution, 10 mmol / L of sodium phosphate buffer (pH 7.4), 4 μmol / L of antisense strand, and 4 μmol / L of sense strand is heated to 95°C and then cooled to room temperature over 4 hours. In order to prevent condensation, a nitrogen flow was circulated in the absorption cell chamber of the spectrophotometer (JASCO, V-730, PAC-743R), and the sample solution was slowly cooled to 10°C. After further maintaining at 10°C for 1 minute, the measurement was started. The temperature was raised to 80°C at a rate of 0.5°C per minute, and the absorbance at 260nm was measured every 0.5°C. It should be noted that in order to prevent concentration changes caused by temperature rise, a covered absorption cell was used for the absorption cell. The results are shown in Table 6.

[1360] Table 6 Tm value determination results

[1361] [Table 6]

[1362]

[1363] As shown in Table 6, the antisense strands comprising various artificial nucleic acids have sense strand binding abilities and mismatch selection abilities that are at least equal to or greater than those of the antisense strand comprising wild-type DNA, known ALNA, ALNA[Me].

[1364] Example 147 In vitro SR-B1 knockdown activity assay

[1365] 2.5×10 3Hepa 1c1c7 cells were cultured for 24 hours, and various modified antisense oligonucleotides with sequences complementary to SRB1 were added at final concentrations of 100, 20, and 4 nmol / L, and quantitative PCR was performed 48 hours later. The same conditions were applied to each of the 3 wells. For antisense activity, the inhibition rate of SRB1 expression when antisense compounds were added was expressed as a percentage based on the ratio of SRB1 to GAPDH in the negative control. The results are shown in Table 7.

[1366] Table 7 In vitro SRB1 knockdown activity

[1367] [Table 7]

[1368]

[1369] The graph shows the target gene (SRB1) knockdown activity of the antisense oligonucleotides containing each artificial nucleic acid in two sequence patterns, 3-10-3 and 2-10-2, at 100 nM of gymnosis.

[1370] The two sequence modes are described below.

[1371] 3-10-3:T(X)T(X)C(X)agtcatgactT(X)C(X)C(X)(same as sequence number 3 in Table 3 above)

[1372] 2-10-2:T(X)C(X)agtcatgactT(X)C(X) (same as sequence number 2 in Table 2 above)

[1373] It should be noted that lowercase letters represent each nucleic acid base of DNA, T(X) and C(X) represent each artificial nucleic acid species having thymine and an artificial nucleic acid species having 5-methylcytosine, respectively, and all phosphate bonds are phosphorothioates.

[1374] As shown in Table 7, ALNA[Ms], ALNA[ipU], ALNA[2Pym], ALNA[Prz], ALNA[Trz], and ALNA[Oxz] have stronger in vitro target gene knockdown activity than ALNA[Me] which is a known ALNA.

[1375] Example 148 In vitro miRNA-21 inhibitory activity assay

[1376] 3.0×10 6HEK293 cells at a concentration of 10 cells / ml were seeded in a 10 cm dish and cultured overnight in a CO2 incubator. The next day, 10 μg of a reporter plasmid containing the complementary sequence of miR-21 cloned in the multiple cloning site of the psiCHECK-2 vector (Promega) was transfected into the cells using FuGENE HD Transfection Reagent and cultured in a CO2 incubator for about 24 hours. The cells were harvested and seeded in 96-well plates with 2.0×10 4 Cells of each cell / well were added, and the miR-21 inhibitors into which each artificial nucleic acid was introduced were added. After the cells were cultured in a CO2 incubator for 96 hours, the Dual-Glo Luciferase Assay System was used to detect the luminescence values ​​of firefly luciferase and Renilla luciferase in the cells with a plate reader. In order to correct the influence of transfection efficiency and cell number by the luminescence value based on Renilla luciferase activity, the ratio between the luminescence value based on firefly luciferase activity was calculated. Further, by the calculated ratio, the ratio in the cells into which the psiCHECK-2 vector was introduced was used as an inhibition rate of 100%, and the ratio of the cells into which the psiCHECK-2 vector cloned with the miR-21 complementary sequence was introduced was used as an inhibition rate of 0%, and each inhibition rate was calculated to obtain the inhibitory activity. The results are shown in Table 8.

[1377] Table 8 In vitro miRNA-21 inhibitory activity

[1378] [Table 8]

[1379]

[1380] The sequences of the antisense oligonucleotides used are described below.

[1381] A(m)C(X)atC(X)agtC(X)tgaT(X)aagC(X)tA(m) (same as sequence number 4 in Table 4 above)

[1382] It should be noted that, here, A(m) represents 2'-MOE adenine nucleoside, lowercase letters represent the nucleic acid bases of DNA, T(X) and C(X) represent artificial nucleic acid species having thymine and artificial nucleic acid species having 5-methylcytosine, respectively, and all phosphate bonds are phosphorothioates.

[1383] As shown in Table 8, ALNA[mU], ALNA[ipU], ALNA[dmU], ALNA[Trz], and ALNA[Oxz] have stronger in vitro microRNA inhibitory activity than ALNA[Me] which is a known ALNA.

[1384] Example 149 In vivo MALAT1 knockdown activity test

[1385] Antisense oligonucleotides targeting MALAT1 (10 mg / kg and 50 mg / kg) were prepared to 10 mg / mL with PBS, diluted to 5 mL / kg with PBS, and administered to the tail vein of 6-week-old C57BL / 6J mice (male, Charles River, Japan). After 72 hours, blood was collected from the abdominal vein of the mouse under isoflurane (Japanese Pharmacopoeia, Pfizer) anesthesia, and the mice were bled to death. After the blood coagulated, it was centrifuged to prepare serum, and it was frozen and stored (set to -80°C) before the measurement. After bleeding to death, the liver, kidney, fat, skeletal muscle (quadriceps, gastrocnemius), lung, heart, stomach, jejunum, testis, skin, spleen, and brain were collected and frozen with liquid nitrogen. The homogenization buffer of the Maxwell RSC simplyRNA Tissue Kit was added to the frozen tissue, and the multi-bead crusher was used to crush it, and the RNA was purified according to the protocol recorded in the kit. After the RT reaction, duplicate samples were used, and the amount of RNA in each reaction was 50-500 ng. For knockdown activity, the inhibition rate of Malat1 expression was expressed as a percentage based on the amount ratio of Malat1 to GAPDH in the background medium (vehicle) group. For standard error, the value of each individual was obtained from the average value of the duplicate samples, and the value was calculated based on the value. The results are shown in Tables 9 and 10.

[1386] Table 9 Malat1 knockdown rate in each organ when 50 mg / kg was administered (%)

[1387] [Table 9]

[1388]

[1389] Table 10 Malat1 knockdown rate in each organ when 10 mg / kg was administered (%)

[1390] [Table 10]

[1391]

[1392] The sequences of the antisense oligonucleotides used are described below.

[1393] G(X)T(X)T(X)cactgaatG(X)C(X) (same as sequence number 5 in Table 5 above)

[1394] It should be noted that, here, lowercase letters represent the nucleic acid bases of DNA, T(X), C(X) and G(X) represent artificial nucleic acid species with thymine, artificial nucleic acid species with 5-methylcytosine, and artificial nucleic acid species with guanosine, respectively, and all phosphate bonds are thiophosphates.

[1395] As shown in Tables 9 and 10, ALNA[Ms] has a strong target gene knocking-down activity in various organs (liver, kidney, skeletal muscle, lung, heart, stomach, jejunum, testis, fat) compared with ALNA[Me] as known ALNA. In addition, ALNA[2Pym] has a strong target gene knocking-down activity in specific organs (heart, jejunum, testis, fat) compared with ALNA[Me] as known ALNA. In addition, ALNA[ipU] has a target gene knocking-down effect in the liver to the same extent as ALNA[Me], and at the same time, for lungs and spleen, ALNA[ipU] has a strong target gene knocking-down effect far exceeding ALNA[Me]. Due to the presence of various immune cells gathering in the spleen, therefore, for the antisense oligonucleotides comprising ALNA[ipU], it is expected to be directed to the effect of immune cells that are considered to be low in migration for common nucleic acid drugs. In addition, ALNA[ipU] can not only reduce toxicity in the liver, but also be expected to have a strong medicinal effect on the lungs and the immune system.

[1396] Example 150 MALAT1 knockdown activity test in various central tissues, liver, and kidney after intracerebroventricular administration

[1397] Under isoflurane anesthesia (Pfizer), 7-week-old C57BL / 6J (male, Charles River, Japan) was fixed to a brain positioning fixture, and the scalp was cut to expose the skull while it was laid flat on a warming pad. After confirming the position of the anterior bregma, a 1-2 mm skull was opened on the upper part of the left ventricle (1.0 mm to the left and 0.4 mm to the back) with a dental electric drill. A 27G needle was inserted into the left ventricle (1.0 mm to the left, 0.4 mm to the back, and 2.3 mm deep), and a micro-infusion pump connected to the needle was used to administer a single antisense oligonucleotide targeting MALAT1 (5 μg / 10 μL / mouse) adjusted to 5 μg / 10 μL with physiological saline at a flow rate of 2 μL / min for 5 minutes. Then, the hole in the skull was blocked with medical adhesive BellFast (Mu Chemical Industry), the incision was sutured, and gentamicin sulfate ointment 0.1% (Takata Pharmaceutical) was applied to prevent infection. 72 hours after administration, blood was collected from the abdominal vein of the mouse under isoflurane anesthesia, and the mouse was bled to death. After the blood coagulated, it was centrifuged to obtain serum, and it was frozen and stored (set to -30°C) before measurement. After bleeding to death, the brain, spinal cord, kidney, and liver were collected. For the brain, after euthanasia, the skull was separated from the spine by incision, and then the brain was taken out, and a sagittal section was made using a slicer Brain Matrices (RBM-2000S, BioResearch Center Co., Ltd.), and thin slices were made on the left side of the midline to a thickness of about 2 ...

Claims

1. A compound represented by general formula I or a salt thereof, [Chemical formula 1] In the formula, B is a base portion of a nucleic acid that may be substituted with one or more substituents; R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl; R5 and R6 are each independently a hydrogen atom, a protective group for a hydroxyl group, or a phosphate group which may be substituted; m is 1 or 2; X is a group represented by the following formula (II-1), (II-2), or (II-3); [Chemical formula 2] Symbols described in formula (II-1), (II-2), or (II-3): [Chemical formula 3] indicates the bonding site to the 2'-amino group; R7 and R8 are each independently a hydrogen atom, a C 1-6 Alkyl, C which may be substituted with one or more substituents 2-6 Alkenyl, C which may be substituted with one or more substituents 2-6 Alkynyl, or an aromatic group which may be substituted with one or more substituents; A is an aromatic group; M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.

2. The compound or salt thereof according to claim 1, wherein B is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

3. The compound or salt thereof according to claim 1 or 2, wherein R1, R2, R3 and R4 are each independently a hydrogen atom; m is 1.

4. The compound or salt thereof according to any one of claims 1 to 3, wherein X is a group represented by formula (II-1); and, R7 and R8 are each independently a hydrogen atom, a C 1-6 An alkyl group or an aromatic group which may be substituted with one or more substituents.

5. The compound or salt thereof according to claim 4, wherein R7 and R8 are each independently a hydrogen atom, a C 1-3 alkyl.

6. The compound or salt thereof according to claim 5, wherein One of R7 and R8 is a hydrogen atom, and the other is a methyl group.

7. The compound or salt thereof according to claim 5, wherein One of R7 and R8 is a hydrogen atom, and the other is an isopropyl group.

8. The compound or salt thereof according to any one of claims 1 to 3, wherein X is a group represented by formula (II-2); and, A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, and the heteroaryl group contains one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

9. The compound or salt thereof according to claim 8, wherein A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, the heteroaryl group comprises two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, the two or three heteroatoms include at least two nitrogen atoms, the substituents are each independently selected from C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A group consisting of an amino group substituted by an alkyl group.

10. The compound or salt thereof according to claim 9, wherein The five-membered or six-membered heteroaryl group is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, and pyrazinyl groups which may be substituted with one or more substituents.

11. The compound or salt thereof according to claim 10, wherein The triazolyl group which may be substituted with one or more substituents is 1,5-dimethyl-1,2,4-triazol-3-yl group.

12. The compound or salt thereof according to claim 10, wherein The oxadiazolyl group which may be substituted with one or more substituents is 5-methyl-1,2,4-oxadiazol-3-yl group.

13. The compound or salt thereof according to claim 10, wherein The thiadiazolyl group which may be substituted with one or more substituents is 3-methyl-1,2,4-thiadiazol-5-yl group.

14. The compound or salt thereof according to any one of claims 1 to 3, wherein X is a group represented by formula (II-3); and, M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

15. The compound or salt thereof according to claim 14, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

16. The compound or salt thereof according to any one of claims 1 to 15, wherein R6 is a hydrogen atom or a DMTr group, and R5 is a hydrogen atom or -P(O(CH2)2CN)(N(iPr)2).

17. A compound selected from the group consisting of: 3-[[(1R,4R,6R,7S)-4-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-6-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-methylsulfonyl-5-oxa-2-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate; N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-purin-6-yl]benzamide; 3-[[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-5-(phenylsulfonyl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino)oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(methylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate; (1R,3R,4R,7S)-3-(6-Benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-methyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxopyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; [9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(isopropylcarbamoyl)-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-2-(2-methylpropionylamino)purin-6-yl]N,N-diphenylcarbamate; (1R,3R,4R,7S)-3-(6-Benzamidopurin-9-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N-isopropyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; (1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; (1R,3R,4R,7S)-3-(4-Benzamido-5-methyl-2-oxo-pyrimidin-1-yl)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-N,N-dimethyl-2-oxa-5-azabicyclo[2.2.1]heptane-5-carboxamide; 3-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; 1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-6-carboxamidine; N'-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]purin-6-yl]benzamide; 3-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrimidin-4-yl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptan-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[4-(trifluoromethyl)pyrimidin-2-yl]-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(5-chloropyrimidin-2-yl)-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-5-methyl-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[6-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[(6-dimethylamino)pyrimidin-4-yl]-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-[2-(dimethylamino)pyrimidin-4-yl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-7-yl]oxy-(diisopropylamino)oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-[2-(dimethylamino)pyrimidin-4-yl]-7-hydroxy-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-pyrazin-2-yl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethyl-formamidine; N-[9-(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(1,5-dimethyl-1,2,4-triazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]purin-6-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; 3-[[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptane-7-yl]oxy-(diisopropylamino)phosphino]oxypropionitrile; N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-(3-methyl-1,2,4-thiadiazol-5-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide; N-[1-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]dihydropyrimidin-2-one; N'-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-N,N-dimethylformamidine; N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphino]oxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide; and N-[9-[(1R,3R,4R,7S)-1-[[Bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methylsulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane-3-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propionamide.

18. An oligonucleotide compound or a salt thereof, which has one or more nucleosides represented by the general formula (I'), [Chemical formula 4] In the formula, B is a base portion of a nucleic acid that may be substituted with one or more substituents; R1, R2, R3 and R4 are each independently a hydrogen atom, or a C atom which may be substituted with one or more substituents. 1-6 alkyl; m is 1 or 2; X is a group represented by the following formula (II'-1), (II'-2), or (II'-3); [Chemical formula 5] Symbols described in formula (II'-1), (II'-2), or (II'-3): [Chemical formula 6] indicates the bonding site to the 2'-amino group; A is an aromatic group which may be substituted with one or more substituents, wherein the aromatic group contains one or more heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom; M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aromatic group which may be substituted with one or more substituents.

19. The oligonucleotide compound or a salt thereof according to claim 18, wherein B is an adenine group which may have one or more protecting groups, a guanine group which may have one or more protecting groups, a cytosine group which may have one or more protecting groups, a 5-methylcytosine group which may have one or more protecting groups, or a uracil group which may have one or more protecting groups.

20. The oligonucleotide compound or a salt thereof according to claim 18 or 19, wherein R1, R2, R3 and R4 are each independently a hydrogen atom; m is 1.

21. The oligonucleotide compound or a salt thereof according to any one of claims 18 to 20, wherein X is a group represented by formula (II'-1); and, R7 and R8 are each independently a hydrogen atom, a C 1-6 An alkyl group or an aromatic group which may be substituted with one or more substituents.

22. The oligonucleotide compound or a salt thereof according to claim 21, wherein R7 and R8 are each independently a hydrogen atom, a C 1-3 alkyl.

23. The oligonucleotide compound or a salt thereof according to claim 22, wherein One of R7 and R8 is a hydrogen atom, and the other is a methyl group.

24. The oligonucleotide compound or a salt thereof according to claim 23, wherein One of R7 and R8 is a hydrogen atom, and the other is an isopropyl group.

25. The oligonucleotide compound or a salt thereof according to any one of claims 18 to 20, wherein X is a group represented by formula (II'-2); and, A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, and the heteroaryl group contains one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

26. The oligonucleotide compound or a salt thereof according to claim 25, wherein A is a five-membered or six-membered heteroaryl group which may be substituted with one or more substituents, the heteroaryl group comprises two or three heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms, the two or three heteroatoms include at least two nitrogen atoms, the substituents are each independently selected from C 1-3 Alkyl groups, halogen atoms, and may be replaced by one or more C 1-3 A group consisting of an amino group substituted by an alkyl group.

27. The oligonucleotide compound or a salt thereof according to claim 26, wherein The five-membered or six-membered heteroaryl group is selected from the group consisting of triazolyl, oxadiazolyl, thiadiazolyl, pyrimidinyl, and pyrazinyl groups which may be substituted with one or more substituents.

28. The oligonucleotide compound or a salt thereof according to claim 27, wherein The triazolyl group which may be substituted with one or more substituents is 1,5-dimethyl-1,2,4-triazol-3-yl group.

29. The oligonucleotide compound or a salt thereof according to claim 27, wherein The oxadiazolyl group which may be substituted with one or more substituents is 5-methyl-1,2,4-oxadiazol-3-yl group.

30. The oligonucleotide compound or a salt thereof according to claim 27, wherein The thiadiazolyl group which may be substituted with one or more substituents is 3-methyl-1,2,4-thiadiazol-5-yl group.

31. The oligonucleotide compound or a salt thereof according to any one of claims 18 to 20, wherein X is a group represented by formula (II'-3); and, M is selected from C which may be substituted by one or more substituents 1-6 A sulfonyl group substituted with one substituent selected from the group consisting of an alkyl group and an aryl group which may be substituted with one or more substituents.

32. The compound or salt thereof according to any one of claims 18 to 31, wherein M is a sulfonyl group substituted with one substituent selected from the group consisting of a methyl group and a phenyl group.

33. The sulfurized oligonucleotide or a salt thereof according to any one of claims 1 to 32, wherein At least one of the phosphate bonds between nucleotides is a phosphorothioate bond.

Images